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Summary
Successful metastasis of a tumour cell involves a series of complex steps comprising of 
several cell-cell and cell extracellular matrix (ECM) interactions. All-trans retinoic acid 
(RA) and pentoxifylline (PX) have previously been shown to modulate various stages of 
metastasis, and this study examines the ability of either drug to modulate tumour cell 
growth, adhesion of tumour cells to various components of the ECM, tumour lysis by 
lymphokine-activated killer (LAK) cells, and plasminogen activator expression. 
Pretreatment of the A375, Hs294T and C8161 human melanoma cell lines for up to 7 days 
with a range of concentrations of RA (10'10M - 10'5M) failed to alter tumour cell growth. 
In contrast, PX induced a time and dose dependent decrease in tumour cell numbers, 
reducing C8161 cells numbers by 67.5%, Hs294T cell numbers by 65.4% and decreasing 
the numbers of A375 cells by 37.2% after 4 days treatment with 250|ig/ml PX. Neither 
PX nor RA had any effect on tumour cell morphology. Pretreatment of the C8161 cells for 
4 days with 1 O^M RA had no effect on adhesion of the cells to fibronectin, laminin, collagens 
type I and type IV or matrigel basement membrane. Although adhesion of C8161 cells 
pretreated with 250pg/ml PX to collagens type I and IV, and laminin was not altered, a 
24.2% reduction in adhesion to fibronectin was observed by 30min.
The ability of either drug to modulate tumour cell lysis by LAK cells was determined 
using the Chromium-51 release assay over a range of effector to tumour cell ratios (E:T). 
Neither drug modulated lysis of the A375 cells but lysis of the Hs294T and C8161 cells 
pretreated for 4 days with 10'6M RA was increased 1.4-fold and 2.8-fold respectively at an 
E:T ratio of 40:1. 4 days pretreatment of the tumour cells with PX (250pg/ml) failed to 
alter lysis of the A375 cells yet increased lysis of the C8161 cells 1.8-fold and in contrast, 
decreased lysis of the Hs294T cells 1.8-fold at the 40:1 ratio. The involvement of 
intercellular adhesion molecule-1 (ICAM-1, CD54) in the modulation of tumour cell lysis 
by either RA or PX was subsequently examined. ICAM-1 is expressed on several cell 
types including melanoma cells and acts as a ligand for lymphocyte function associated 
antigen (LFA-1, CD 11 a/CD 18) present on the surface of lymphocytes. Analysis of 
alterations in membrane ICAM-1 (mICAM-1) by flow cytometry revealed RA (10'10M - 
10 7M) had no effect on mICAM-1 expression in the Hs294T and C8161 cells whereas at 
the higher concentrations (10'6M - 10'5M), a slight increase in mICAM-1 levels became 
evident. Using the A375 cell line, 4 days pretreatment with 1010M - 10'7M RA induced
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only a marginal increase in mICAM-1 expression, which further increased with lO^M - 
10'5M RA. Despite the RA-induced increase in mICAM-1 levels, PX (10|Xg/ml - 250pg/ 
ml) failed to alter mICAM-1 expression in any of the three cell lines. Addition of blocking 
ICAM-1 antibody over a range of concentrations to the cytotoxicity assays at the 40:1 
ratio reduced lysis of the C8161, A375 and Hs294T cells. Using the C8161 cells, blocking 
ICAM-1 antibody at the optimum concentration of 10|ig/ml induced a 2.3-fold reduction 
in lysis of the tumour cells. In the Hs294T cell line, an optimum 1.8-fold reduction in lysis 
was observed using 5pg/ml blocking ICAM-1 antibody. Using the A375 cells, lOfig/ml 
blocking ICAM-1 antibody induced an optimum 2-fold reduction in lysis. This antibody 
also reduced lysis of RA-pretreated C8161 cells 3-fold using 10pg/ml antibody, and the 
Hs294T cells 1.3-fold using 5jig/ml. Lysis of PX-pretreated C8161 and Hs294T cells was 
also reduced 2.1-fold (5pg/ml) and 1.5-fold (lOjig/ml) respectively. Despite showing 
weak expression of the major histocompatibility complex (MHC) class 1 on all 3 cell 
lines, blocking of this molecule using a specific antibody had no effect on tumour cell 
lysis. Collectively, this data shows that ICAM-1 is partially involved in the lysis of RA/ 
PX-treated and untreated tumour cells but other molecules involved in the tumour/LAK 
cell interaction must also be altered to account for the observed RA/PX induced modulation 
of tumour lysis.
ICAM-1 can also exist as a soluble form (sICAM-1) which has the ability to bind to LFA- 
1 thereby blocking the binding site of LFA-1 for membrane ICAM-1 on the tumour cell 
surface. This prevents the tumour cells from being lysed by the lymphocytes and is thought 
to be one possible mechanism as to how tumour cells evade immunosurveillance. Using a 
specific ELISA detection system, expression of sICAM-1 was measured from each cell 
line. The A375 cells secreted 50.5fg/cell, compared to 36.9fg/cell for the C8161 cells, and 
7.2fg/cell for the Hs294T cells. RA (1010M - 10'5M) did not alter sICAM-1 expression in 
the C8161 and Hs294T cells, but in contrast, levels were increased in the A375 cells 1.4- 
fold using 10'6M RA. PX (10pg/ml - 250pg/ml) induced a dose-dependent increase in 
sICAM-1 expression in all three cell lines. Using 250[ig/ml PX, sICAM-1 expression was 
increased 4.3-fold, 4.7-fold, and 1.7-fold in the C8161, Hs294T and A375 cells respectively. 
Addition of sICAM-1 to the cytotoxicity assays of C8161 and Hs294T cells had no effect 
on tumour cell lysis. In contrast, addition of the soluble form to RA-pretreated C8161 
cells induced a 3.1-fold reduction in lysis yet did not alter lysis of the Hs294T cells. This 
shows that sICAM-1 appears to be unimportant in the evasion of the C8161 and Hs294T
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cells, but in combination with alterations in cell surface molecules, may play a role in 
escape of RA-pretreated C8161 cells from the immune system.
As well as the heterotypic cell interactions occuring during the metastatic process, tumour 
cells must also have the ability to interact with and invade the surrounding tissues. The 
plasminogen activation system consists of a series of secreted enzymes which play a pivotal 
role in invasion by the tumour cell. Two well documented plasminogen activators are 
urokinase type (uPA) and tissue type (tPA) plasminogen activators which convert 
plasminogen into the active zymogen plasmin which has a broad substrate specificity 
degrading a wide variety of ECM components. Using confocal microscopy, it was shown 
that all 3 cell lines expressed cell-associated uPA although expression was much stronger 
in the Hs294T and C8161 cells compared to the A375 cells. tPA was also found to be 
associated with greater than 95% of the Hs294T, C8161 and A375 cells, with the staining 
being much weaker in the Hs294T and C8161 cells than the uPA staining. A specific 
ELISA was used to detect secreted uPA and tPA expression from each cell line. Levels of 
secreted uPA were undetectable in the A375 cell line, whereas, in contrast, the highly 
metastatic C8161 cell line was found to secrete on average 215-fold higher levels of uPA 
than the poorly metasatic Hs294T cell line. Expression of secreted tPA was 6.4-fold and 
6.9-fold higher in the A375 and Hs294T cells respectively than in the C8161 cells. RA 
(10'10M - 10'5M) failed to induce expression of uPA from the A375 cells. Nevertheless, 
the same treatment of the C8161 cells induced a maximun 3.4-fold increase in uPA 
expression using 10'8M RA compared to a 1,6-fold increase in the Hs294T cells. Secretion 
of tPA was increased with 10'8M - 10'5M RA pretreatment of the C8161, achieving a 
maximum 3.7-fold increase using 10‘6M RA. In the Hs294T cell line, tPA secretion was 
increased with 10'9M - 10'5M RA where an optimum 3.8-fold increase in tPA expression 
was induced using 10'6M RA. Preliminary measurements of the modulation of uPA and 
tPA expression by PX (10|ig/ml - 250pg/ml) indicated PX treatment of the C8161 and 
Hs294T cells induced an increase in uPA expression 2.6-fold and 2.7-fold respectively. 
The effect of PX on secreted tPA expression in the A375 and Hs294T cells has still to be 
investigated. In the C8161 cells, the PX-induced change in tPA expression was marginal, 
where expression decreased 1.4-fold using 250|Lig/ml PX. The biological significance of 
these alterations in uPA and tPA expression by RA and PX remains to be examined.
The retinoid-induced changes in tumour LAK cell-mediated lysis and plasminogen 
activation and the apparent lack of alterations in adhesive interactions in the cell lines led
15
to an interest in the mechanisms involved in these observed responses. All-trans RA 
exerts its effect via 3 subtypes of nuclear receptor namely RARa, P and y which can form 
homo or heterodimeric complexes with the retinoid X receptors (RXR). The receptors 
exert there physiological actions by binding to specific sites on the DNA termed the retinoic 
acid response element (RARE) on target genes to regulate their expression. Using the 
polymerase chain reaction (PCR) to amplify specific regions of the cDNA from each cell 
line, followed by Southern blot analysis to confirm the identity of the amplicons, it was 
shown that all three cell lines expressed RARp and y with and without 4 days pretreatment 
with 10_6M RA. In contrast the C8161 and Hs294T cells lacked expression of RARa with 
and without RA pretreatment whereas, RARa was expressed in the A3 75 cells but was 
down regulated on treatment with 10‘6M RA. In relation to the studies on ICAM-1 and 
PA, RARp has been shown to be involved in the upregulation of mICAM-1 by RA, and 
certainly all 3 cell lines expressed this subtype allowing for the potential of RARp to be 
involved in the RA-induced increase in mICAM-1 levels in all 3 cell lines. The RA induction 
of tPA expression in other cell types has been reported to involve RARa, and as all 3 cell 
lines lacked expression of this subtype on treatment with RA, this suggests other 
mechanisms must exists, possibly involving RARp and y to regulate tPA expression by 
RA.
16
Chapter 1: Introduction
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1. General Introduction
1.1 Development of a malignant tumour
The development of a malignant tumour is a three step process involving initiation, 
promotion and progression (Weinstein IB, 1988). The transformation events can be initiated 
by genetic predisposition, exogenous factors such as chemical carcinogens, and endogenous 
factors including hormones. The growth and expansion of the initiated cell occurs during 
the promotion phase which is followed by progression leading to a genetically unstable 
cell. During this progression, the cells undergo several characteristic and phenotypic 
changes involving deletions in putative suppressor gene loci (Shih and Herlyn, 1993), the 
acquired loss of dependence of exogenous growth factors, and loss of susceptibility to 
negative growth regulators (Rodeck U, 1993; Lu and Kerbel, 1994). Once the 
transformation events have taken place, the resulting neoplastic cells proliferate to form 
the primary tumour. The genetic instability of the cells within a tumour contributes to the 
generation of heterogeneity which may determine the ability of a tumour cell to metastasise.
1.2 Steps involved in metastasis
The term metastasis, which describes the spread of malignant cells to secondary sites 
throughout the body, was first coined in 1829 by the French physician Joseph Claude 
Recamier. He made the observation that patients with breast cancer also had secondary 
deposits on the brain and noted many of the veins located near the affected sites were 
invaded with tumour cells. Most deaths in cancer are due to metastatic disease which 
involves a series of sequential steps (Liotta and Stetler-Stevenson, 1991), beginning with 
the dissociation of the tumour cells from the main tumour mass. This is followed by 
adhesion to and penetration of basement membrane barriers during vascular and lymphatic 
invasion. Tumour cells are carried in the circulation where they must escape 
immunosurveillance and then penetrate blood vessel walls of target organs and invade the 
surrounding tissue. Once they finally establish at a distant site, the tumour cells begin to 
proliferate and induce their own blood supply, a process called angiogenesis.
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Adhesion Events
The importance of cell adhesion to the process of metastasis is well documented (Pignteli 
and Vessey, 1994). Reduced cell adhesion must occur to allow tumour cell detachment 
from the primary mass yet there needs to be an increase in cell adhesive properties to 
promote attachment of tumour cells to microvessel endothelial cells, subendothelial 
basement membrane or the extracellular matrix (ECM) during invasion. A decrease in 
adhesion is aided by reduction or loss of specific cell adhesion molecules such as the 
cadherins, where loss of expression of E-cadherin has been correlated with poor prognosis 
of high grade breast cancer tumours (Oka et al, 1993). Tumour cell adherence to endothelial 
cells is mediated by the immunoglobulin superfamily of adhesion molecules which are 
involved primarily in cell-cell communication. 2 members of this family, ICAM-1 and 
vascular cell adhesion molecule-1 (VCAM-1) have been implicated in the progression of 
neoplasms, particularly melanoma (Johnson et al, 1989; Denton et al, 1992). In contrast, 
interaction of the tumour cells with the ECM is mediated largely by integrins which allow 
the tumour cells to interact with a variety of components of the ECM including fibronectin, 
laminin, collagens, proteoglycans and vitronectin. Changes occurring in adhesion receptors 
as a consequence of transformation tend to be tumour type and integrin specific (Juliano 
and Varner, 1993). Tumour cell adhesion to the ECM may also provide a signal for secretion 
of autocrine and /or paracrine growth factors resulting in enhanced tumour cell proliferation 
(Nicolson GL, 1993) and can trigger a host of other cellular functions including cell 
migration, release of ECM-degrading enzymes, and the release of matrix-bound angiogenic 
factors such as basic fibroblast growth factor (bFGF) which are required for the initiation 
of neovascularisation (McCormick and Zetter, 1992; Stetler-Stevenson et al, 1993).
Invasion Events
Destruction of natural tissue barriers consisting of interstitial connective tissue and basement 
membrane represents the first step in tumour invasion and permits the local and regional 
movement of the tumour cells (Tryggvason et al, 1987). The basement membrane is 
involved in compartmentalisation and also regulates many cellular functions. The major 
components of the basement membrane include type IV collagen, laminin, heparan sulphate 
proteoglycan, and destruction of these components correlates with invasion and metastasis 
of the tumour cells. This step requires the coordinated expression of destructive enzymes
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and their inhibitors of which there are 4 main classes namely; serine proteinases, matrix 
metalloproteinases (MMPs), cysteine proteinases and aspartyl proteinases which allow 
the tumour cells to escape from the primary mass, and undergo intra and extravasation 
from the vasculature. MMPs comprise of type IV collagenases named MMP-2 and 9 
(gelatinase A and B respectively); interstitial collagenases (MMP-1 and 8) and the 
stromelysins, namely MMP-3,10,11 and 7 (stromelysin-1,2 ,3  and matrilysin respectively). 
As well as degrading a wide variety of ECM components, the MMPs, specifically MMP- 
7 and the recently discovered MMP-14, can activate procollagenase and progelatinase 
respectively, and the activity of the MMPs has been correlated with the ability of a tumour 
cell to metastasise.
The serine proteinases include plasmin, cathepsin G, thrombin, trypsin, uPA and tPA. 
uPA and tPA are two of the most well documented serine proteinases, and convert 
plasminogen into plasmin which can degrade a wide variety of ECM components. uPA 
binds to a cell surface receptor known as the uPAR which plays a pivitol role in the migration 
of tumour cells, and both uPA and uPAR have been positively correlated with tumour cell 
invasiveness. tPA is thought to play a less dominant role in tumour progression than uPA 
since most tumour cells lack expression of tPA.
The cysteine proteinases include cathepsin B and L which have cysteine residues at their 
active sites and have been implicated in metastasis (Foekens et al, 1998), as has cathepsin 
D, which belongs to the aspartyl proteinases (Solomayer EF, 1998).
Migration o f  the tumour cells
An important step following destruction of the basement membrane is the migration of the 
tumour cell through membrane barriers. This process is stimulated by factors secreted 
from the tumour cells or from host stromal cells such as autocrine motility factor (AMF) 
or hepatocyte growth factor (HGF).
Evasion o f Immunosurveillance
Once in the lymph or blood vessels, tumour cells must escape destruction by either 
immunosurveillance or blood turbulence. During transport, tumour cells can travel 
individually as single cells or as emboli composed of tumour cells (homotypic) or tumour/
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host cells (heterotypic). Most of the tumour cells which leave the primary mass will be 
destroyed (Weiss L, 1990) leaving as few as one in 10000 of the tumour cells to initiate a 
new tumour colony at a secondary site (Fidler IJ, 1973). An effective immune response 
capable of eliminating tumour cells is provided by cytotoxic T cells (CTL) which recognise 
cell surface epitopes associated with major histocompatibility complex (MHC) class 1 
antigens present on the tumour cell surface. The natural killer (NK) cell plays a significant 
role in the control of metastasis where low levels of MHC class 1 leads to elevated NK 
sensitivity (Karre et al, 1986). Other tumour cell surface molecules such as ICAM-1 and 
LFA-3 have been implicated in the cytotoxic response towards tumour cells by interacting 
with LFA-1 and LFA-2 respectively on the lymphocyte surface. Soluble forms of ICAM- 
1 have been shown to interfere with the immune targeting of tumour cells by binding to 
the lymphocyte aiding in the escape of the tumour cells from the immune system. Antibodies 
secreted by B-lymphocytes (plasma cells) directed towards specific tumour antigens also 
function to eliminate tumour cells.
Arrest and Organ Colonisation
In the majority of cases, a metastasising cell passes through the heart before finding a 
resting place by adhering to a vessel lining. Because the heart pumps all the blood through 
the lung capillaries, the lungs are often a common site for metastasis. Liver metastasis 
often arises from colon cancers because the liver receives the direct drainage of venous 
blood from the large intestine. Nevertheless, simply lodging of tumour cells into an organ 
due to the emboli being too large to traverse a capillary lumen is insufficient for metastasis 
to develop (Rusciano and Burger, 1992), and instead, requires a favourable environment 
for successful organ colonisation. This will depend on a number of factors including the 
appropriate growth factors and hormones to stimulate the tumour cells (Rusciano et al,
1992), and the growth of new blood vessels. Tumour cells may also arrest in specific 
organs by exhibiting different capacities to attach to endothelial cells regulated by various 
chemotactic factors (Lichtner et al, 1989).
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Angiogenesis
The formation of a blood supply is a complex process requiring dissolution of the basement 
membrane, endothelial cell migration and proliferation, vascular formation and development 
of a new basement membrane. Degradation of the basement membrane by proteolytic 
enzymes such as MMPs and uPA is essential for successful angiogenesis to occur. Factors 
such as platelet derived growth factor (PDGF), HGF, and TNFa stimulate the formation 
of new tumour blood vessels, and integrins such as ocvP3, a vp5 and Pj also play a role in 
angiogenesis as they are required for vascular proliferation.
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1.3 Cell-Extracellular Matrix Interactions
Disruption of the cell-ECM associations is essential for successful metastasis of the tumour 
cells allowing changes in the adhesive interactions to occur between tumour cells and the 
surrounding ECM. The ECM is a complex network of collagenous proteins, glycoproteins, 
proteoglycans and glycosaminoglycans, and provides a supportive scaffold for cells as 
well as mediating a variety of cellular processes such as cell attachment, migration and 
differentiation.
Collagens
Although the primary role of the collagens is structural, they are also involved in cell 
attachment and differentiation, and can also function as chemotactic agents and as antigens 
in immunopathological processes.
There exists greater than 20 collagens which form the major constituents of the ECM. All 
have domains with a triple helical conformation where each domain has 3 subunits known 
as a  chains. The a  chains each contain a (Gly-X-Y)n repetitive sequence motif where X 
and Y can be any amino acid but are usually proline or hydroxyproline which stabilises 
the helical structure.
Type IV  collagen
Type IV collagen is found in the basement membrane and can form a network structure 
interacting with laminin, nidogen, and heparan sulphate proteoglycan. It exists as 
heterotrimers of two a l  and one a2 chain where separate molecules associate end to end. 
The procollagen form of the molecule is incorporated directly into the basement membrane 
structure without undergoing extracellular processing. Collagen type IV has a major cell 
binding site which interacts with the integrin receptors and a,P, (Vandenberg et al,
1991).
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Collagen Type I
Type I collagen belongs to the fibrillar collagens and can be isolated from adult connective 
tissue such as skin, bone, tendon and cornea. Greater than 95% of the classic fibril-forming 
collagens are composed of 3 helical chains which wrap around one another to produce the 
tight triple helical structure of the molecule. Each molecule of type I collagen consists of 
two a l  chains and one a2 chain which are stabilised by interchain hydrogen bonds. The 
peptide bonds linking adjacent amino acids are buried within the interior of the molecule 
making the triple helical region highly resistant to attack. Fibrillar collagens can interact 
with cells directly via specific cell surface receptors or indirectly via other ECM components. 
A specific region of Type 1 collagen termed the DGEA site has been shown to block the 
breast adenocarcinoma cell adhesion to collagen type 1 and laminin (Staaz et al, 1991).
Fibronectin
Fibronectin is a large glycoprotein which can be secreted by a wide variety of cell types 
and is also present in plasma, loose connective tissue and embryonic (but often not adult) 
basement membranes. It mediates a variety of processes including cell adhesion, embryonic 
cell migration, wound healing, differentiation and cytoskeletal organisation.
A number of variant forms exist due to alternative splicing of its precursor mRNA (Hirano 
et al, 1983) and the initial secreted form of fibronectin is composed of a dimer of two 
subunits held together by a pair of disulphide bonds near the C-terminal. In the ECM, 
fibrils of fibronectins are further disulphide bonded into high molecular weight polymers. 
The structure of fibronectin comprises of three general types of homologous repeating 
units termed I, II, III, of which there are 12 type I repeats (45 amino acids long), two 60 
amino acid type I repeats and 15-17 type III repeats each 90 amino acids long.
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Figure 1. Structure o f  fibronectin
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Specialised domains arise from the repeating units which can bind to specific cell surface 
receptors or to collagens, proteoglycans or other ECM molecules. Type I forming domains 
bind heparin, fibrin or collagen whereas the major collagen binding domain comprises 
largely of Type II repeats which may not actually be essential for the binding of collagen 
(Ingham et al, 1989). Type III repeats bind to cells or to heparin but not to collagen and 
most cells adhere to fibronectin at the cell binding domain containing an RGD recognition 
motif. This RGD motif was the first sequence to be reported active in promoting adhesion 
(Yamada KM, 1991) and the sequences surrounding the RGD motif appear to be important, 
specifically, the amino terminal site which promotes cell adhesion by acting synergistically 
with the RGD site (Obara et al, 1988). Experimental metastasis of murine melanoma cells 
after intravenous injection can be inhibited with monomeric (Humphries et al, 1986; 1988) 
and multimeric peptides containing this RGD motif (Saiki et al, 1989).
Laminin
Laminin is one of the major components of the basement membrane and is implicated in 
roles such as cell adhesion, migration and differentiation. Various isoforms exist (laminins 
1-6) where the basic structure comprises of three different subunits linked together by 
disulphide bonds. This cross-like structure of laminin can interact with other basement 
membrane components including type IV collagen, heparan sulphate proteoglycan and 
nidogen.
Laminin contains multiple active sites (Beck et al, 1990) and synthetic peptides comprising 
of the central region of laminin have been shown to block experimental metastasis 
(Kleinman et al, 1989). The YIGSR sequence located on the B1 chain can inhibit tumour 
growth (Fridman et al, 1990; Iwamoto et al, 1987) and metastasis by reducing tumour cell 
adhesion to laminin, and also inhibits angiogenesis (Sakomoto et al, 1991; Daneker et al, 
1989). This peptide has also been found to interact with normal cells and influence cell 
differentiation (Kleinman et al, 1987). Two other peptides located on the B 1 chain, namely 
PDSGR and RYVVLPR also inhibit tumour metastasis (Murata et al, 1989; Sakamoto et 
al, 1991; Skubitz et al, 1990). In contrast, a different sequence of laminin known as the 
PA22-2 protein increases tumour metastasis, growth, angiogenesis, plasminogen activation 
and collagenase IV activity (Kanemoto et al, 1990; Stack et al, 1990).
At least 6 integrin receptors bind to laminin where the major site of interaction of these
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receptors is located at the end of the long arm and near the centre of the laminin cross.
Integrin receptors
There are a number of families of adhesion molecules involved in cell matrix interactions 
of which the largest and probably most significant are the integrin receptors. As well as 
providing anchorage to the ECM, integrins are involved in intracellular signalling and 
have been shown to regulate gene expression affecting processes such as cell migration, 
proliferation, differentiation and apoptosis (Juliano and Haskill, 1993). They are expressed 
by most cell types and consist of one a  chain non-covalently associated with one p chain.
Role o f  integrin receptors in tumour progression
There have been several studies to illustrate the role of certain integrin receptors in tumour 
progression where changes in expression of the integrin profile are associated with tumour 
progression. Although the fibronectin receptor a 5P, and the vitronectin receptor a vP3 are 
not expressed in benign melanocyte lesions and early primary melanoma, they emerge in 
advanced primary melanomas and metastases, and induce enhanced expression of 
metalloproteases which results in an increase in tumour invasion through matrigel (Seftor 
et al, 1992; 1993). The collagen receptor a 2Pj is more strongly expressed in invasive 
melanoma compared to in situ melanoma (Van Duinen et al, 1994) and this reflects in 
vitro studies where a 2pj is associated with enhanced invasion of melanoma cell lines (Klein 
et al, 1991). The a 3Pt receptor for fibronectin, laminin and collagen is expressed by greater 
than 80% of metastatic melanomas and enhanced expression on tumour cells correlates 
with dermal invasiveness (Natali et al, 1993). Expression of the a 4p, integrin which binds 
to fibronectin and a vP3 (Delannet et al, 1994) are significantly increased in metastatic 
melanomas (Schadendorf et al, 1993).
In contrast, a 5p, has been shown to have a tumour suppressor effect in Chinese hamster 
ovary cells whereby clones overexpressing a 5P, were shown to grow less rapidly in nude 
mice compared to clones lacking the fibronectin receptor (Schreiner et al, 1989). Melanoma 
cells expressing a vp3 have been found to grow more slowly in nude mice compared to 
clones expressing high levels of this receptor (Felding-Habermann et al, 1992).
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1.4. Involvement of the plasminogen activation system in tumour invasion and 
metastasis
Once a tumour cell has adhered to the ECM, it must invade the surrounding basement 
membrane in order to proceed with the metastatic process. Tumour cell invasion requires 
the localised expression of a number of proteolytic enzymes which facilitate invasion of 
the tumour cells through surrounding tissues (Liotta et al, 1991; Mignatti and Rifkin,
1993), and the plasminogen activation system has been shown to play a pivotal role in 
such tumour cell invasion (Dano et al, 1985). Plasminogen activators (PAs) mediate the 
conversion of the inactive zymogen plasminogen into the active component, plasmin, which 
has a broad substrate specificity, and which is inhibited by a2 macroglobulin and oc2 anti- 
plasmin. Plasmin can convert the precursors of growth factors such as TGFp to the 
biologically active form (Flaumenhaft et al, 1992) and is also is a key player in degrading 
a wide variety of ECM components (Dano et al, 1985) such as fibronectin, laminin, type 
IV collagen and tetranectin. As well as ECM degradation, plasmin can also activate 
procollagenases which play an important role in tumour cell invasion (Meissauer et al, 
1992). Two well documented activators of plasminogen are uPA and tPA.
Urokinase type plasminogen activator
The human 6.4kb uPA gene which is located on chromosome 10, contains 11 exons and 
codes for a 53kDa protein which acts as a fibrin-independent, largely cell surface receptor- 
bound plasminogen activator. Melanoma cells can utilise uPA for both matrix degradation 
(Quax et al, 1991; Stahl and Mueller, 1994) and invasion (Stahl and Mueller, 1994; Supino 
et al, 1992). The importance of uPA in the metastatic spread of tumour cells has previously 
been demonstrated by the addition of anti-uPA antibody which has been shown to inhibit 
the metastatic spread of mouse B16F10 melanoma cells (Hearing et al, 1988). Further 
supporting evidence for a role of uPA in metastasis has been demonstrated using uPA- 
negative B16F1 cells which, when transfected with sense human uPA, results in a more 
metastatic phenotype, and likewise, the antisense transfection of uPA in uPA-producing 
B16F10 cells results in a less metastatic phenotype (Yu and Schultz, 1988). Synthetic 
peptides comprising of the binding domain of uPA are able to inhibit spontaneous metastasis 
in the nude mouse (Kobayashi et al, 1994). The invasive properties of tumour cells and
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their ability to degrade the ECM can be reduced when pretreated with anti-uPA antibody 
(Mignatti et al, 1986; Reiter et al, 1993). As well as having a role in tumour invasion, uPA 
can also act as an (autocrine) mitogen, as inhibition of uPA-binding has been shown to 
inhibit cell proliferation (Kirchheimer et al, 1989). uPA is also thought to play a dominant 
role in tissue remodelling processes such as wound healing (Grondahl-Hansen et al, 1988), 
monocyte invasion (Kirchheimer and Remold, 1989) and angiogenesis (Bacharach et al,
1992). Tumour progression is accompanied by the loss of differentiation markers and 
gain of progression markers like uPA, and Supino et al, (1992; 1994) found an inverse 
relationship between melanin production and uPA production where invasiveness was 
correlated with uPA production and inversely correlated with melanin content. The 
correlation of uPA with invasiveness and metastatic potential has been exploited in the 
clinical situation where it has been found that in breast carcinomas, high levels of uPA are 
associated with poor prognosis (Janicke et al, 1990; Grondahl-Hansen et al, 1993).
uPA receptor
uPA binds with high affinity to a 55-60kDa GPI-linked membrane receptor known as the 
uPAR (Ploug et al, 1991) via its amino terminal domain. uPA exists as both a single and 
a two chain form, however for the single chain form (pro-uPA) to become active, it must 
bind to the uPAR (Blasi F, 1988). This interaction, which occurs within the proximity of 
receptor bound plasmin, accelerates the conversion of pro uPA into active uPA (Quax et 
al, 1991). uPA and uPAR play a diverse role in processes mediating cell migration and 
homing during embryogenesis, inflammation, angiogenesis, wound healing, tumour cell 
invasion and metastasis (Vassalli et al, 1991) and have been identified as markers of 
melanoma progression (de Vries et al, 1994; Delbaldo et al, 1994). uPA bound to the 
uPAR is a key step in the migration of tumour cells (Bruckner et al, 1992) and monocytes 
(Kirchheimer et al, 1989b), and can be correlated with the invasive capacity of the tumour 
cell (Will et al, 1994). Both uPA and its receptor are expressed at focal cell-cell or cell- 
substrate adhesion sites, and in cultured keratinocytes, uPA colocalises with E-cadherin 
(Jensen and Wheelock, 1992). In migrating cells, uPAR is concentrated at the ruffled 
edge of cells and in the proximity of focal adhesion sites. The uPAR is found to associate 
with the (32 integrin family of adhesion molecules (Bohuslav et al, 1995) and also with the 
a v(33 integrin which colocalises with the uPAR in cultured glioblastomas (Gladson et al,
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1995) and in metastatic melanoma cells (Nip et al, 1995). Unoccupied uPAR can also 
function as an adhesion molecule for vitronectin (Waltz and Chapman, 1994) suggesting a 
role for this receptor in adhesive processes as well as invasion. The regulation of uPAR 
synthesis is thought to involve PKC which has been implicated in post adhesion, integrin- 
mediated signalling and the inhibition of PKC was shown to block cell spreading as well 
as the phosphorylation of focal adhesion kinase, ppl25FAK (Shattil et al, 1994).
The importance of the uPAR in metastasis can be demonstrated by blocking this receptor 
with anti-uPAR antibody which abolishes cell surface plasminogen activation (Ronne et 
al, 1991) making cells less invasive in matrigel (Mohanam et al, 1993). Pro-uPA can 
compete with the soluble form of uPAR thereby preventing pro-uPA from binding to its 
receptor which can also inhibit invasion (Wilhelm et al, 1994).
Tissue type plasminogen activator
The gene for tPA is located on chromosome 8 and consists of 14 exons encoding a 70kDa 
protein. tPA acts as the major circulating activator which binds to and is activated by 
fibrin. tPA plays a role in fibrinolysis and long term memory (Qian et al, 1993) and can 
activate plasminogen in the adult brain (Sappino et al, 1993). Levels of this PA can be 
induced by matrix fragments as demonstrated by Stack et al, (1993) who showed a 10-fold 
increase of tPA activity in conditioned medium of B16F10 cells incubated with laminin A 
fragments. Expression of tPA is thought to play a less dominant role in metastasis than 
uPA as t-PA levels are almost undetectable in many human tumours. However, the 
exception appears to be melanoma cells which have been shown to express higher levels 
of tPA than most other tumour cell types, and are therefore often the source for large scale 
purification of tPA (Collen et al, 1982). High production of tPA by tumour cell lines is 
apparently unique for melanoma and neuroblastoma cell lines (Vaheri et al, 1994) and this 
appears to be typical for neural crest-derived cells. In vitro primary cultures of melanocytes 
also produce tPA (Hashimoto et al, 1986), but despite this finding, no tPA has been detected 
from melanocytes either single or grouped as naevi in normal skin.
The expression of tPA from melanoma cells has been correlated with the ability of these 
tumour cells to invade a reconstituted matrix and degrade the ECM (Meissauer et al, 1992) 
and the use of anti-tPA antibodies inhibits migration of the tumour cells through a 
keratinocyte layer (Meissauer et al, 1991). Invasion of the mouse melanoma cell line, M2
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can also be reduced by addition of tPA antibodies to the upper chamber of a Boyden 
chamber assay (Reich et al, 1988) whereas, in contrast, Mignatti et al, (1986) showed 
there was no inhibitory effect of anti-tPA antibodies on invasion of B16 cells. Xenografts 
of non-uP A producing non-metastatic melanoma cells contained approx 8 times more tP A 
than xenografts of moderately metastatic cells (Quax et al, 1991) supporting the lack of a 
role for tPA in metastasis. In contrast, uveal lesions of melanoma with a poor prognosis 
produce higher levels of tPA (De Vries et al, 1995) and tPA transfected melanoma cells 
injected into the eyes of mice give rise to a higher frequency of metastasis (Alizadeh et al, 
1995) which can be inhibited by anti-tPA antibodies.
Plasminogen activator inhibitors
Several plasminogen activator inhibitors exist namely, PAI-1, PAI-2, protease nexin 1 
and PAI-3 (Kruithof EK, 1988) which belong to the group of serpins (serine protease 
inhibitors). In nude mouse xenografts of PAI-1 positive melanoma cells and in human 
melanomas, the tumour cells make the mRNA for PAI-1 but protein is deposited in the 
ECM and can associate with vitronectin in the ECM (Seiffert et al, 1990; Hagege et al, 
1992). Both PAI-1 and PAI-2 are capable of inhibiting tPA and uPA but do not bind to pro 
uPA (Andreasen et al, 1986). The complex of uPA/PAI-1 is recognised by the LDL receptor- 
related protein, LRP (also known as a2 macroglobulin receptor) and can be internalised 
via a clathrin coat pit mechanism. Following PAI-1 binding, the uPAR:uPA:PAI forms a 
complex with the 515kDa chain of LRP. uPA:PAI-l are targeted to the lysosomes for 
eventual degradation and the uPAR and LRP are recycled and redistributed at new focal 
adhesion sites on the cell surface (Herz et al, 1992). Unlike PAI-1, PAI-2 is not secreted 
into the extracellular matrix and is localised mainly in the cytoplasm (Berlin et al, 1989). 
It would be expected that high levels of PAI-1 would be beneficial by inactivating uPA. 
However, in breast cancers, high levels of PAI-1 are associated with worse prognosis 
(Grondahl-Hansen et al, 1993) and expression of PAI-1 correlates with metastatic capability 
in nude mice (Quax et al, 1991). In contrast, melanoma cells transfected with PAI-2 give 
rise to significantly less metastasis in nude mice and in vitro, PAI-1 or 2 effectively inhibits 
matrix degradation (Reiter et al, 1993).
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1.5. Tumour cell evasion of the immune system
During metastasis, the tumour cells have to evade immunosurveillance by cells of the 
immune system. The immune system comprises of various subsets of lymphocytes, often 
referred to as effector cells, where specific cell types have the ability to lyse target tumour 
cells. B and T lymphocytes are the principle mediators of an effective immune response 
and are under the control of dendritic cells (reviewed in Banchereau and Steinman, 1998). 
Dendritic cells are located in most tissues and capture and process antigens then display 
them in their major histocompatibility complex (MHC) molecules. They then migrate to 
the lymphoid organs where they can activate T lymphocytes which in turn, induces B cell 
growth and antibody production directed towards specific antigens. T lymphocytes express 
receptors (TcR) which recognise processed antigen in the context of MHC on the surface 
of antigen-presenting cells, and cytotoxic T cells and helper T cells recognise MHC class 
I and class II molecules respectively.
In tumour immunosurveillance, several cell surface molecules play a pivitol role in the 
recognition and binding of the tumour cells to lymphocytes, and these include MHC class 
1 and ICAM-1.
1.5.1. Major histocompatibility complex class-1
MHC class-1 molecules, also known in humans as human leucocyte antigen ABC (HLA- 
ABC), are cell surface polypeptide structures which have short hydrophobic segments 
spanning the membrane. The complex consists of 2 chains, namely the a  (or heavy) chain 
which is approximately 44kDa, and the P chain (12kDa). The principle function of the 
HLA-ABC molecule is to bind fragments of foreign proteins which can be presented and 
recognised by the lymphocytic cells. A subpopulation of lymphocytes termed natural 
killer cells (NK cells) express inhibitory receptors which recognise the presence of the 
HLA-ABC complex, and in doing so, inhibit lysis of the tumour cell (Kaufman et al, 1995; 
Litwin et al, 1994). In malignant transformation, HLA-ABC levels are often reduced 
therefore, the NK cells do not receive the signals and target cell lysis occurs (Mingari et al, 
1997). T cells also express these inhibitory receptors which can block the T-cell mediated 
activation of cytotoxic T lymphocytes. As well as the role of the MHC class 1 complex in 
tumour cell lysis, the molecular mechanisms behind this lytic process require the binding
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of tumour cells to the effector cells, and ICAM-1 expression is critical for this interaction.
1.5.2, Intercellular adhesion molecule-1
The transmembrane glycoprotein, ICAM-1 (CD54) is a member of the immunoglobulin 
superfamily (Staunton et al, 1988) whose basic function is the induction of specific and 
reversible cell-cell adhesion. Other members of this group include ICAM-2, ICAM-3 
(CD45), neural cell adhesion molecule (NCAM), vascular cell adhesion molecule (VCAM) 
and platelet endothelial adhesion molecule (PECAM).
1C AM  Receptors
All 3 ICAM members bind to 2 integrin receptors namely leucocyte function associated 
receptor (LFA-1; CDlla/CD18) (Marlin and Springer, 1987; Binnerts et al, 1994) and 
Mac-1 (CD 11 b/CD 18) (Diamond et al, 1990) which both belong to the 02 integrin subfamily 
and are expressed by leucocytes (Springer TA, 1990). ICAM-1 exhibits the highest and 
ICAM-3 the lowest affinity for LFA-1. Both LFA-1 and Mac-1 require activation to 
expose a high affinity ICAM-1 binding epitope which is dependent on the presence of 
divalent cations. This results in signalling pathways involving activation of PKC and 
increases in intracellular calcium concentrations, and is inhibited by rises in the levels of 
cAMP. Only a small population of Mac-1 binds effectively to ICAM-1 (Diamond et al,
1991), but the structure of ICAM-1 probably allows both LFA-1 and Mac-1 to bind to 
ICAM-1 simultaneously (Staunton et al, 1988). Activation of LFA-1 by binding to ICAM- 
3 on leucocytes can enhance the avidity of LFA-1 for ICAM-1 which is possibly mediated 
by the phosphorylation of the 0 chain of LFA-1 resulting in a conformational change in 
the molecule. Although LFA-1 is probably the most important ligand for ICAM-1 in vivo 
since it is highly conserved between species, other less well characterised receptors for 
ICAMs exist. One such receptor is sialophorin (CD43), which is abundantly expressed by 
leucocytes and platelets (Rosenstein et al, 1991), although its role in adhesion is unclear. 
ICAM-1 also serves as a receptor for soluble fibrinogen and hyaluronan (Languino et al, 
1993; McCourt et al, 1994). The binding of soluble fibrinogen requires the clustering of 
ICAM-1 as has previously been demonstrated to occur on endothelial cell projections
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(Stolpe et al, 1993) and also requires the presence of divalent cations. Human ICAM-1 
also serves as a receptor for the major group of rhinoviruses (Greve et al, 1989) and an 
additional epitope within the first domain of human ICAM-1 has been characterised as the 
binding site for Plasmodium falciparum-infected erythrocytes.
ICAM Gene and Protein
The human ICAM-1 and ICAM-3 genes map very close together on chromosome 19p 13.2- 
13.3 (Bossy et al, 1994) whereas the human ICAM-2 gene maps to chromosome 17q23-25 
(Sansom et al, 1991). The human ICAM-1 gene consists of seven exons separated by six 
introns which encodes 5 Ig-like domains, as is similar for ICAM-3 (Fawcett et al, 1992), 
whereas, ICAM-2 has only 2 Ig-like domains (Staunton et al, 1989). Each of the 5 Ig-like 
domains is encoded by a separate exon (Voraberger et al, 1991). Human ICAM-1 cDNA 
appears to have a limited homology (55-65%) with that of murine, rat and canine cDNA. 
The ICAM-1 protein comprises of a total of 505 amino acids and 453 of these amino acids, 
most of which are predominantly hydrophobic, form the Ig-like domains. The hydrophobic 
transmembrane domain is made up of 24 residues and the other 28 amino acids form the 
charged cytoplasmic tail (Staunton et al, 1988).
The extracellular part of ICAM forms a hinged rod with length of approx 19nm and width 
2-3nm suggesting the possibility of end to end alignments of the Ig domains (Staunton et 
al, 1990; Giranda et al, 1990). Free cysteine residues are located close to the membrane 
which may allow formation of intermolecular disulphide bonds suggesting the possibility 
of dimer formation (Staunton et al, 1988). The amino terminal first Ig-like domain of 
ICAM-1 is responsible for binding to LFA-1 (Staunton et al, 1990) whereas on LFA-1, the 
ICAM-1 binding site is located on domains 5 and 6 of the CD1 la  subunit (Stanley et al, 
1994). The ICAM-1 protein does not contain a calcium-binding RGD sequence suggesting 
its conformation is not dependent on the presence of calcium, unlike the usual ligands for 
receptors of the integrin family (Staunton et al, 1990).
Glycosylation o f  ICAM-1
The molecular weight of ICAM-1 varies and is dependent on the differential glycosylation 
state of the molecule, which is in turn, dependent on the cell type giving rise to molecular
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weights between 80 and 114kDa (Rothlein et al, 1986). Deglycosylation of the molecule 
can also occur and results in a protein of 60 kDa (Dustin et al, 1986). Glycosylation may 
act as a mechanism of affinity regulation as N-linked glycosylation has been reported to 
reduce affinity of ICAM-1 for Mac-1 whereas, in contrast, glycosylation seems to have no 
effect on binding of LFA-1, rhinovirus or malaria-infected erythrocytes. Differences in 
the actual activity of glycosylation enzymes adds further to the cell specificity of ICAM- 
1 protein expression.
Cytoskeletal association and signalling role o f the ICAMs
Association of ICAM-1 with the cytoskeleton may induce changes in ICAM-1 conformation 
and ligand affinity. ICAM-1 is distributed in the membrane in a polarised fashion and can 
associate and colocalise with oc-actinin (a cytoskeleton binding protein) (Carpen et al, 
1992). The cytoplasmic tails are the most divergent regions of the molecules suggesting 
that the ICAMs might have evolved to develop different signalling or cytoskeletal roles. 
No evidence exists for proteins interacting with the cytoplasmic tail of ICAM-2. However 
there does appear to be a role for ICAM-3 in a number of signalling events. ICAM-3 has 
been shown to transduce signals into the cell and to induce changes in intracellular calcium 
levels and tyrosine phosphorylation and can also signal to LFA-1 to upregulate binding to 
ICAM-1 (Hernandez et al, 1993). Signalling via ICAM-1 is also thought to occur as 
cross-linking of ICAM-1 with antibodies leads to the inhibition of IFNy, TNFa and IL-1 
from lymphocytes. In brain endothelial cells, activation of the kinase pp60src occurs 
during ICAM-1 cross-linking and is associated with phophorylation of target proteins 
including the cytoskeletal binding protein, cortactin.
Regulation o f  ICAM-1
ICAM-1 is expressed in a wide variety of cell types including endothelial, epithelial, 
macrophages, fibroblast-like cells and dendritic cells in the human thymus, lymph nodes, 
intestine, skin, kidney and liver. In hemopoietic cells, ICAM-1 is also expressed on bone 
marrow progenitors and on cells of the lymphoid and myeloid lineage. The expression of 
ICAM-1 is regulated predominantly at the transcription level where Northern blot analysis 
reveals the presence of 2 transcripts, although their significance is unclear as they do not
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give rise to 2 different proteins, nor are they the result of alternative splicing or differential 
usage of transcription initiation sites (Voraberger et al, 1991; Staunton et al 1988). 
Expression of ICAM-1 can be induced or up regulated by cytokines such as TNFa, IFNy, 
IL-1 and IL-6, whereas the glucocorticoids (Stolpe et al, 1993) act as inhibitory agents of 
ICAM-1 expression. The 51 region flanking the human ICAM-1 gene contains 3 
transcription initiation sites (Degitz et al, 1991) which may be used differentially depending 
on cell type and stimulus (Voraberger et al, 1991). IL-6 and IFNy (Caldenhoven et al, 
1994; Jahnke and Johnson, 1994) regulate ICAM-1 transcription through a shared 
palindromic sequence designed pIRE. Both IL-6 and IFNy induce binding of the same 
transcription factor, probably related to the p91 signal transducer and activator of 
transcription 1 (STAT 1 or INFy activating factor), while in addition, IL6 induces binding 
of signal transducer and activator of transcription 3 (STAT-3). The kB enhancer in the 
ICAM promoter conveys responsiveness to TNFa, IL-1 and lipopolysaccharide (Ledebur 
and Parks, 1995). This enhancer binds a complex of transcription factors of RelA or Rel 
A/c-Rel in addition to the nuclear factor (NF) kB transcription factor (NFicBl-RelA) (Parry 
and Mackman, 1994). The glucocorticoid receptor physically interacts specifically with 
the RelA subunit of the NFkB complex causing inactivation of the transcription factor 
(Caldenhoven et al, 1995).
The first intron of ICAM-1 has other putative enhancer elements which include 2 KB-like 
elements and an Spl sequence. Spl sites probably regulate constitutive ICAM-1 
transcription as elimination of the Spl site results in a drop in basal promoter activity. 
The AP-1 proteins, jun and fos act synergistically withNFicB to transactivate a kB enhancer 
element or an AP-1 site (Stein et al, 1993) to modulate ICAM-1 transcription. The AP-2- 
like site in the ICAM-1 promoter has been shown to mediate the UVA but not UVB 
effects on ICAM-1 transcription (Grether-Beck et al, 1995).
Although transcriptional regulation of ICAM-1 accounts for most regulatory effects of 
ICAM-1, IFNy may also upregulate ICAM-1 expression by stabilising mRNA. The 3' 
untranslated region of ICAM-1 mRNA contains multiple destabilising AUUUA sequences 
which act as targets for the mRNA stabilising agents (Ohh et al, 1994).
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In Vivo Mouse Model o f  ICAM-1
The importance of ICAM-1 in vivo has been demonstrated using mice which have an 
inactivated gene for ICAM-1 (by homologous recombination in embryonal stem cells). 
The animals develop normally and are viable. However, blood neutrophil counts are 
increased (Xu et al, 1994) and activation and migration of leukocytes to places of 
inflammation is reduced (Sligh et al, 1993). The absence of ICAM-1 seems to protect 
mice from lethal septic shock induced by bacterial LPS by reducing leukocyte-endothelial 
cell interactions (Xu et al, 1994).
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1.5.3. Soluble intercellular adhesion molecule-1
One possible mechanism as to how tumour cells evade immunosurveillance by lymphocytes 
is through the release of a soluble form of ICAM-1 (sICAM-1) which may exist as a 
multimeric form or complexed with other proteins due to the existence of various isoforms 
(240,430, and >500kDa) (Seth et al, 1991). sICAM-1 is of lower molecular mass (80kDa) 
(Rothlein et al, 1991) than membrane ICAM-1 (90kDa) (Marlin and Springer, 1987) and 
is similar to recombinant sICAM-1 comprising of the extracellular part of ICAM-1. 
Glycosylation of sICAM-1 can occur, which is cell type-specific and may also contribute 
to variations in molecular weight. Mononuclear cells, endothelial cells, keratinocytes, 
hepatocytes and melanoma cells are sources of sICAM-1 which is also present in plasma, 
cerebrospinal fluid and sputum. The expression of sICAM-1, like mICAM-1, is also 
regulated by IL-1, TNFa , IFNy which have been shown to induce increased shedding of 
sICAM from melanoma cells (Becker et al, 1991), yet IL-6 which alters mICAM-1 
expression, is unable to induce this shedding. Serum levels of sICAM-1 have been reported 
to increase in various disease states (Banks et al, 1993) which include human malignant 
melanoma (Haming et al, 1991), but the biological consequences of such increases remains 
controversial. Serum levels are also increased in patients with leucocyte adhesion deficiency 
who lack the p2 integrin chain of LFA-1 (Rothlein et al, 1991) due either to increased 
ICAM expression associated with chronic infection or to the absence of functional LFA-1 
and Mac-1 molecules to bind sICAM. Expression is also elevated in patients with renal 
failure, non-Hodgkin lymphoma, ovarian and breast carcinoma, gastrointestinal tumours, 
renal and bladder carcinoma. It is possible that binding of sICAM-1 to the LFA-1 receptor 
could prevent the lymphocyte from interacting with mICAM-1 and thus prevent tumour 
cell lysis occurring. This is supported by reports from various groups (Altomonte et al, 
1993; Becker et al, 1992) but which is in contrast to the recent data from Young et al 
(1997) who reported on the inability of sICAM-1 to affect tumour cell lysis. Monomeric 
sICAM containing only the first 2 N-terminal domains is able to bind malarial-infected 
erythrocytes, and sICAM-1 also inhibits cellular infection by a major group rhinovirus 
(HRV54) and coxsackie A13 virus (Crump et al, 1993; Marlin et al, 1990) which both use 
ICAM-1 as their membrane receptor. sICAM-1 has also been reported to inhibit adhesion 
of monocytic cells to purified ICAM-1 (Welder et al, 1993).
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1.6. Why study melanoma?
Melanoma is one of the most aggressive cancers known and in the UK, is the 4th most 
common cancer in women and the seventh commonest in men in the 15-35 age group. 
Melanocytes originating from neural crest cells located within the basal layer of the 
epidermis closely interact with surrounding basal keratinocytes to form a functional structure 
defined as the epidermal-melanin unit. Melanocytes protect keratinocytes against UV 
damage through the synthesis of melanin pigment and the transfer of melanosomes to 
adjacent basal keratinocytes by long dendritic processes. Melanoma is derived from these 
melanocytes, and sun exposure which induces irreversible DNA damage, is the major 
causal factor for skin cancer.
The incidence of cutaneous melanoma has steadily increased worldwide with an increase 
from 3.5 to 7.8 cases per 100 000 per year in men and from 6.8 to 12.3 per 100 000 per year 
in women during the period of 1979-1994. In 1979, deaths occurring due to cutaneous 
malignant melanoma rose in men from 1.3 per million per annum to 2.3 per million per 
annum by 1994. The figures for women show that in 1979,2.4 deaths occurred per million 
per annum which fell to 1.9 million per annum in 1994 (MacKie et al, 1997). Survival 
rates depend on the depth of invasion of the primary tumour and subsequent involvement 
of regional and distant lymph nodes and the overall 5 year melanoma-free survival rate in 
men is currently 69% and 82% in women (MacKie et al, 1997). Non-invasive, benign 
lesions are limited to the epidermis with progression occurring to the papillary dermis 
followed by invasion of the adjacent reticular dermis and subcutaneous fat cells. The 
spread of melanoma cells into the bloodstream can be detected at very early stages of the 
disease (Brossart et al, 1993) and high mortality rates occur due to the widespread metastasis 
of melanoma to sites including the liver, lungs, bone, brain, adrenal glands and heart (Herlyn 
M, 1990; Clark etal, 1986).
Surgical excision of localised melanoma lesions generally results in a high cure rate (Morton 
et al, 1993) but no curative therapy is currently available for advanced melanomas. 
Therefore, it is important to gain a better understanding of melanoma metastasis to allow 
further insight into the basics of tumour biology which may lead to the development of 
more effective therapies.
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1.7. The use of retinoic acid and pentoxifylline in tumour biology
Two drugs which have been exploited for their potential use as anti-tumour agents are the 
vitamin A metabolite, retinoic acid (RA), and the phosphodiesterase inhibitor pentoxifylline 
(PX). RA has reached clinical trials having been used as a therapeutic agent to delay, 
reverse or block cancer development (Greenwald et al, 1995, Karie et al, 1994) and is 
known to have the ability to modulate various steps of metastasis including inhibiting 
cancer cell proliferation (Houle et al, 1991) and enhancing apoptosis (Lotan R, 1995). On 
the otherhand, PX has been shown to enhance chemotherapeutic drugs, improving the 
cytotoxic effects of alkylating agents in vitro and in vivo (Boike et al, 1990; Tanaka et al, 
1991; Teicher et al, 1991) and can significantly enhance cisplatin-induced cytotoxicity 
directed against human ovarian and cervical cancer cell lines (Boike et al, 1990).
The following two sections give a general overview of either drug explaining their possible 
mechanisms of action and their effects on a range of biological processes.
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1.8. Introduction to retinoic acid
Structure o f  Retinoic Acid
Retinoic acid (RA) belongs to the family of molecules termed the retinoids which are 
biologically active and synthetic derivatives of vitamin A. RA is a yellow crystalline 
polyene carboxylic acid produced from the metabolic oxidation of vit A and is systematically 
known as 3 ,7-dimethyl-9-(2,6,6, -trimethyl-l-cyclohexen-l-yl)-l, 4,6, 8-nonatetraenoic 
acid. This hydrophobic molecule is insoluble in water and its biological activity can be 
modified by cis or trans isomerisation to produce 9-cis or all-trans RA. There is evidence 
that the interconversion of all-trans and 9-cis RA occurs in mammalian cell lines in vitro 
(Heyman et al, 1992; Allegretto et al, 1993) and all-trans RA can also undergo isomerisation 
to 13-cis RA (isotretinoin).
Vitamin A Deficiency
Reports dated as far back as 1925 show that vitamin A-deficient animals develop a wide 
range of abnormalities such as squamous metaplasia in the epithelia of the eye, nasal 
passage and the respiratory tract (Wolbach and Howe, 1925). Epidemiological studies in 
humans indicate individuals with a lower dietary vitamin A intake are at a higher risk of 
developing cancer (Hong et al, 1995).
Since then, it has been shown the retinoids, in particular RA, are essential for growth, 
differentiation, formation of the nervous system, limb morphogenesis (Goodman DS, 1984), 
spermatogenesis (Skinner MR, 1991) and the immune system (Smith et al, 1987, Buck et 
al, 1990).
Vitamin A metabolism
The main source of vit A are dietary, derived from provitamin A carotenoids from vegetables 
(eg (3-carotene) or fatty acid retinyl esters (R-FA) from animal sources or dietary 
supplements (Olson JA, 1989). p-carotene can either be absorbed intact or cleaved in the 
intestinal tract to form two molecules of retinaldehyde. Subsequently, retinaldehyde is 
reduced by an aldehyde reductase to retinol.
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R-FA is hydrolysed in the intestinal lumen to free retinol which is absorbed by enterocytes 
of the gut (Blomhoff et al, 1992). Serum retinol binding protein (RBP) stored and 
synthesised in the liver (Blaner WS, 1989) acts as a transport system for retinol from the 
liver to other tissues. Retinol uptake by cells is mediated by membrane receptors for RBP 
(Bavik et al, 1992) but the molecular mechanisms are not clear. In blood plasma, it is 
found associated with transthyretin (TTR), a 55kDa protein. When plasma RBP levels 
decrease, plasma retinol is also decreased (Bemi and Formelli, 1992).
Cellular Retinoic Acid Binding Proteins
The intracellular concentration and types of RA metabolites entering the cell appear to be 
regulated by 4 retinoid-binding proteins, namely cellular retinol binding proteins I and II 
(CRBP I, II) and the cellular retinoic acid binding proteins (CRABP I, II).
The dietary retinol in the enterocytes is bound by a cellular retinol binding protein (CRBP 
II), esterified to R-FA by lecithinrretinol acyltransferase (LRAT), and incorporated into 
lipoprotein particles (also called chylomicrons). In hepatic parenchymal cells, the free 
retinol interacts with CRBP I (Ross A, 1993) and can either be transferred to newly 
syntheisied RBP for secretion or transferred to neighbouring hepatic stellate cells for 
esterification and storage in conditions of dietary sufficiency. The rate of retinol uptake 
from serum RBP decreases in Sertoli cells when available CRBP sites have been occupied 
(Shingleton et al, 1989). CRBP II, unlike the widely distributed CRBP I is restricted to the 
small intestine (Chytil and Ong, 1987). CRBP I has been postulated to capture retinol 
which when bound, serve as substrate for a specific NADP-dependent dehydrogenase and 
a cytosolic retinal dehydrogenase leading to all-trans RA synthesis (Posch et al, 1992; 
Napoli et al, 1995).
CRABP 1 can function as a carrier for the catabolism of all-trans RA to more polar 
metabolites in vitro (Fiorella and Napoli, 1991). Overexpressing CRABP I in the RA- 
responsive F9 teratocarcinoma cells alters amounts and types of all-trans RA metabolites 
and reduces the half life of RA (Boylan and Gudas, 1992) resulting in a reduction of 
expression of RA-responsive genes (Boylan and Gudas, 1991). Embryonic tissues 
expressing CRABP I are most sensitive to the teratogenic action of RA (Ruberte et al,
1992).
CRABP II is induced by RA (Astrom et al, 1991) and binds all-trans RA (Fiorella and
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Napoli, 1991) suggesting it prevents RA from becoming excessive and causing a teratogenic 
effect (Maden et al, 1988; Giguere V, 1994). CRABPs may also sequester all-trans RA in 
the cytoplasm and prevent the retinoids from reaching nuclear receptors. Neither CRABP 
1 nor CRABP II bind 9-cis RA (Fogh et al, 1993) suggesting the existence of a distinct 
metabolic pathway for 9-cis retinoids which is independent of CRBPs or may involve a 
distinct family of binding proteins. Availability of active retinoids or their precursors is 
dependent also on the cellular ratios of CRBP and CRABP (Gustafson et al, 1993).
It is unclear how cells which may lack CRBPs would be protected from toxic levels of 
retinol as CRBP levels have been found not to be the major determinants of retinol uptake 
and esterification in squamous carcinoma cell lines (Wahlberg et al, 1989).
CRABP Null Mice
Mice homozygous for a null mutation of CRABP I gene are phenotypically normal, and 
double mutant mice for CRABP I and CRABP II are also normal (Lampron et al, 1995). 
This indicates that either CRABP I and II do not play crucial roles in retinoid function 
(Gorry et al, 1994) or alternatively, the possibility of redundancy with other proteins may 
exist.
1.8.1. Retinoid mechanisms of action
The retinoids exert their effects through nuclear receptors belonging to the superfamily of 
nuclear ligand activated transcriptional regulators, which includes the thyroid hormone 
receptor (TR) and the vitamin D3 receptor (VDR). The retinoids interact with 2 classes of 
receptor, namely the retinoic acid receptor (RAR) which binds all-trans and 9-cis RA and 
the retinoid receptor (RXR) which binds only 9-cis RA (Heyman et al, 1992), although 9- 
cis RA has a higher affinity for RARs than RXRs (Kersten et al, 1996). Each subclass of 
receptor can be divided into 3 subtypes namely alpha (a) (Petkovich et al, 1987; Giguere 
etal, 1987;Mangelsdorfetal, 1990),beta (p) (Brand etal, 1988; Leidetal, 1992; Benbrook 
et al, 1988) and gamma (y) (Krust et al, 1989). Focusing on the RARs, there are 3 major 
isoforms of a , seven of the y subtype, and 4 major isoforms of the p subtype (Dolle et al,
1990).
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In humans, each subtype is encoded by a distinct gene where RARa is mapped to 
chromosome 17q21.1; RARp to chromosome 3p24 and RARy to chromosome 12ql3 
(Mattei et al, 1991). The RXRa subtype in humans maps to 9q34.3; RXRp to 6p21.3 
whereas RXRy maps to chromosome Iq22-q23 (Almasan et al, 1994).
Structure o f  the receptors
Both the RARs and the RXRs have conserved structures and their amino acid sequence 
can be divided into 6 regions termed A-F based upon homology among themselves and 
with other members of the nuclear receptor superfamily (Leid et al, 1992).
NH,— A/B C D E F2 COOH
Figure 2. Retinoic acid receptor structure
Regions A/B encode transcriptional activation function (AF-1) which modulates target 
gene transcription and does not require ligand for its activity. The AF-ls show cell-type 
specificity (Folkers et al, 1993) which suggests they do not interact directly with the basic 
transcriptional machinery but provide intermediary contacts with cell-type specific proteins. 
The isoforms for each receptor subtype differ from each other in their A region and these 
subtypes arise due to alternative splicing and differential usage of 2 promoters, one of 
which is RA-inducible (Leroy et al, 1992). Transcriptional activity can be enhanced via 
the phosphorylation of serine residues in the amino terminal domain of the RARs 
(Huggenvik et al, 1993) and is common for RARy (Rochette-Egly et al, 1991). Region C 
marks the DNA-binding domain which regulates target gene expression by recognising 
specific sites on the target DNA. This region is highly conserved between all 3 RAR 
subtypes (94-97%). Region D acts as a hinge region between regions C and E, and region 
E itself contains the ligand-binding domain, the ligand-dependent transcriptional activation 
function (AF-2) (Nagpal et al, 1993) and the receptor dimerisation surface. RXR AF-2s 
are unmasked or activated in the presence of 9-cis RA and RAR AF-2s are activated in the 
presence of 9-cis RA or all-trans RA (Nagpal et al, 1993). Thus binding of the hormone
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induces a conformational change that allows the appearance of an activation domain at the 
surface of the protein. The AF-1 s of the A/B domain show weak activation properties by 
themselves but can strongly synergise with their corresponding AF-2 (Nagpal et al, 1993). 
The function of the F region remains unknown.
Interaction o f  the receptors with target genes
The receptors act as ligand-dependent transcription factors which bind to specific sites on 
the DNA termed the retinoic acid response elements (RARE) (Naar et al, 1991). The 
RARE sequences are characterised by direct repeats (DR) of (A/G)GGTCA separated by 
2 or 5 (DR2 or DR5) nucleotides (Umesono et al, 1991). The RAR and RXR form 
heterodimeric complexes with one another which bind to the RARE (de The et al, 1990). 
RXRs can also function on their own in the presence of specific ligands and form 
homodimers (Zhang et al, 1992a) and can act as coreceptors for thyroid hormone receptors 
(TRs), vitamin D receptors (VDRs) and other receptors (Yu et al, 1991; Zhang et al, 1992b; 
Kliewer et al, 1992). The autoinduction of RAR expression occurs due to the existence of 
RARE sequences in the promoter regions of RARa2, (32 and y2 which can be upregulated 
by RA (Maden et al, 1988, Giguere et al, 1994). This allows for the autoinduction of the 
RARs which gives the potential for amplification of the retinoid signal. The expression of 
RARa and RARy is less sensitive to RA and inducible by only high levels of the ligand, 
nevertheless, both RARa and y promoters contain similar RAREs (Lehmann et al, 1992; 
Leroy et al, 1991). However, the RARa RARE has a lower affinity for RARs than the 
RAR|3 RARE (Leroy et al, 1991) hence the difference in sensitivity towards RA.
The retinoid receptors can regulate transcription without binding to specific DNA sequences 
but by interaction with other transcription factors (Yang Yen et al, 1991; Schule et al,
1991). The retinoid receptors interact with nuclear proteins that function as repressors or 
coactivators. Binding of ligand causes a conformational change of the receptor thereby 
altering the interaction of the receptor with other nuclear proteins. In one scenario, binding 
of RA to RAR induces dissociation of a repressor and allows association of a coactivator 
resulting in transactivation of the target gene (von Bauer et al, 1996). In another scenario, 
binding of RA leads to binding of a repressor to the receptor resulting in the repression of 
transcription of the target gene (Chen and Evans, 1995). Transcriptional repression may 
involve the formation of inactive heterodimers which compete for DNA binding sites.
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Another mechanism is the direct inhibition of gene transcription, termed silencing. RARa 
exhibits silencer activity (Baniahmad et al, 1992) however, the repression effect is cell- 
type specific where in certain cells, RARa may show repressor activities but may also act 
as a weak activator in other cell types.
Unique functions o f  each receptor subtype and isoforms
It had been suggested that each RAR subtype and isoform may perform unique functions 
due to the observation of distinct spatiotemporal expression patterns for RAR (and RXR) 
transcripts in the developing embryo and various adult tissue. A tissue-specific 
physiological role has been identified for RARa in spermatogenesis (Lufkin et al, 1993) 
whereas RARy is linked to major functions in the skin (Lohnes et al, 1993). Evidence 
exists to support the idea that RAR subtypes perform unique fimction(s) in cancers, such 
as some human squamous cancer cell lines (Hu et al, 1991), and in many human lung 
carcinoma cell lines (Gebert et al, 1991, Houle et al, 1991). In these cancerous cells, 
RARa and y are often expressed constituitvely but RARp is suppressed. The normal 
counterparts of these cells express RARP suggesting selective suppression of RARp is 
related to the process of malignant transformation in epithelial cells. Reduced expression 
of RARP has also been associated with head and neck cancer (Xu et al, 1994). A potential 
role for RARa and y during the development and/or progression of squamous cell 
carcinomas (SCC) has been suggested by Xu et al, (1996) whose study of SCC showed 
that 94% of the samples analysed had reduced expression of RARa and yin comparison to 
normal epidermis. Inhibition of breast cancer cells by retinoids selective for RARy has 
also been demonstrated (Fanjun et al, 1996), implicating a role for RARy in the growth 
inhibitory effect of the retinoids.
Specific isoforms of a receptor may also express unique functions as they appear to be 
regulated by tissue specific expression (Zelent et al, 1991; Leroy et al, 1991). RARP2 has 
been shown to have tumour suppressor activity in certain lung cancer cells (Berard et al,
1994) and is induced in many tissues by exogenous all-trans RA (de The et al, 1989; Lovat 
etal, 1993; Redfem etal, 1990; 1994; Viallet etal, 1991). In contrast, RARp4 is positively 
correlated with neoplasia in lung and breast tissue (Houle et al, 1993; Berard et al, 1994). 
The RARp4 isoform lacks all except 4 amino acids of the A domain (Nagpal et al, 1992) 
suggesting that this isoform could act as a dominant negative receptor able to bind to a 
RARE in a ligand-dependent manner but unable to activate transcription.
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Null Mice Models
The importance of the RAR in vivo can be shown experimentally using the null mouse 
model. In this system, mice deficient for either RA Ral (Li et al, 1993), RARp2 
(Mendelsohn et al, 1994) or RARy2 (Lohnes et al, 1993) were found to be phenotypically 
normal. RARp-null homozygotes were apparently viable and fertile (Luo et al, 1995) 
whereas RARa-null homozygotes displayed a limited range of defects consisting of early 
post-natal lethality and testis generation (Lufkin et al, 1993). RARy-nulls displayed growth 
deficiency, early lethality and male sterility due to squamous metaplasia of seminal vesicles 
and prostate (Lohnes et al, 1993). Many more abnormalities were observed in compound 
null mutants (RARal p2, a ly l etc) which died in utero or soon after birth. Mice had 
multiple eye, skeletal, neck, trunk and abdominal region abnormalities, similar to those 
observed in vitamin A deficiency syndrome (VAD) (Wilson, 1953). The data from these 
null mice suggests the possibility of functional redundancy existing between receptors, 
such that loss of one isoform may be rescued by a different isoform of the same subtype, 
and does not rule out the possibility of the existence of some other compensatory mechanism. 
Little work has been carried out on RXR null mice, however, research so far has shown 
RXRa homozygous null mice suffer from embryonic lethality with cardiac defects and 
liver malfunction (Sucov et al, 1994). These may result as a lack of RXR to form 
heterodimers with RAR which would interfere with retinoid-dependent pathways.
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1.9. Introduction to pentoxifylline fPXJ
PX as a Phosphodiesterase Inhibitor
PX [3, 7-dimethyl-l (5-oxohexyl)-xanthine], also known as oxpentifylline, is a 
methylxanthine derivative with properties similar to theobromine, caffeine and theophylline 
(Ward and Clissold, 1990).
Pentoxifylline is a specific inhibitor of cAMP-specific phosphodiesterases (Stefanovich 
V, 1974; Meskini et al, 1994) enhancing intracellular levels of cAMP. The increase in 
cAMP levels results in the activation of cAMP-dependent protein kinase A which can 
proceed to phosphorylate many target proteins. In mononuclear and polymorphonuclear 
cells, PX has been reported to induce a dose-dependent increase in cAMP expression 
(Bessler et al, 1986) thought to be due to this inhibition o f cAMP-dependent 
phosphodiesterase. PX has also been shown to inhibit lymphocyte activation involving a 
cAMP-dependent pathway that promotes downregulation of the immune response 
(Rosenthal et al, 1992).
In Vivo and In Vitro Effects o f PX
PX was initially marketed in the USA where it was found to have a protective effect 
against infections such as gram negative sepsis and meningitis (Ward and Clissford, 1990) 
and was originally introduced as a hemorrheologic agent for the treatment of peripheral 
vascular disease (Muller and Lehrach, 1981; Grigoleit and Jacobi, 1977). But in contrast 
to other methylxanthines, it has few cardiac effects (Maxwell GM, 1975). PX is usually 
administered through oral or intravenous routes and greater than 90% of absorbed PX is 
excreted in the urine in the form of six metabolic products.
PX has also been shown to alter red blood cell (rbc) physiology although the exact 
mechanisms are not well understood. It is thought to improve membrane deformability by
increasing the amount of membrane ATP (Porsche and Stefanovich, 1978) via the inhibition
2+
of ATPase which decreases the active intracellular transport of Ca . PX can also alter rbc
membrane protein phosphorylation patterns, increase protein kinase activity and decrease
2+ +
Ca -dependent K efflux (Seidler and Swislocki, 1992). As well as inducing micro vascular 
constriction, PX also stimulates fibrinolysis, decreases plasma fibrinogen levels, prevents 
rbc and platelet aggregation and increases leukocyte adhesion (Ely H, 1988; Sonkin et al,
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1992; Hammerschmidt et al, 1988).
PX also affects cytokine expression resulting in an inhibition of leucocyte stimulation by 
TNFa and IL-1, and can also suppress monocyte production of TNFa (Hakim et al, 1990).
Use o f PX  in Tumour Biology
With relation to cancer biology, Ambrus et al (1991) have reported on the ability of PX to 
inhibit tumour implant angiogenesis using human tumour implants in the cornea of rabbits 
and non-human primates. In contrast, Edward and Mackie (1991) observed PX-enhanced 
lung colonisation by B16 melanoma cells injected into syngeneic C57BL mice. PX-treated 
tumour cell GAG production was reduced by 36% and the charge density of chondroitin 
sulphate was diminished. Berman et al, (1990) has shown PX inhibits the amount of 
collagen, GAG and fibronectin production. Fibroblasts cultured in the presence of PX 
were shown to produce twice as much collagenase activity which may explain the decreased 
amounts of collagen (Berman et al, 1989). Schiano et al, (1991) showed that in vitro 
enhancement of cisplatin-induced cytotoxicity by PX was mediated by the inhibition of 
DNA repair during the S and G2 cell cycle phases. PX also enhances radiation damage in 
murine fibrosarcomas of mice, which Lee et al (1992) suggested was as a result of increased 
tumour oxygenation.
Hypothesis
Since the previous results from our laboratory, using the B16 murine melanoma cell line, 
demonstrated the ability of RA and PX to modulate experimental metastasis and adherence 
of the cells to ECM components, we hypothesised that either drug may also induce changes 
in the properties of human melanoma cell lines in vitro which could consequently alter 
metastasis of the human cells in vivo.
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1.10. Aims of the study
The overall aim of this project was to analyse the ability of RA and PX to modulate the 
following steps of human melanoma cell metastasis:
1) melanoma cell proliferation
2) adhesion of the tumour cells to various ECM components
3) tumour cell lysis by LAK cells
4) expression of plasminogen activator components
The human melanoma cell lines selected for this investigation were the poorly metastatic 
A375 and Hs294T cells and the highly metastatic C8161 cells. All three cell lines have 
previously been well characterised, are widely available, and have different metastatic 
potentials allowing cell parameters to be correlated with ability of the tumour cells to 
metastasise.
Retinoid and PX modulation o f  tumour cell proliferation and cell-ECM interactions 
This study began by analysing the ability of RA and PX to modulate tumour cell growth 
since numerous reports demonstrate the ability of RA to exert anti-proliferative effects on 
a variety of tumour cells, whilst Berman et al, (1990) reported on the inhibition of human 
fibroblast proliferation by PX.
A tumour cell's ability to metastasise can be correlated with adhesion to certain basement 
membrane and ECM components, therefore, if  RA or PX were to alter tumour cell 
adherence, this may ultimately affect tumour cell metastasis (Terranova et al, 1982; Chung 
et al, 1988). Both RA and PX have the ability to alter adhesion of cells to various 
components of the ECM. Kato and De Luca, (1987) demonstrated a RA-induced increase 
in adhesion of mouse fibroblasts to laminin and collagen type IV, whereas Santos et al, 
(1994) reported on the RA-induced increase in melanoma cell adhesion to vitronectin. In 
contrast, research from our own laboratory has shown B16 murine melanoma cell adhesion 
to laminin and collagen type IV was reduced with RA treatment (Edward et al, 1989) as 
was adhesion to vascular endothelial cells and subendothelial ECM (Edward et al, 1992). 
PX is known to prevent the TNF-a induced adherence of polymorphonuclear cells to 
vascular endothelium (Salyer et al, 1990), and can decrease IL-6-induced neutrophil
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adherence and aggregation. Gastpar et al (1974; 1977) have reported on the ability of PX 
to prevent adherence of tumour cells to capillary endothelial cells. Similarly, our laboratory 
has shown murine melanoma cell aggregation and adhesion to subendothelial ECM was 
increased with PX treatment which may have contributed to the observed PX-induced 
increase in lung tumour formation (Edward et al, 1992). In this section of the study, the 
ability of RA and PX to alter adhesion of the C8161 cells to fibronectin, collagens type I 
and type IV, laminin and basement membrane was examined with the potential of correlating 
any changes in adherence to modulation of the tumour cell adhesion molecule profile. 
The ability of the A375 cells to adhere to basement membrane matrigel was subsequently 
examined since adhesion of these cells to matrigel had previously been reported by Hendrix 
et al (1990), to be reduced on treatment with all-trans RA.
Retinoid and PX modulation o f tumour lysis
The effect of either drug on tumour cell adhesive properties was preceeded by an 
investigation into the effect of RA and PX on lysis of all three cell lines by both unactivated 
peripheral blood lymphocytes (PBL) and IL-2 activated lymphokine activated killer (LAK) 
cells. The effect of either drug treatment on mICAM-1 expression was subsequently 
examined followed by analysis of the role of mICAM-1 and MHC class 1 in the tumour/ 
LAK cell interaction. It has previously been suggested that RA may render many tumour 
cells more susceptible to attack by cytotoxic T lymphocytes (Smith et al, 1992), and as the 
promoter region of the gene for ICAM-1 contains a RARE (Aoudjit et al, 1994), this 
suggests RA has the ability to alter ICAM-1 expression (Cilenti et al, 1995) which may 
ultimately modulate tumour cell lysis.
Although the intracellular signalling pathways for ICAM-1 are not well understood, various 
reports suggest PX could modulate ICAM-1 expression which potentially could affect 
tumour cell lysis. A report by Panettiere et al (1995) suggested cAMP-dependent pathways 
might be involved in ICAM-1 signalling which may ultimately alter ICAM-1 expression. 
PX may also exert its effect through NFkB (Biswas et al, 1994) and the promoter region of 
the gene for ICAM-1 contains an NFkB site (Degitz et al, 1991; Voraberger et al, 1991) 
which would allow for the potential of PX to alter ICAM-1 expression. In support of this, 
PX has been demonstrated to inhibit the protein kinase A-catalysed activation of NFkB in 
human T-cells and human embryo kidney cells (Biswas et al, 1994) which in turn, could
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affect the expression of ICAM-1. Indeed, PX has been shown to reduce the expression of 
ICAM-1 by human epidermal Langerhans cells (de Fraissinett et al, 1990). With reference 
to MHC class 1 expression, PX has been reported to modulate MHC class 1 (Rosenthal et 
al, 1993). Therefore, the ability of this drug and also RA to alter expression of ICAM-1 
and MHC class 1 may consequently affect the interaction of the tumour cells with LAK 
cells.
The effect of RA and PX on sICAM-1 expression was also investigated using a specific 
ELISA detection system. Expression of sICAM-1 was measured from each of the cell 
lines with and without PX/RA treatment to examine first of all, whether any of the cell 
lines secreted sICAM-1, and to demonstrate a possible correlation between alterations in 
mICAM-1 and sICAM-1 expression with either drug. Since tumour cells are thought to 
secrete sICAM-1 as a possible means to evade immunosurveillance, the ability of sICAM- 
1 to interfere with Hs294T and C8161 cell lysis was also examined.
Retinoid and PX modulation o f lung colony formation and uPA/tPA expression 
In this section, the experimental metastasis model was used to show the effect of RA and 
PX on tumour lung colony formation. Gastpar H (1974; 1977) had previously shown that 
PX decreased pulmonary metastasis which was in contrast to our own laboratory which 
reported on the PX-induced enhancement (Edward and MacKie, 1991) and the RA-induced 
reduction of lung colonisation by B16 melanoma cells injected into syngeneic C57BL 
mice (Edward et al, 1992).
The effect of PX and RA on expression of uPA and tPA followed, where previous research 
has shown that uPA can be regulated by increases in cAMP levels suggesting PX could 
alter uPA expression. In contrast, RA has been shown to decrease uPA levels in prostate 
carcinoma cells (Waghray and Webber, 1995) yet increase tPA expression in endothelial 
cells (Kooistra et al, 1995). PX and its metabolites have also been shown to stimulate the 
release of tPA (Tranquille and Emeis, 1991; Klocking et al, 1987) yet decrease levels of 
the tPA inhibitors; a  1-antitrypsin, a2-antiplasmin, a2-macroglobulin (Di Perri et al, 1984).
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Analysis o f  retinoic acid receptor expression
The retinoid-induced alterations in studied stages of metastasis led to an interest in analysing 
the expression of the retinoic acid receptors in an attempt to gain a better molecular 
understanding of some of the data produced from previous sections. It was initially proposed 
to perform Northern blot analysis of the cell line RNA using probes specific for each 
receptor subtype. However, preliminary experiments raised doubts as to the identity of 
the probes, and due to time constraints, it was decided instead, to use the polymerase chain 
reaction to amplify specific regions of the DNA encoding RARa, p and y, and to confirm 
the identity of the PCR products by Southern blotting, using probes specific for each 
receptor subtype.
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Chapter 2. Materials and Methods
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2. Materials and Methods
2.1. Materials
Cell Biology Reagents
Eagle’s minimal essential medium (MEM), Dulbecco’s modified eagle medium (DMEM), 
RPMI-1640, phosphate buffered saline (PBS), fetal calf serum (FCS), penicillin/ 
streptomycin, L-glutamine, trypsin and Nunclon tissue culture plastics were obtained from 
Life Technologies Ltd, Paisley, Scotland. All-trans RA, PX, bovine serum albumin (BSA), 
fibronectin, collagen type IV and laminin were purchased from Sigma Chemical Co, Dorset, 
England. Basement membrane matrigel was obtained from TCS Biologicals Ltd, 
Buckingham, England, whilst collagen type I was prepared from rat tendon. Ficoll-hypaque 
research grade was from Pharmacia Biotech, Hertfordshire, England. Chromium-51 was 
obtained from Amersham International pic, Buckinghamshire, England. Human 
recombinant interleukin-2 (h-rIL2), recombinant sICAM-1 and the sICAM-1 ELISA were 
from R&D Systems Europe, Abingdon, England. Sheep serum used in the confocal 
stainings was provided by the Scottish Antibody Production Unit (SAPU), Law Hospital, 
Scotland.
Antibodies
FITC-conjugated anti-human intercellular adhesion molecule-1 (ICAM-1) antibody and 
anti human ICAM-1 blocking antibody were from R&D Systems Europe, Abingdon, 
England. Non-specific mouse IgG control antibody and FITC-labelled sheep anti-mouse 
IgG were from the Scottish Antibody Production Unit (SAPU), Law Hospital, Scotland. 
Mouse anti-human HLA-ABC antibody was purchased from Serotec Ltd, Oxford, England. 
All antibodies used in the tPA and uPA ELISAs were kindly provided by Professor R. 
Leake, Division of Molecular Biology and Biochemistry, Institute of Biological and Life 
Sciences, Glasgow University, Scotland. The secondary FITC-conjugated sheep anti­
rabbit IgG antibody used in the confocal analysis of tPA and uPA was obtained from the 
Scottish Antibody Production Unit (SAPU), Law Hospital, Scotland.
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Plasminogen activator ELISA buffers
All buffers were kindly provided by Professor Robin Leake, Division of Biochemistry and 
Molecular Biology, Instutute of Biological Life Sciences, Glasgow University. The coating 
buffer contained 15mmol/l sodium carbonate, 35mmol/l sodium hydrogen carbonate at 
pH 9.6. The dilution buffer was prepared by adding 1% (w/v) BSA to 0.1% (v/v) in 
Tween-20 prepared in PBS. The washing buffer consisted of 0.1% (v/v) Tween-20 in 
PBS and the substrate buffer was made of 76mmol/l sodium dihydrogen phosphate and 
35mmol/l citric acid, pH5.0.
Molecular Biology Reagents
RNA Isolation solution (RNAzol) and oligonucleotides were purchased from Genosys, 
Cambridge, England. RNEasy Spin columns, Plasmid Midi-kit and taq polymerase were 
obtained from Qiagen, Surrey, England. Deoxynucleotide triphosphates were from 
Pharmacia, Herts, England and superscript II reverse transcriptase was from Gibco BRL, 
Paisley, Scotland. Sequenase T7 ploymerase sequencing kit, Hbond nucleic acid transfer
32membrane and [y- P]ATP (1000-3OOOCi/mmol) were both purchased from Amersham 
International pic, Buckinghamshire, England. XL-1 Blue bacteria (referred to in text as 
E.coli), NucTrap gel filtration columns were obtained from Stratagene, Cambridge, England 
and polynucleotide kinase from Promega, Southampton, England. The TA Cloning kit 
was from Invitrogen, The Netherlands whereas the Rapid Pure Minipreps kit was obtained 
from Bio 101 Inc, La Jolla, California.
Preparation o f  Buffers
RNase-free lOx MOPS buffer used in the gel electrophoresis of RNA was prepared by 
adding 0.1% (v/v) DEPC to 0.2M MOPS (pH7.0), 0.05M sodium acetate and 0.1M EDTA 
(pH8.0). The solution was left to shake overnight then autoclaved to inactivate the DEPC. 
TBE buffer was prepared by adding 75mM tris to 25mM boric acid and 0.1M EDTA, 
adjusting the pH to 8.9.
TE buffer was prepared by the addition of lOmM Tris-HCl (pH7.6) to ImM EDTA.
For Northern transfer, 20x SSC was made by adding 3M sodium chloride to 0.3M sodium 
citrate, adjusted to pH 7.0. 20x SSPE used in Southern transfer was prepared by adding
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3M sodium chloride and 200mM sodium dihydrogen phosphate to 20mM EDTA with the 
pH adjusted to 7.4. Prehybridisation solution and hybridisation solution was prepared by 
adding 5x SSPE, 5x Denhardts solution (1% SDS w/v; 1% PVP w/v; 1% BSA w/v in 
distilled water), 100pg/ml denatured sheared salmon sperm DNA and 50% (v/v) formamide. 
0.04% methylene blue and 0.5M sodium acetate (pH5.2) were used to produced the 
methylene blue stain.
Preparation o f  bacterial culture solutions
LB agar solution was prepared by adding 1% (w/v) Select peptone 140, 0.5% (w/v) yeast 
extract, 1.2% (w/v) agar to 0.5% (w/v) sodium chloride.
LB broth was prepared by adding 1% (w/v) Select peptone 140, 0.5% (w/v) yeast extract 
(w/v) to 0.55% (w/v) sodium chloride.
Both solutions were prepared in distilled water, dissolved by microwaving, and autoclaved 
prior to use.
2.2. Cell Culture
The highly metastatic human melanoma C8161 cell line was established from an abdominal 
wall metastasis and characterised by Welch et al (1991) and was kindly supplied by Mary 
J.C. Hendrix, University of Arizona, Tucson, AZ, USA. The low metastatic Hs294T cell 
line (Creasey et al, 1979), derived from a lung node metastasis, and the low metastatic 
A3 75 cell lines were obtained from the American Tissue Culture Collection (ATCC, HTB- 
140). The MCF-7 human breast adenocarcinoma cell line, used as a positive control in the 
retinoic acid receptor analysis, was purchased from the European Collection of Animal 
Cell Cultures (ECACC). All cell lines were routinely cultured in MEM supplemented 
with 10% heat-inactivated FCS, penicillin (lOOunits/ml) and streptomycin (lOOjig/ml). 
Cells were maintained in a humidified atmosphere of 5% CO2 in air at 37°C. Viability of 
the tumour cells was measured by trypan blue staining where cells which did not take up 
the dye were defined as viable and cells which did were described as non-viable. 0.5ml of 
a 0.4% (w/v) trypan blue solution was added to 0.3ml PBS and 0.2ml cell suspension and 
left for 5min before cells were counted using a hemocytometer.
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2.3. Methods
2.3.1. Growth Assays
Tumour cells were set up at the appropriate densities and incubated for 4hr in complete 
medium before the addition o f either PX (10|ig/m l-500pg/m l) or RA 
(10 !°M -10 5M) to fresh medium. Media changes took place on days 2 and 4. Cells were 
detached on days 1, 2, 3, 4 and 7 using 0.05% trypsin in Ca2+ and Mg2 -free PBS/EDTA 
and counted in a Coulter counter.
2.3.2. Adhesion Assays
Tissue culture dishes were coated with substrate concentrations at which maximal adhesion 
was observed following lhr incubation at 37°C. Excess substrate was removed and rinsed 
with PBS. Remaining protein absorption sites were blocked with BSA (lOmg/ml) for 2hr 
at 37°C after which excess BSA was washed away with PBS. 7.5x10^ tumour cells were 
added to each prepared well, and after the appropriate incubation time, non-adherent cells 
were removed before wells were washed twice with PBS. Tumour cells were detached 
using trypsin/EDTA and samples removed for counting on a Coulter counter.
2.3.3. Assessment of peripheral blood lymphocyte and lymphokine activated killer 
cell-mediated tumour cell lysis
Preparation o f  Lymphocytes
80ml of heparinized blood from a healthy volunteer was subjected to Ficoll density gradient 
centrifugation and the peripheral blood mononuclear cell layer removed. Adherent cells 
were removed by two cycles of adherence to tissue culture plastic. The non-adherent 
peripheral blood lymphocytes (PBL) were collected and maintained in RPMI supplemented 
with 10% FCS and lymphocytes activated by the addition of 2nM human rIL-2 to 10^ 
cells for at least 6 days to produce lymphokine-activated killer cells (LAK).
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Chromium-51 release assay
5x10^ tumour cells, either untreated or treated with 10"^M RA or 250fig/ml PX for 4 
days, were radiolabelled with Chromium-51 (400|iCi/10^ cells, specific activity 200- 
500mCi/mg) and incubated for 2hr at 37°C. Excess radiolabelled chromium was removed 
and labelled tumour cells incubated with varying numbers of lymphocytes to produce the 
effector:tumour cell ratio (E:T). After 4hr incubation, a 70jnl sample of supernatant was 
removed for liquid scintillation counting (Canberra - Packard). Spontaneous release was 
measured by incubating the tumour cells in complete media and maximum release 
determined by lysing the cells in 0.1M HC1. For all the assays shown, spontaneous release 
was always less than 10% of the maximum release. Blocking anti-ICAM-1 antibody and 
blocking MHC class 1 antibodies were used at concentrations ranging from l|ig/ml to 
25|ig/ml, and a non-specific mouse IgG antibody used as an isotype control. sICAM-1 
was added at a concentration of lOOng/ml.
Quantitative analysis o f  cytotoxicity
The percentage of lysis occurring was calculated as follows :
% specific lysis = (dpm experimental well - dpm spontaneous release) + (dpm maximal 
release - dpm spontaneous release).
Immunofluorescence analysis o f  mICAM-1 and MHC Class 1
For the ICAM-1 staining, tumour cells were fixed using acetone and labelled with 200|xl 
of FITC-conjugated mouse anti-human ICAM-1 antibody (20|ig/ml) for 2hr at room 
temperature in the dark. Excess antibody was removed by washing cells four times in 
PBS to remove unbound antibody. Propidium iodide (l|ig/ml) was used as a counterstain 
prior to examination using a confocal microscope.
For the MHC class-1 staining, tumour cells were incubated with 10% sheep serum before 
the addition of200|il of mouse anti-human HLA-ABC antibody for 2hr at room temperature. 
Excess antibody was removed by washing cells three times in PBS. Secondary FITC- 
labelled sheep anti-mouse IgG was added at a 1:200 dilution and left for 2hr at room 
temperature in the dark. Excess antibody was removed by washing cells four times in PBS 
to remove unbound antibody. Propidium iodide (1 pg/ml) was used as a counterstain prior 
to examination using a confocal microscope.
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Flow Cytometric Analysis o f  mICAM-1
Tumour cells were prepared for flourescent-activated cell sorter analysis by the addition 
of lOjxl of FITC-conjugated ICAM-1 antibody (equivalent to one test as described by 
R&D systems) to 106 tumour cells and incubated for 15min. Excess antibody was removed 
by washing the cells twice in PBS. Fluorescent staining was analysed using a FACscan 
(Becton Dickinson). The corresponding background fluorescence was obtained using 
tumour cells minus antibody. Intensity of fluorescence was recorded on a logarithmic 
scale.
2.3.4. Soluble intercellular adhesion molecule-1 assay
The procedure for measuring sICAM-1 was as described in the R&D Systems parameter 
handbook. Briefly, lOOjxl of anti-ICAM-1 horse radish peroxidase conjugate was added 
to each well coated with mouse anti-human ICAM-1 antibody. This was followed by the 
addition of 1 OOjil of diluted supernatant from cells pretreated with either 10|ig/ml - 250|ig/ 
ml PX or 10,0M -10 5M RA for 4 days. The plate was incubated for 2hr at room temperature 
before the contents of each well was removed. Wells were washed 6 times with 300j l l 1 of 
wash buffer, afterwhich 1 OOjil of substrate was added to each well and left to incubate at 
room temperature for 30min. 1 OOjil of the stop solution was added to each well and the 
optical density of the plate read in a microtitre plate reader set at 450nm with correction of 
620nm.
2.3.5. Tumour Lung Colonisation
Tumour cells were set up at the appropriate densities and pretreated for 4 days with either
-6
10 M RA or 250jig/ml PX. Cells were then trypsinised and counted on a Coulter counter. 
Treated or untreated tumour cells were injected into the tail vein of athymic nude mice 
(nu/nu), with 8 mice per experimental group. Mice were killed after 21 days, the lungs 
excised and nodules counted.
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2.3.6. Plasminogen activation analysis
Confocal Microscopy o f  Membrane-Associated uPA and tPA Expression 
Tumour cells were fixed using acetone and incubated with 10% sheep serum before being 
labelled with 200jnl of rabbit anti-human tPA or uPA antibody (20|Xg/ml) for 2hr at room 
temperature. Excess antibody was removed by washing three times in PBS. FITC-labelled 
secondary sheep anti-rabbit IgG was added at 1:200 dilution and left for 2hr at room 
temperature. Cells were washed four times in PBS to remove unbound antibody. Propidium 
iodide (l|xg/ml) was used as a counterstain prior to examination using a confocal 
microscope.
ELISA measurements o f  secreted uPA and tPA
ELIS As were performed essentially as described by Grebenschikov et al, 1997. Briefly, 
96 well microtitre plates were coated with sheep anti-chicken IgG and incubated at 4°C 
overnight. Plates were washed 4 times in washing buffer before the addition of 300|il of 
blocking buffer to each well. Plates were incubated at 37°C for 2hr then washed four 
times in washing buffer. 100|Lil of controls and samples (of various dilutions) were 
transferred into each well and incubated at 4°C overnight. After washing samples 4 times 
with washing buffer, IOOjllI of the appropriate catching antibody (chicken anti-human uPA/ 
tPA) was added to each well and plates incubated at 37°C for 2hr. Plates were washed a 
further 4 times before the addition of the appropriate tagging antibody (rabbit anti-human 
uPA/tPA) to each well and plates incubated at room temperature for 2hr. Plates were 
washed 4 times then incubated for 2hr at room temperature with detecting antibody (goat 
anti-rabbit IgG). Samples were washed a further 4 times then 1 OOjil substrate solution 
added to each well. Plates were incubated in the dark for 30min at room temperature. The 
reactions were stopped with 100p,l of 1M sulphuric acid and readings taken in a 
spectrophotometer at wavelengths 492nm/620nm.
2.3.7. Statistical analysis of data
Unless otherwise stated in the figure legend, samples were performed in triplicate and 
expressed as the average ± standard error of the mean (SEM). Statistical analysis of the 
data was performed using the students 2-tailed T-test.
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2.3.8. Analysis of RAR expression
Preparation o f  Competent E.coli
Competent E.coli were prepared by inoculating 2ml of LB broth with a single colony of 
XL-1 Blue bacteria which were incubated overnight at 37°C. 1ml of this culture was 
added to 100ml LB broth and cells allowed to grow with vigorous shaking at 37°C until
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the density reached 5x10 cells/ml (ie. where the optical density at 550nm equalled 0.2). 
Cultures were centrifuged and cells resuspended in 50ml ice-cold 50mM CaCl2 containing 
lOmM Tris-HCl (pH 8.0). The cells were repelleted and resuspended in 6ml ice cold 
50mM CaCl2 and stored on ice for immediate use.
Transformation o f  the RAR containing pSG5 Vectors
The pSG5 plasmids containing either the cDNA insert for a , p or y RAR were kindly 
supplied by P. Chambon (INSERM, Strasbourg, France) as shown in Figure 45, Chapter 
3. On arrival, plasmids were eluted from Whatman 5MM paper with 50pl lOmM Tris- 
HCl, pH 7.6. The samples were vortexed and centrifuged, and the supernatant used to 
transform bacteria. The vectors were transformed into competent E.coli by adding 5|il of 
vector to 0.2ml cells with 2jil of 0.5M p-mercatoethanol and left for 30min on ice. Cells 
were subject to heat shock at 42°C for 30sec before the addition of 450pl SOC medium. 
Cells were incubated for lhr at 37°C then 50|il and 200jil aliquots were plated on agar 
plates containing ampicillin (lOOjxg/ml). Plates were inverted and left overnight at 37°C 
in a incubator and plated on LB agar containing ampicillin (100pg/ml). The following 
day, 3 colonies of each receptor were picked and cultured overnight in 3mls LB broth 
containing ampicillin (100pg/ml). The resultant suspension was separated into 2 tubes 
and subject to centrifugation. One sample was added to 15% glycerol in LB broth and 
stored at -70°C and the other sample was used to purify vector using Rapid Pure Minipreps 
kit. The eluted plasmid DNA was subject to the following restriction enzyme digests for 
2hr, 37°C using the following enzymes:
RARoc - EcoRl, Pstl, EcoRl/Pst; RARp - EcoRl; RARy- EcoRl, Pstl, EcoRl/Pstl.
10|il of each digest was loaded on a 1% agarose/lx TBE gel containing ethidium bromide 
(lp.g/ml)and run at 60V for 60-90min. The gel was visualised by UV transillumination 
and photographed.
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Amplification o f  pGS5 Vector Inserts
Since the restriction enzyme digests produced unexpected results, it was decided to try to 
amplify specific regions of the RARa, p and y inserts and attempt to subclone them into 
the pCR2.1 vector for partial sequence analysis.
The following set of primers obtained from Genosys, Cambridge were used to amplify the 
inserts of human nucleotide sequences contained within the purified vectors:
Amplicon (bp)
RARa 5' TGGGTGGACTCTCCCCGCCA 3' 486
5' ACCTCCGGCGTCAGCGTGTA 3'
RARP 5' CACTGGCTTGACCATCGCAGACC 3' 522
5' TTGAATGAGAGGTGGCATTGATCCA 3'
RARy 5' GGCCTGGGCCAGCCTGACCTC 3' 641
5' AGAGCCCCAGATCCAGCTGCAC 3'
The vectors were used directly as templates for polymerase chain reaction and used as 
serial 10-fold dilutions in sterile water. 15pi cDNA template was added to a mix containing 
lx PCR buffer (Qiagen), lx  Solution Q (Qiagen), lOmM each of dATP, dCTP, dGTP and 
dTTP, lpmol of each primer and 2.5 units taq polymerase made up to a final volume of 
50pl. Amplification began with denaturing the cDNA for 5 min at 95°C followed by 90s 
at 55°C for annealing and 90s at 72°C for extension. The next cycle began with 90s at 
95°C and was repeated for a total of 35 cycles. Reactions with no vector added were used 
as negative controls, and each reaction was performed in lOOpl overlayed with mineral 
oil. Amplification took place using a Crocodilelll, TC2000 PCR thermal cycler (Appligen, 
Oncor, USA).
Subcloning o f  the PCR product into the pCR2.1 vector (TA vector)
EcoRl _____________EcoRl
J ^ Jp C R p ro d u c tj—J J
3.9 kb
amp
Figure 3. The pCR2.1 cloning vector.
Ligation of each PCR product into the pCR2.1 cloning vector (also known as the TA 
vector) (Figure 3) was performed using the TA cloning kit. Ligation reactions were 
incubated at 14°C for 4hr. Competent E.coli were prepared and 2fil of ligation mixture 
transformed into cells as already described. 50pl and 200|il aliquots were plated and 10 
colonies of each receptor picked and cultured overnight at 37°C in 3ml LB broth containing 
ampicillin (lOOpg/ml). The vectors from each culure were purified using the Plasmid 
Midi Kit. Purified vector was subject to EcoRl digestion and a sample was electrophoresed 
through a 1% agarose/lx TBE gel containing ethidium bromide to confirm the presence of 
the insert.
Sequencing o f  the pCR2.1 vector containing PCR insert
5|Hg of purified vector containing the correct insert was denatured in 0.2M NaOH followed 
by neutralisation in 0.45M sodium acetate (pH5.4) and precipitation in 3 volumes of absolute 
ethanol. Samples were stored at -70°C for 30min then washed in 70% ethanol. Samples 
were heated at at 60°C to evaporate residual ethanol. Sequencing was carried out using 
the Sequenase T7 polymerase Sequencing Kit using the supplied Ml 3 forward primer. 
The T7 primer was used to sequence the pSG5 RARy vector.
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M l3 forward primer 5' GTAAAACGACGGCCAG 3' 
T7 primer 5' TAATACGACTCACTA 3'
Samples were run on a 6% acrylamide/7M urea preheated gel in lx  TBE which was 
transferred to 3 MM Watmann filter paper and dried. The gel was then exposed to film 
overnight.
RARa and (3 probe production
The RARa and p vectors derived from the same clones as used in the sequencing reactions 
were used to produce probes for the Northern blot analysis. Each clone was cultured in 
100ml LB broth containing ampicillin (100|ig/ml) overnight at 37°C, the vectors were 
purified and subject to large scale EcoRl digestion.
The products produced on the large scale EcoRl digestion of RARa and p were excised 
from the gel and purified using the gel extraction kit. A small aliquot from each extraction 
was run on a 1% agarose gel/1 x TBE and visualised under UV light.
DNA probes were prepared using either a) the PCR product or b) the actual pCR2.1 vector/ 
insert, where the insert was separated using EcoRl restriction enzyme digestion (as 
previously described) and purified from the gel using Quiagen Quick Spin columns.
5' End-labelling of both the PCR products and the purified digests was performed using 
T4 polynucleotide kinase and [y-32P]ATP (1000-3OOOCi/mmol) in a final volume of 70jil.
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For random labelling, the Klenow fragment of DNA polymerase and [a- P]dCTP (3000 
Ci/mmol) was used. Probes were passed through a NucTrap gel filtration column to remove 
unincorporated nucleotide, denatured in 1M NaOH and incubated at 37°C for lOmin.
Preparation o f  RNA for Northern Blot Analysis
Cells were detached from tissue culture plates using trypsin/EDTA and resuspended in 
MEM containing 10% FCS. Cells were subject to centrifugation and the pellet lysed in 
RNA Isolation solution, (0.2ml/106 cells). Chloroform was added to each sample (0.2ml/ 
2ml sample) and the organic and aqueous phases separated by centrifugation at 12000g 
for 15min, 4°C. The aqueous phase was removed and precipitated with an equal volume 
of isopropanol. Samples were left for 15min at 4°C before being centrifuged for a further
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15min. The RNA pellet was washed once with 75% ethanol then resuspended in RNase- 
free water. Quantification of the RNA sample was performed by measuring the absorbance 
at 260/280nm on a spectrophotometer. Samples were further purified using an RNEasy 
Mini Kit where necessary, based on these absorbance readings, and requantified. Samples 
were loaded onto a 1% agarose/lx TBE gel and stained using ethidium bromide. The gels 
were visualised by UV transillumination and photographed. The rest of the samples were 
stored at -70°C.
Northern Blot analysis o f tumour RNA
1 OjLtg total RNA was precipitated in 0.1 volume of 3M sodium acetate, pH5.4 and 3 volumes 
absolute ethanol. Samples were stored at -70°C for 30min, centrifuged and the pellet 
washed in 75% ethanol and resuspended in TE buffer. Each RNA sample was 
electrophoresed through a 1% agarose/formaldehyde gel overnight at 30V, 4°C then 
transferred to a nylon membrane by capillary Northern blotting technique. The membrane 
was then washed in 5% (v/v) acetic acid followed by staining for 15min in 0.04% (w/v) 
methylene blue/5% (v/v) acetic acid to visualise RNA nucleic acids. Excess stain was 
removed by washing with distilled water. After removal of excess water, the RNA was 
cross-linked to the membrane by UV illumination.
Filters were prehybridised for 4 hr at 42°C in prehybridisation buffer. Hybridisation with 
the labelled probe was performed in hybridisation buffer overnight at 42°C. The blot was 
then washed for 2 x 15min at room temperature in the same solution followed by 2 x 
15min washes in 0.1X SSC, 0.1% (w/v) SDS at 37°C then autoradiographed.
Amplification o f  RARa, p and y from cell line cDNA
5pg RNA was added to a mix containing l|ig  oligo d(T) , 0.02M DTT, ImM dNTPs
12-18
(Pharmacia, St Albans, Herts) and 200 units Superscript II reverse transcriptase (Gibco 
BRL), in a final volume of 20|il. Samples were incubated for lhr at 42°C.
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RAR amplification primers and conditions
Essentially, as previously described by Harant et al, (1993), the following set of primers 
were used to amplify the reverse transcribed templates from Hs294T and C8161 RNA.
Amplicons
RARa sense 5' GACTGTGGAGTTCGCCAAGC 3' 620bp
antisense 5' CCCCGCCAGGCAGCTGTAG 3’
RARp sense 5’ AGGAGACTTCGAAGCAAG 3’ 771 bp
antisense 5’ GTCAAGGGTTCATGTCCT 3’
RARy sense 5’ GGAAGAAGGGTCACCTGA 3’ 587bp
antisense 5’ CGGCGCCGGGCGTACAGC 3’
GAPDH sense 5' AGGTCGGAGTCAACGGATTTG 3' 321 bp
antisense 5' ATGGAGAAGGCTGGGGCTCAT 3'
Amplification was achieved under standard conditions in a Crocodilelll, TC2000 PCR 
thermal cycler (Appligen, Oncor, USA). The reaction was performed in 50|l l 1 using taq 
polymerase, as described for the previous PCR amplifications. The amplification conditions 
began with denaturing the cDNA for 5 min at 95°C followed by 60s at 65°C for annealing 
and 60s at 72°C for extension for RARa and 60s at 60°C for annealing and 60s at 72°C for 
extension of RARP and y. The next cycle began with 30s at 95°C and was repeated for a 
total of 30 cycles. The negative controls included were a) the reverse transcription performed 
with no template RNA, b) the PCR mix with no template, and c) PCR performed on 
template RNA. The human breast carcinoma MCF-7 cell line was chosen as a positive 
control for RARa as Widshwendter et al, (1995) had previously shown expression of 
RARa in this cell line. This positive control was necessary as the initial run of PCR on the 
C8161 cells was negative even though cDNA synthesis was confirmed by amplification 
of GAPDH.
Southern Blot Analysis o f PCR products.
PCR products were subjected to electrophoresis in a 1 % agarose/1 x TBE gel then transferred 
to a nylon membrane by capillary action. The membrane was then washed in 5% (v/v) 
acetic acid followed by staining for 15min in 0.04% (w/v) methylene blue/5%(v/v) acetic
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acid to visualise nucleic acids. Excess stain was removed by washing with distilled 
water, afterwhich, the DNA was cross-linked to the membrane by UV irradiation. 
Synthetic oligonucleotide probes complementary to exon / exon boundary sequences were 
designed to confirm the identity of the PCR products, and to show that the amplification 
was specifically from processed mRNA.
RARa probe 5' CATCCTGATCCTGCGGATCTGCACGCGGTA 3'
RARp probe 5' ATACACCACGGTAAGATCCTAGAATTCCAG 3'
RARy probe 5' TGCCTAGATATCCTGATGCTGCGTATCTGCA 3'
32
5' End-labelling of the probes was performed using polynucleotide kinase and [y- P] ATP 
(1000-3OOOCi/mmol) in a final volume of 70(il at 37°C for 30min. Probes were passed 
through a NucTrap gel filtration column to remove unincorporated nucleotide. Membranes 
were prehybridised for 4hr at 42°C in prehybridisation buffer. Hybridisation with the 
labelled probe was performed overnight at 42°C using hybridisation buffer. The membranes 
were then washed for 2 x 15min at room temperature in 5x SSPE, 0.1% SDS (w/v) in the 
same solution followed by 2 x 15min washes in O.lx SSPE, 0.1% SDS (w/v) at 37°C then 
subjected to autoradiography.
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Chapter 3. Results
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3. Results
3.1. Retinoid-induced modulation of tumour cell growth and adhesion to various 
ECM components
Effect ofRA (l(yi0M-lQr5M) on tumour cell growth
RA over a range of concentrations (10'10M - 10‘5M) did not significantly alter Hs294T cell 
numbers over a four day period (Figure 4A). Only after 7 days pretreatment of the cells 
with 10'5M RA was a slight decrease in cell numbers observed from 8.2 xlO5 cells to 
6.9x105 cells, however, this treatment reduced viability of the cells to below 75%.
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Figure 4A. Effect of RA (□  control; ■ 10-,0M; O109M; #10-8M; <M07M; ♦ 106M; A l0 5M) on Hs294T 
cell numbers. Values represent the average ±  SEM of triplicate experimental dishes.
69
A similar outcome was obtained using the C8161 cell line, where RA over a range of 
concentrations (10’10M - 10’5M) did not significantly alter cell numbers over a four day 
period (Figure 4B). After 7 days pretreatment of the cells with 10'5M RA, a slight decrease 
in cell numbers was observed from 2.96xl06 cells to 2.21xl06 cells. But again, this treatment 
reduced viability of the cells to below 75%.
350 i
300 -
*o 250 “
£  200 -  
00 
'•B
— 150 -j/>
75
O  100 -
50 -
10 2 3 4 5 6 7
Incubation time (days)
Figure 4B. Effect of RA (□  control; ■1010M; O109M; •10-8M; ^1 0 ‘7M; ♦ 106M; AlO-5M)onC8161 cell 
numbers. Values represent the average ±  SEM of triplicate experimental dishes.
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In the A375 cell line, 4 days pretreatment using a range of concentrations of RA (10'10M - 
10‘5M) did not significantly alter cell numbers (Figure 4C). The exception was using 
10'6M - 10'5M RA pretreatment for 7 days. But as with the C8161 and Hs294T cells, 
prolonged treatment of the tumour cells at the higher concentrations of RA reduced viability 
to less than 75%.
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Figure 4C. Effect of RA (□  control; BIO^M; O 109M; #10-8M; <>10-7M; ♦ lO^M; Al0'5M) on A375 cell 
numbers. Values represent the average ±  SEM of triplicate experimental dishes.
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Determining optimum concentrations o f  ECM components for the time-point adhesion 
assays o f  C8161 cells pretreated for 4 days with 10'6M  RA.
38% of control cells and 39% of RA-treated cells adhered to 10|ig/ml fibronectin (Figure 
5A). Values were similar using 50jig/ml fibronectin with 35% and 38% of control and 
RA-treated tumour cells adhered respectively. Therefore, the optimum concentration of 
10(ig/ml fibronectin was used to coat dishes in the time-point adhesion assay.
co
’5>©.c
■o<
50
40
30
20
10
0
0 10 20 30 40 50
Fibronectin (p,g/ml)
Figure 5A. Adhesion of C8161 cells pretreated without (□) and with 10‘6M RA (■) to various concentrations 
of fibronectin. Values are represented as the average ± SEM of triplicate experimental dishes.
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An average of 23% of control cells and 27% of RA-treated cells adhered to 20|ig/ml laminin, 
compared to 26% adherence for both control and RA-treated cells using 50|ig/ml laminin 
(Figure 5B). Therefore 20|ig/ml laminin was selected to coat dishes in the time-point 
adhesion assays.
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Figure 5B. Adhesion of C8161 cells pretreated without (□ ) and with 10'6M RA (■) to various 
concentrations of laminin. Values are represented as the average ± SEM of triplicate experimental dishes.
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17% of control cells and 20% of RA-treated cells adhered to 10|Lig/ml collagen type 1 
(Figure 5C). In comparison, using 20|ig/ml substrate, 22% of control cells and 21% of 
RA-treated cells adhered. Values were similar at the higher concentration of 50|Xg/ml 
collagen type 1, with 21% of control cells and 23% of RA-treated cells adhering. Hence 
the optimum concentration of collagen type 1 used in the time-point adhesion assays was 
lOpg/ml.
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Figure 5C. Adhesion of C8161 cells pretreated without (□) and with 10'6M RA (■) to various concentrations 
of collagen type I. Values are represented as the average ± SEM of triplicate experimental dishes.
Optimum adhesion of cells to collagen type IV occured using 5(Xg/ml of substrate where 
adhesion of both control and RA-treated cells was 24% (Figure 5D). Similar values were 
obtained using 10|ig/ml where 25% of control cells adhered compared to 22% of RA- 
treated cells.
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Figure 5D. Adhesion of C8161 cells without (□ ) and with (■) 4 days pretreatment of lO^M RA to a range 
of concentrations of collagen type IV. Values are represented as the average ± SEM of triplicate experimental 
dishes.
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Effect ofRA (10'I0M-10~5M) on adherence o f  the C8161 cells to ECM components
The adherence of C8161 cells to various components of the ECM did not alter significantly 
using a range of concentrations of RA (10'10M - 10'6M) (Figure 6). Only at the higher 
concentration of 10'5M was there a reduction in adherence to collagen type I and IV, 
however, viability of the tumour cells was reduced to below 75%. Therefore, tumour cells 
were treated with 10'6M RA for use in the time-point adhesion assays.
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Figure 6. Adherence of C8161 cells pretreated with RA (10'10M - 10'5M) to fibronectin (□); collagen type 
IV (■); laminin (O) and collagen type I (•). Values represent the average ± SEM of triplicate experimental 
dishes where the value at zero concentration was determined by adhesion of untreated cells to substrate.
76
Time point adhesion assays analysing adherence o f  C8161 cells with and without 
10~6M  RA pretreament to various ECM components
Adhesion of C8161 cells pretreated with 10'6M RA for 4 days to fibronectin did not differ 
significantly from the untreated C8161 cells of which 19% adhered to fibronectin by 1 Omin, 
increasing to 37% by 30min, then to 51% by 90min (Figure 7A).
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F i g u r e  7A. Adhesion of untreated C81 6 1  cells (□ ) and 10'6M RA-pretreated C81 6 1  cells (■) to fibronectin. 
Values represent the average ± SEM of triplicate experimental dishes.
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Adherence of C8161 cells to laminin was not significantly altered on pretreatment of the 
tumour cells with lO^M RA (Figure 7B). 10% of untreated tumour cells adhered by 
lOmin, increasing marginally to 12% by 30min and reaching 35% by 90min.
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Figure 7B. Adhesion of untreated C8161 cells (□ ) and 10‘6M RA-pretreated C8161 cells (■) to laminin. 
Values represent the average ± SEM of triplicate experimental dishes.
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Adherence of C8161 cells to collagen type I was not significantly altered on pretreatment 
of the tumour cells with 10’6M RA (Figure 1C). 7% of untreated tumour cells adhered by 
lOmin, increasing marginally to 9% by 30min, and increasing 3-fold to 27% by 90min. 
Values were similar in RA-treated cells.
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Figure 7C. Adhesion of untreated C8161 cells (□) and 10‘6M RA-pretreated C8161 cells (■) to collagen 
type I. Values represent the average ± SEM of triplicate experimental dishes.
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RA (lO^M) did not significantly alter adhesion of the C8161 cells to collagen type IV. 4% 
of untreated C8161 cells adhered by 1 Omin, compared to 7% by 30min and 44% by 90min 
(Figure 7D).
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Figure 7D. Adhesion of untreated C8161 cells (□ ) and 10'6M RA-pretreated C8161 cells (■) to collagen 
type IV. Values represent the average ± SEM of triplicate experimental dishes.
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Adhesion of the C8161 cells to matrigel was not altered on treatment of the tumour cells 
with 10'6M RA (Figure 7E). 12% of untreated C8161 cells adhered to the matrigel by 
1 Omin. Adherence was increased to 27% by 30min, and to 50% by 90min.
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Figure 7E. Adhesion of untreated C8161 cells (□) and 106M RA-pretreated C8161 cells (■) to 
matrigel. Values represent the average ± SEM of triplicate experimental dishes.
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Time point adhesion assays analysing adherence o f  A3 75 cells with and without 
10~6M  RA pretreament to basement membrane (Matrigel).
Adherence of the A375 cells to matrigel was unaltered with 4 days pretreatment of 10‘6M 
RA (Figure 8). 13% of untreated tumour cells adhered by lOmin, increasing to 27% by 
30min, reaching 53% by 90min.
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Figure 8. Adhesion of untreated A375 cells (□ ) and lO^M RA-pretreated A375 cells (■) to matrigel. 
Values represent the average ± SEM of triplicate experimental dishes.
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3.2. PentoxifVlline-induced modulation of tumour cell growth and adhesion to various
ECM components
Effect o f  PX (10jXg/ml-500\ig/ml) on tumour cell growth
Although PX had no effect on cell morphology, it induced a dose and time-dependent 
decrease in growth of the Hs294T, C8161 and A375 cells (Figures 9A, 9B and 9C 
respectively). Viability of all the cell lines (as determined by trypan blue staining) was 
always greater than 90% on treatment of the tumour cells with PX, except using the highest 
concentration of 500|Xg/ml PX where viability was reduced to below 70%.
After 4 days treatment of lOpg/ml PX, a 22.0% reduction (p<0.05) in cell numbers was 
observed in the Hs294T cell line (Figure 9A). Cell numbers were further reduced using 
1 OOpg/ml PX by 30.8% (p<0.05) in the Hs294T cell line after 4 days pretreament. Using 
250pg/ml PX, cell numbers were reduced by 65.4% (p<0.0005) (Figure 9A).
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Figure 9A. Effect of PX (□  control; ■ 10pg/ml; O 100|ig/ml; •  250pg/ml; 500pg/ml) on Hs294T cell
numbers. Data represents the average ± SEM of triplicate samples.
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After 4 days treatment of the C8161 cell line with 10|ig/ml PX, cell numbers were not 
significantly altered. However, using lOOjig/ml PX, C8161 cell numbers were reduced by 
20.3% (p<0.05) and by 67.5% (p<0.01) using 250pg/ml PX (Figure 9B). Pretreatment of 
the tumour cells with 500jig/ml PX reduced viability to below 70%.
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Figure 9B. Effect of PX (□  control; ■ 10|ig/ml; O 100pg/ml; •  250pg/ml; ^  500|ig/ml) on C8161 cell 
numbers. Data represents the average ± SEM of triplicate samples.
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After 4 days treatment of the A3 75 cell line using 100|Llg/ml PX, cell numbers were reduced 
by 10.4% (p<0.001) and by 37.2% (p<0.001) using 250|ig/ml PX (Figure 9C). Pretreatment 
of the tumour cells with 500|ig/ml PX reduced viability to below 70%.
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Figure 9C. Effect of PX (□  control; ■ lOfig/ml; O lOOgg/ml; •  250pg/ml; 500pg/ml) on A375 cell
numbers. Data represents the average ± SEM of triplicate samples.
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Determining optimum concentrations o f  ECM components for the time-point adhesion 
assays o f  C8161 cells pretreated with 250\lg/ml PX.
Adhesion of the PX-treated C8161 cells to fibronectin was reduced at all concentrations of 
fibronectin tested, with a reduction of 32% and 28% using 10|ig/ml and 20|ig/ml fibronectin 
respectively (Figure 10). 10|Lig/ml fibronectin was selected as the optimum concentration 
used in the time-point adhesion assay.
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Figure 10. Adhesion of C8161 cells without (□ ) and with ( • )  4 days pretreatment of 250jig/ml PX to a 
range of concentrations of fibronectin. Values are represented as the average ± SEM of triplicate experimental 
dishes.
Adhesion of C8161 cells pretreated with 250|ig/ml PX to various concentrations of laminin, 
collagen type 1 and type IV was not altered (Figures 11 A, 11B and 11C respectively). 
Therefore, the optimum concentrations of each substrate used in the time point adhesion 
assays was kept the same as those used in the time-point ahesion assays of RA-treated 
cells (20(Xg/ml laminin; 10|ig/ml collagen type 1; 5fig/ml collagen type IV).
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Figure 11. Adhesion of C8161 cells without (□ ) and with ( • )  4 days pretreatment of 250p.g/ml PX to a 
range of concentrations A) laminin; B) collagen type I; C) collagen type IV. Values are represented as the 
average ± SEM of triplicate experimental dishes.
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Effect o fP X  (10\ig/ml - 500\ig/ml) on adherence o f  the C8161 cells to ECM components
Adherence of the C8161 cells pretreated with 10|ig/ml - 250|Hg/ml did not alter adherence 
to laminin, collagen type 1 and type IV (Figure 12). A significant reduction in adherence 
to collagen type 1 and type IV was observed pretreating cells with 500|Lig/ml PX, but at 
this concentration, viability of the cells was greatly reduced to below 70%.
35
30
25
20
15
10
5
0
0 100 200 300 500
PX (ng/ml)
Figure 12. Adherence of C8161 cells pretreated with PX (10|ig/ml - 500|ig/ml) to collagen type IV (□); 
laminin (■) and collagen type I (O). Values represent the average ± SEM of triplicate experimental dishes 
where the value at zero concentration was determined by adhesion of untreated cells to substrate.
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Effect o f  PX(10\ig/ml - 500\ig/ml) on adherence o f the C8161 cells to fibronectin
PX reduced adherence of the C8161 cells by 26.5% (p<0.05) using lOjiig/ml PX which 
was similar at the higher concentration of250|ig/ml where adhesion was reduced by 24.9% 
(p<0.05) (Figure 13).
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Figure 13. Effect of PX(10|Ig/ml- 500|Ig/ml) on adherence of C8161 cells to fibronectin. Values represent 
the average +  SEM of triplicate experimental dishes where the value at zero concentration was determined 
by adhesion of untreated cells to fibronectin.
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Time point adhesion assays analysing adherence o f  C8161 cells with and without 250\ig/ 
ml PXpretreament to various ECM components.
PX pretreatment (250|ig/ml) of the C8161 cell line for a 4 day period caused a significant 
(24.2%) reduction in adherence of the tumour cells to fibronectin by 30 min (p<0.05) with 
a similar reduction of 29.8% (p<0.05) maintained at the 40min time period (Figure 14).
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Figure 14. Adherence of C8161 cells without (□) and with ( • )  4 days pretreatment of 250|iig/ml PX to 
fibronectin. Values represent the average ± SEM of triplicate experimental dishes.
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Adhesion of C8161 cells pretreated for 4 days with PX (250jig/ml) to laminin, collagen 
type I and IV was not altered in comparison to untreated tumour cells (Figures 15 A, B and 
C respectively).
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Figure 15. Adherence of C8161 cells to A) laminin; B) collagen type I; C) collagen type IV without (□) 
and with ( • )  4 days pretreatment of 250|ig/ml PX. Values represent the average ± SEM of triplicate 
experimental dishes.
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PX (250|4g/ml) failed to alter adhesion of the C8161 cells and the A375 cells to basement 
membrane matrigel (Figures 16A and 16B respectively).
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Figure 16. Adherence of A) C8161 cells and B) A375 cells without (□ ) and with ( • )  4 days pretreatment 
of 250|ig/ml PX to basement membrane matrigel. Values represent the average ± SEM of triplicate 
experimental dishes.
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3.3. Retinoid-modulation of tumour LAK cell-mediated lysis
Effect o f  RA on lysis o f  the human melanoma cell lines.
Unactivated peripheral blood lymphocytes were unable to lyse any of the three cell lines 
tested (data not shown). 10’6M RA-treated Hs294T and C8161 cells incubated with LAK 
cells for a period of 4hr were found to become more susceptible to lysis than untreated 
control cells (Figures 17A and 17B respectively), whereas RA was unable to alter lysis of 
the A3 75 cells (Figure 17C). In the Hs294T cell line (Figure 17A), lysis was increased
3.7-fold at the 5:1 ratio from 13.1% to 48.4% (p<0.005), from 39.5% to 55.5% at the 20:1 
ratio (1.4-fold), and from 54.9% to 76.1% at the 40:1 ratio (1.4-fold) with p values<0.05.
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Figure 17A. IL2-activated PBL lysis of Hs294T cells pretreated with (■) and without (□ ) 10'^M RA. 
Values are respresented as the average ± SEM of five samples where *P<0.05 and **P<0.005.
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A similar pattern was observed using the C8161 cell line (Figure 17B), where lysis was 
increased 3.3-fold from 3.5% to 11.5% at the 20:1 ratio (p<0.05) with similar increases of
2.8-fold (p<0.005) and 2.1-fold (p<0.005) at the 40:1 and 80:1 ratios respectively.
60 i
50 -
40 -
o
E  30 -o0)a
co 20 -
10 -
0 20:1 40:1 60:1 80:1
E:T ratio
Figure 17B. IL2-activated PBL lysis of C8161 cells pretreated with (■) and without (□ ) 10'^M RA. 
Values are represented as the average ± SEM of five samples where *P<0.05 and **P<0.005.
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Pretreatment of the A3 75 cells with 10'6M RA failed to alter tumour cell lysis (Figure 
17C).
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Figure 17C. IL2-activated PBL lysis of A375 cells pretreated with (■) and without (□) 10 6M RA. Values 
are represented as the average ± SEM of five samples.
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Confocal Analysis and Flow Cytometric Analysis o f mICAM-1 Expression 
All three cell lines were found to express mICAM-1 (Figures 18A, B and C for C8161, 
Hs294T and A375 cells respectively) and MHC class 1 (Figures 19A, B and C for C8161, 
Hs294T and A375 cells respectively). Negative controls for MHC class 1 staining are 
shown in Figure 20. Flow cytometric analysis of membrane IC AM-1 expression of C8161 
cells and Hs294T cells (Figures 21A and 2IB respectively) exposed for 4 days to RA at
-10 -7
concentrations of 10 M - 1 0 M  did not significantly alter membrane IC AM-1 expression
-6 -5
but a positive shift in intensity became apparent at concentrations of 10 M - 10 M RA. 
This positive shift in fluorescent intensity corresponds to an increase in mICAM-1 levels.
-10 -7
Using the A375 cells, pretreatment with 10 M -10 M RA marginally induced mlCAM- 
1 expression (Figure 21C) which further increased on treatment with 10^M -10 5M RA.
Confocal Microscopy Analysis
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Figure 19. Expression of ICAM-1 in A) C8161; B) Hs294T; C) A375 cells.
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Figure 20. Expression of MHC class 1 in A) C8161; B) Hs294T ; C) A375 cells.
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Figure 21. Staining of A)C8161; B) Hs294T; C) A375 cells with secondary FITC-conjugated antibody 
used in MHC Class 1 staining.
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Flow Cytometric analysis o f mICAM-1 Expression
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Figure 21 A. Flow cytometric analysis of membrane ICAM-1 expressed on C8161 cells. Tumour cells 
were incubated for 4 days in the presence (unshaded area) and absence (shaded area) of RA. mICAM-1 was 
detected using FITC-labelled anti-human ICAM-1 antibody (**). Sample minus antibody was used to 
determine background fluorescent intensity denoted by *. The x-axis represents log fluorescent intensity 
and the y-axis, cell numbers.
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Figure 2IB. Flow cytometric analysis of membrane ICAM-1 expressed on Hs294T cells. Tumour cells 
were incubated for 4 days in the presence (unshaded area) and absence (shaded area) of RA. mICAM-1 was 
detected using FITC-labelled anti-human ICAM-1 antibody (**). Sample minus antibody was used to 
determine background fluorescent intensity denoted by *. The x-axis represents log fluorescent intensity 
and the y-axis, cell numbers.
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Figure 21C. Flow cytometric analysis of membrane ICAM-1 expressed on A375 cells. Tumour cells were 
incubated for 4 days in the presence (unshaded area) and absence (shaded area) of RA. mICAM-1 was 
detected using FITC-labelled anti-human ICAM-1 antibody (**). Sample minus antibody was used to 
determine background fluorescent intensity denoted by *. The x-axis represents log fluorescent intensity 
and the y-axis, cell numbers.
102
Effect o f  anti-ICAM-1 and HLA-ABC antibody on tumour LAK-cell mediated lysis.
For all comparisons, lysis on addition of blocking ICAM-1 antibody was compared to a 
non-specific IgG control antibody. Using the Hs294T cell line (Figure 22A), blocking 
ICAM-1 at the optimal concentration of 5|ig/ml significantly reduced lysis of control cells
1.8-fold from 57.1 % to 31.1 % (p<0.001) at the 40:1 ratio. This reduction was also observed 
using 1 Opg/ml ICAM-1 antibody which reduced lysis 1.9-fold (p<0.001). Anti-HLA- 
ABC antibody over a range of concentrations had no effect on Hs294T cell lysis (Figure 
22A).
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Figure 22A. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of Hs294T cells (open bar) at an E:T ratio of 40:1. Non specific IgG 
antibody was also included as a control (forward-hatched bar). Values are represented as the average ± SEM 
of five samples where *P<0.0005 and represents comparison of control IgG with specific antibody.
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In the C8161 cells, addition of 5 jig/ml of ICAM-1 antibody at the 40:1 ratio (Figure 22B) 
caused a highly significant 1.5-fold decrease in lysis of control C8161 cells (from 16.2% 
to 10.7%,p<0.0005). Optimum inhibition was achieved using lOfig/ml of ICAM-1 antibody 
which reduced lysis from 19.6% to 8.4% (a 2.3-fold difference, p<0.0005). This inhibition 
was maintained at the higher concentration of antibody. As with the Hs294T cells, addition 
of anti-HLA ABC antibody had no effect on lysis of the C8161 cells (Figure 22B).
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Figure 22B. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of C8161 cells (open bar) at an E:T ratio of 40:1. Non-specific IgG antibody 
was also included as a control (forward-hatched bar). Values are represented as the average ± SEM of five 
samples where *P<0.0005 and represents comparison of control IgG with specific antibody.
Addition of blocking ICAM-1 antibody (5 fig/ml) significantly reduced lysis of the A3 75 
cells 1.6-fold (pO.OOl), and by 2.0-fold using 10|J,g/ml antibody. Blocking HLA-ABC 
antibody had no effect on cell lysis.
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Figure 22C. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of A375 cells (open bar) at an E:T ratio of 40:1. Non-specific IgG antibody 
was also included as a control (forward-hatched bar). Values are represented as the average ± SEM of five 
samples where *P<0.0005 and represents comparison of control IgG with specific antibody.
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Effect o f  anti-ICAM-1 and HLA-ABC antibody on LAK-cell mediated lysis o f RA 
pretreated tumour cells.
On treatment of Hs294T cells with lO^M RA (Figure 23 A) lysis was significantly reduced 
using ICAM-1 antibody at 5|ig/ml which caused a 1.3-fold reduction in lysis from 67.8% 
to 53.4% (p<0.05). Similar reductions were observed at all other antibody concentrations 
tested. Anti-HLA ABC antibody had no effect on LAK cell mediated lysis (Figure 23A).
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Figure 23A. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of Hs294T cells pretreated for 4 days with lO'^M RA (solid bar) at an E:T 
ratio of 40:1. Non-specific IgG antibody was also included as a control (forward-hatched bar). Values are 
represented as the average ± SEM of five samples where *P<0.05 and **P<0.005, and represents comparison 
of control IgG with anti-ICAM-1 antibody.
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A similar pattern was also observed in RA-treated C8161 cells (Figure 23B) where lysis 
was reduced at 5|ig/ml ICAM-1 antibody from 43.7% to 20.5% (p<0.005). Optimum 
inhibition was also achieved using 10pg/ml ICAM antibody which induced a 3-fold 
reduction in lysis of the cells from 44.0% to 14.4% (p<0.005) which was similar at the 
higher concentration of antibody. Lysis was not altered on addition of HLA-ABC antibody.
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Figure 23B. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of C8161 cells pretreated for 4 days with 10'^M RA (solid bar) at an E:T 
ratio of 40:1. Non-specific IgG antibody was also included as a control (forward-hatched bar). Values are 
represented as the average ± SEM of five samples where *P<0.005 and represents comparison of control 
IgG with anti-ICAM-1 antibody.
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Blocking ICAM-1 and HLA-ABC antibodies were unable to alter lysis of RA-treated 
A375 cells (Figure 23C).
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Figure 23C. Effect of blocking ICAM-1 antibody (horizontal hatched bar) and blocking HLA-ABC antibody 
(back-hatched bar) on the lysis of A375 cells pretreated for 4 days with 10 6M RA (solid bar) at an E:T ratio 
of 40:1. Non-specific IgG antibody was also included as a control (forward-hatched bar). Values are 
represented as the average ± SEM of five samples and represents comparison of control IgG with specific 
antibody.
3.4. Retinoid modulation of sICAM-1 secretion
A standard curve was constructed from samples of known concentrations of sICAM-1 
(Figure 24) to allow the unknown levels of sICAM-1 to be determined from the tumour 
cell supernatants.
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Figure 24. Standard curve of sICAM-1 where y=0.042x. The data represents the average of duplicate 
samples.
The Hs294T cell line secreted 7.2fg/cell of soluble ICAM-1 which did not change 
significantly following treatment with 1 0 " -  10"^M RA (range 7.2fg/cell - 11.8fg/ 
cell) (Figure 25A).
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Figure 25A. Effect of RA on sICAM-1 secretion from the Hs294T cells. Values represent the average of 
duplicate samples.
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C8161 cells secreted basal levels of 36.9fg ICAM-1 per cell (Figure 25B). Levels were 
not altered on treatment of tumour cells with 10"^M  - 10"^M RA (range 29.9fg/cell - 
43.4fg/cell).
80 i
60 -
oo
o>
control
RA (M)
Figure 25B. Effect of RA on sICAM-1 secretion from the C8161 cells. Values represent the average of 
duplicate samples.
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The A375 cells secreted basal levels of sICAM-1 of 50.5fg/cell (Figure 25C). At the 
higher concentrations of 1 O^M and 10 5M RA, sICAM-1 expression was increased to 70.9fg/ 
cell and 70.7fg/cell respectively.
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Figure 25C. Effect of RA on sICAM-1 secretion from the A375 cells. Values represent the average of 
duplicate samples.
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Addition o f sICAM-1 to the cytotoxicity assays
At the 40:1 ratio, addition of sICAM-1 to control C8161 cells did not alter their susceptibility 
but RA treatment of cells in combination with sICAM-1 addition, significantly reduced 
lysis from 76.0% to 24.3% (Table 1).
In contrast, addition of sICAM-1 at the 40:1 ratio, using control or RA-treated Hs294T did 
not alter tumour cell lysis (Table 1). Addition of sICAM-1 to A375 cells has not been 
investigated.
C8161 Hs294T
- sICAM + sICAM - sICAM + sICAM
control 35.6% ±3.7 36.5% ± 2.7 46.4% ±1.8 48.3% ±1.1
10'6M RA 76.0% ±3.3 24.3% ±3.4 80.9% ± 8.4 81.3% ±5.9
Table 1. Effect of soluble ICAM-1 on the lysis of C8161 cells and Hs294T cells with and without treatment 
of 10'6M RA.
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3.5. Pentoxifylline modulation of tumour LAK cell-mediated lysis
Unactivated PBL failed to induce lysis of all untreated/treated tumour cells and at all E:T 
ratios tested (data not shown).
Pretreatment of tumour cells for 4 days with PX (250|ig/ml) induced the Hs294T cells to 
become less susceptible to lysis by LAK cells (Figure 26A) and had the opposite effect on 
the C8161 cells (Figure 26B). At the 40:1 E:T ratio, lysis of PX-treated Hs294T cells was 
reduced from 54.9% to 31.3% (p<0.005) at the 40:1 ratio and from 64.4% to 40.4% (p<0.05) 
at the 80:1 ratio (Figure 26A).
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Figure 26 A. Lysis of Hs294T cells with (□) and without (■) 4 days pretreatment of PX (250|ig/ml). Data 
represents the average ± SEM of five samples where *P<0.05 and **P<0.005.
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PX treatment of the C8161 cell line increased LAK cell-mediated lysis from 16.8% to 
29.4% (p<0.0005) at the 40:1 ratio and from 20.1% to 41.7% (p<0.0005) at the 80:1 ratio 
(Figure 26B).
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Figure 26B. Lysis of C8161 cells with (■) and without (□ ) 4 days pretreatment of PX (250|ig/ml). Data 
represents the average ± SEM of five samples where *P<0.0005.
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4 day pretreatment of the low metastatic A375 cell line with 250jig/ml PX failed to alter 
LAK cell-mediated lysis of the tumour cells at all E:T ratios tested (Figure 26C).
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Figure 26C. LAK cell lysis of A375 cells pretreated with (■) and without (□ ) 250pg/ml PX. Values are 
represented as the average ± SEM.
Facs Analysis o f  mICAM-1 expression
PX pretreatment over a range of concentrations (10-250|ig/ml) was unable to significantly 
alter mICAM-1 expression (data not shown).
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Effect o f  anti-ICAM-1 and HLA-ABC antibody on LAK cell-mediated lysis ofPXpretreated 
tumour cells.
Both cell lines were pretreated for 4 days with 250|ig/ml PX before each experiment. For 
all comparisons, lysis on addition of blocking antibody was compared to a non-specific 
IgG control antibody. 10|ng/ml of blocking ICAM-1 antibody significantly reduced lysis 
of PX-pretreated Hs294T cells 1.5-fold from 30.0% to 21.3% (p<0.05) and by 1.5-fold 
from 33.5% to 23.7% (p<0.05) using 25pg/ml ICAM-1 antibody (Figure 27A). Blocking 
HLA-ABC antibody had no effect on LAK cell-mediated lysis of PX-pretreated Hs294T 
cells (Figure 27A).
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Figure 27A. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back hatched bar) on the lysis of Hs294T cells pretreated for 4 days with 250|Llg/ml PX (solid bar) at an E:T 
ratio of 40:1. Non-specific IgG antibody was also included as a control (forward hatched bar). Values are 
represented as the average ± SEM where *P<0.05 and represents comparison of control IgG with specific 
antibody.
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In PX-pretreated C8161 cells, lysis was significantly reduced using 5[ig/ml ICAM-1 
antibody from 27.6% to 13.1% (2.1-fold, p<0.0005) with similar decreases of 2.3-fold 
(p<0.0005) using both 10|Xg/ml and 25pg/ml of blocking ICAM-1 antibody (Figure 27B). 
Blocking HLA-ABC antibody failed to alter LAK cell-mediated lysis of PX-pretreated 
C8161 cells.
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Figure 27B. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back hatched bar) on the lysis of C8161 cells pretreated for 4 days with 250|Ig/ml PX (solid bar) at an E:T 
ratio of 40:1. Non-specific IgG antibody was also included as a control (forward hatched bar). Values are 
represented as the average ± SEM where *P<0.0005 and represents comparison of control IgG with specific 
antibody.
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Addition of blocking ICAM-1 antibody and blocking MHC class 1 antibody had no effect 
on lysis of PX-pretreated A375 cells (Figure 27C).
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Figure 27C. Effect of blocking ICAM-1 antibody (cross-hatched bar) and blocking HLA-ABC antibody 
(back hatched bar) on the lysis of A375 cells pretreated for 4 days with 250|ig/ml PX (solid bar) at an E:T 
ratio of 40:1. Non-specific IgG antibody was also included as a control (forward hatched bar). Values are 
represented as the average ± SEM and represents comparison of control IgG with specific antibody.
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3.6. Effect of pentoxifylline on expression of sICAM-1
The standard curve (Figure 24) was used to determine the amount of sICAM-1 released 
from untreated and PX-treated cell lines.
4 days pretreatment of the Hs294T cells with PX caused a dose dependent increase in 
sICAM-1 levels at all concentrations of drug tested (Figure 28A). Using 10|ig/ml PX, 
sICAM-1 was increased 1.5-fold whereas, at the higher concentration of lOOpg/ml PX, 
expression was increased 2.3-fold. A 4.7-fold increase was observed in the Hs294T cells 
on pretreatment of the tumour cells with 250(Ltg/ml PX (Figure 28A).
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Figure 28A. Effect of PX on sICAM-1 secretion from the Hs294T cells. Values represent the average of 
duplicate samples.
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C8161 cells secreted basal levels of 36.9fg ICAM-1 per cell (Figure 28B).
Using 10(ig/ml PX, sICAM-1 expression was increased 1.3-fold, and 2.5-fold using lOOjig/ 
ml PX. A 4.3-fold increase in sICAM-1 expression was observed on pretreatment of the 
tumour cells with 250|ig/ml PX (Figure 28B).
control 10 100 250
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Figure 28B. Effect of PX on sICAM-1 secretion from the C8161 cells. Values represent the average of 
duplicate samples.
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The A375 cells secreted basal levels of sICAM-1 of 50.5fg/cell (Figure 28C). Only at the 
higher concentration of PX (250|ig/ml) was there an increase in sICAM-1 expression (from 
50.5fg/cell to 85.5fg/cell).
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Figure 28C. Effect of PX on sICAM-1 secretion from the A375 cells. Values represent the average of 
duplicate samples.
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3.7. Effect of retinoic acid and pentoxifylline on lung tumour colony formation using 
the experimental metastasis model
The Hs294T cell line failed to produce any lung colonies and pretreatment o f these cells 
with either 10^M RA or 250pg/ml PX failed to alter tumour counts (data not shown). 
Both the A375 cell line and the C8161 cell line (Figure 29) produced lung tumour colonies 
(Tables 2A and 2B respectively), with the highly metastatic C8161 cells producing a much 
greater number o f colonies (average o f 31 compared to an average of 3 for the A3 75 cells).
A B
Figure 29. Lung tumour colony formation using C8161 cells (A). Control lungs from a mouse not 
injected with tumour cells are shown in B.
Cell line Treatment No. lung colonies Range Average no. lung 
colonies
A3 75 control 0, 0, 0, 0, 0, 3, 8, 9 0-9 3
lO^M RA 0, 0, 0, 0, 0, 8,61, 12 0-61 11
250p.g/ml PX 0, 0, 0, 3, 8, 4, 6, 4 0-5 2
Table 2 A. Effect of RA and PX on A375 lung tumour colony formation.
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Cell line Treatment No. lung colonies Range Average no. 
lung colonies
C8161 control 0 ,3 ,3 , 19, 26, 88, 75 0-88 31
10'6M RA 0, 0, 0, 4, 14,71, 103 0-103 28
250|ig/ml PX 0, 0, 6, 26, 42, 72,100, 128 0-128 47
Table 2B. Effect of RA and PX on C8161 lung tumour colony formation.
PX pretreatment of the A375 cell line appeared to have no significant effect on lung tumour 
formation (Table 2A), and although the average was greater for RA treatment compared to 
the control, this was due to the response of one mouse producing a much greater number 
of tumours than the rest of the group. The experiment would need to be repeated to see if 
this was a truely significant increase due to RA or simply an extreme response by one 
mouse.
lO^M RA pretreatment of the C8161 cells did not produce any striking effect on lung 
tumour formation (Table 2B). Although PX produced a greater number of tumours on 
average than the untreated A375 cells, again, due to the variation in responses of the mice, 
it is difficult to conclude this difference is due to the drug treatment as most of the lung 
tumour counts were similar in both groups with only a few exceptions. The experiment 
would have to be repeated on a much larger scale to provide sound evidence that either 
drug had any effect on tumour colony formation.
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Confocal microscopy o f  membrane-associate uPA and tPA expression
Cell-associated uPA was strongly expressed in greater than 95% of C8161 cells (Figure 
30A) and Hs294T cells (Figure 30B), and although the A375 cells did express uPA (Figure 
30C), expression was much weaker than the other two cell lines. tPA was also found to be 
associated with greater than 95% of the C8161, Hs294T and A375 cells (Figures 31 A, 
3IB and 31C respectively) although at much lower levels than uPA. Controls staining 
with secondary antibody only were negative (Figures 32A, B, C).
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Figure 30. Expression of uPA in A) C8161 cells; B) Hs294T cells; C) A375 cells.
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Figure 31. Expression of tPA in A) C8161 cells; B) Hs294T cells; C) A375 cells.
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Figure 32. Staining of A) C8161 cells; B) Hs294T cells; C) A375 cells with secondary FITC-conjugated 
antibody used in uPA and tPA staining.
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3.8. ELISA determination of secreted uPA and tPA
For each experiment, standards of known concentration of either uPA or tPA were used to 
plot a standard curve. The equation of the line was calculated for each experiment and 
used to allow the concentration of PA from the cell lines to be determined. The initial 
standard curve measuring uPA levels (Figure 33) allowed samples of unknown 
concentrations of uPA with optical density values no greater than 1 to be determined.
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Figure 33. Standard curve of uPA where y=0.552x. All samples were performed in duplicate and are 
represented as the average.
129
Preliminary experiments to determine the range o f dilutions required to measure secreted 
uPA in the A375, C8161 and Hs294T cells.
Initially, the supernatants from untreated Hs294T, C8161 and A375 cells were added to 
the ELISA plates over a range of dilutions from 1/5 to 1/200. The unknown concentration 
of uPA in each cell line was determined from figure 33, and the results expressed as the 
amount of uPA secreted per cell (Table 3).
Hs294T
Dilution
Absorbance
(ng/ml)
uPA
(ng/5ml)
total uPA 
(fg/cell)
uP A/cell
undiluted 0.301 0.55 2.75 2.37
1/5 0.052 0.47 2.35 2.02
1/20 0.035 1.27 6.35 5.47
1/50 0.0195 1.35 6.75 5.81
1/100 0.0075 1.77 8.85 7.62
1/200 0 0 0 0
1/400 0 0 0 0
Table 3. Initial measurement of uPA secretion from the Hs294T cell line. Samples were analysed in 
duplicate and the amount of uPA determined by standards in figure 33.
In preliminary experiments, over the range of chosen dilutions, uPA expression was 
undetectable in the A375 cell line, whereas, in contrast, using the C8161 cell line, the 
absorbancies obtained were outwith the limits of the uPA assay indicating the C8161 
supernatant contained levels of uPA which were too high to be measured even at the 
highest dilution (data not shown). In the Hs294T cell line, uPA expression was detectable 
at the selected dilutions and increased with increasing dilution factor (Table 3) from 2.4fg/ 
cell in undiluted supernatant to 7.6fg/cell at a dilution factor of 1/100. At the higher 
dilutions of 1/200 and 1/400, the uPA in the sample became so dilute that it was undetectable.
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Preliminary mesurements o f  tPA expression
The standard curve produced from samples of known concentrations of tPA produced a 
plateau rather than a straight line (Figure 34A).
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Figure 34A. Standard curve of tPA.
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Therefore, the linear part of figure 34A was used to construct the standard curve (Figure 
34B) to determine the concentration of tPA in the cell line supernatants.
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Figure 34B. Linear part of figure PA2 used to determine the amount of secreted tPA from the tumour cell 
lines where y=2.73x.
132
Using Figure 34B, the expression of tPA from all three cell lines was determined 
(Table 4).
Cell line
Expression of tPA (fg/cell)
Undiluted 1/5 1/20 1/50 1/100 1/200
C8161 0.66 1.04 1.16 1.60 1.60 2.31
Hs294T * 7.72 9.59 11.23 12.14 15.77
A375 * 7.15 10.69 13.05 12.35 11.38
Table 4. Expression of tPA from untreated C8161, Hs294T and A375 cells. The data represents the 
average of duplicate samples. * denotes samples with absorbance values outwith the valid range of the 
assay.
All three tumour cell lines were found to express tPA (Table 4) with the C8161 cells 
secreting the lowest levels (range 0.7 - 2.3fg/cell) over the range of dilutions tested. Both 
the the Hs294T cells (7.7 - 15.8fg/cell) and the A375 cells (7.2 - 13.1fg/cell) secreted 
higher levels of tPA, with expression of tPA from either cell line being similar. As with 
the initial determination of uPA expression, the general trend appeared to show that levels 
of tPA increased as the samples became more dilute (Table 4).
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3.9. Retinoid modulation of uPA expression
A fresh batch of cells were cultured with and without 4 days pretreatment using a range of 
concentrations of RA (10'10M - 10‘5M) and the supernatant collected to determine uPA 
expression. Figure 35 was constructed to allow the expression of uPA to be calculated 
from the samples.
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Figure 35. Standard curve of uPA where y=0.565x. Data represents the average of duplicate samples.
RA was unable to induce expression of uPA from the A3 75 cells which, in the preliminary 
experiment, had been shown to lack expression of uPA (data not shown).
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Using the C8161 cells, absorbancies from the supernatants diluted 1/600 (Table 5) from 
cells pretreated with 10‘7M - 10'5M RA were outwith the valid range of the assay (as 
determined by Figure 35). However, at the 1/800 dilution, RA caused a maximum 2.4- 
fold increase in uPA expression in the C8161 cell line using 10‘7M RA (Table 5).
C8161 Control 10'10M
RA
10'9M
RA
10'8M
RA
10‘7M
RA
10'6M
RA
10'5M
RA
1/600 1.06 1.30 1.38 2.47 * * *
1/800 1.21 1.05 1.2 2.13 2.86 2.72 2.57
Table 5. Determining the amount of secreted uPA from the C8161 cell line with and without 4 days 
pretreatment with a range of concentrations of RA. Figure 35 was used to determine uPA expression and * 
denotes samples whose absorbances were outwith the valid range of the assay. All samples were performed 
in duplicate and values expressed as pg uPA/cell. All values at the 1/400 dilution were outwith the valid 
range of the assay.
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Using the Hs294T cells, there was a slight increase in uPA secretion on treatment of the 
tumour cells with RA, with a maximum 2-fold increase observed using 10'9M RA (1/20 
and 1/50 dilution) (Table 6).
Hs294T Control 10-10M
RA
10'9M
RA
10'8M
RA
10‘7M
RA
lO^M
RA
10‘5M
RA
1/5 1.79 1.68 1.38 1.92 3.68 4.24 3.07
1/20 3.14 1.52 6.55 2.61 3.89 3.29 4.49
1/50 4.66 2.44 8.98 2.62 5.67 3.65 2.93
Table 6. Determining the amount of secreted uPA from the Hs294T cell line with and without 4 days 
pretreatment with a range of concentrations of RA. Figure 35 was used to determine uPA expression and all 
samples were performed in duplicate with values expressed as fg uPA/cell.
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3.9.1 Repeating the experiments on a new batch of tumour cells to examine the retinoid 
modulation of uPA expression
A new batch of tumour cells were set up with and without 4 days pretreatment with RA 
(10'10M -1 0'5M). The standard curve was constructed for uPA using the standards (Figure 
36) to allow determination of expression of uPA from the experimental samples.
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Figure 36. Standard curve of uPA where y=0.344x.
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Figure 37A shows that RA (10'8M - 10'5M) induced an increase in uPA expression with 
the lower concentrations of 1010M - 10'9M having minimal effects on uPA expression. A 
maximum value of 3230fg uPA/cell was achieved using 10'8M RA which corresponded to 
a 3.4-fold increase in uPA expression at the 1/2000 dilution.
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Figure 37A. Effect of RA(«10 l0M; OlO*9M; •10-»M; ^10  7M; ♦ 1 0  6M; ^10  5M; □  control) on secretion 
of uPA from the C8161 cell line. Data represents the average of duplicate samples where the secretion of 
uPA from the unknowns were calculated from the standards from figure 36. Absorbance readings at the 
dilution of 1/4000 were negative for all samples tested.
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10‘9M RA and 10'8M RA induced an increase in uPA expression in the Hs294T cell line, 
with maximum expression achieved using 10’8M RA which increased uPA expression 
from 4.41fg/cell to 7.0fg/cell at the 1/200 dilution (Figure 37B). Levels of expression 
decreased to similar values as the control using lO^M and 10'5M RA.
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Figure 37B. Effect of RA (BIO'^M; O10'9M; •  10'8M; ♦ 1 0 ‘6M; A10'5M; □  control) on secretion
of uPA from the Hs294T cell line. Data represents the average of duplicate samples where the secretion of 
uPA from the unknowns were calculated from the standards from figure 36. Absorbance readings at the 
dilution of 1/400 were negative for all samples tested.
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Figure 38 combines the data from figures 37A and 37B at the highest dilution tested for 
each cell line (1/2000 for the C8161 cells and 1/200 for the Hs294T cells) to show a 
comparison between the retinoid-induced alterations in uPA expression in the 2 cell lines.
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Figure 38. Comparison of uPA secretion from C8161 cells (■) and Hs294T cells (□). Values represent the 
average of duplicate samples.
140
3.10. Retinoid modulation of tPA expression
Figure 39A was constructed to allow the unknown concentrations of tPA to be determined 
from the same supernatant used to analyse uPA expression (Tables 5 and 6). As with the 
previous tPA assay, the linear part of the graph was used to determine tPA levels in the 
experimental samples (Figure 39B).
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Figure 39A. Standard curve of tPA.
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Figure 39B. Linear part of figure 39B used to determine the amount of secreted tPA from the tumour cell 
lines where y=1.867x. Values represent the avearge of duplicate samples.
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Expression of tPA from the C8161 cells was shown to increase as the dilution factor 
increased (Table 7). At the 1/50 dilution, 10'6M RA induced a 3.9-fold increase in tPA 
expression, with maximum expression induced (5.6-fold) using 10'5M RA. Similar increases 
were found at the 1/200 dilution where 10‘6M RA induced a 3.1-fold increase in tPA 
expression compared to a 3.8-fold increase using 10'5M RA (Table 7).
C8161 Control 1010M
RA
10'9M
RA
10‘8M
RA
10"7M
RA
10'6M
RA
10'5M
RA
1/5 1.61 2.45 2.3 2.48 * * *
1/50 2.24 2.89 3.76 3.92 6.64 8.64 12.63
1/200 4.29 3.5 7.58 9.22 9.51 13.3 16.12
Table 7. Determining the amount of secreted tPA from the C8161 cell line with and without 4 days 
pretreatment with a range of concentrations of RA. Figure 39B was used to determine tPA expression and 
* denotes samples whose absorbances were outwith the valid range of the assay. All samples were performed 
in duplicate and values expressed as fg tPA/cell.
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The expression of tPA also increased in the Hs294T cells with increasing dilution factor 
(Table 8). At the 1/50 dilution, maximum induction of tPA expression was observed with 
10‘7M RA, which increased tPA levels 2.5-fold. Expression was increased 4.6-fold with 
the same pretreatment at the higher dilution of 1/200 (Table 8).
Hs294T Control 10'10M
RA
10’9M
RA
10'8M
RA
10-7M
RA
10'6M
RA
10'5M
RA
1/50 25.62 19.58 37.21 40.42 64.25 41.29 38.94
1/200 21.02 24.39 79.79 88.85 97.16 81.50 79.63
Table 8. Determining the amount of secreted tPA from the Hs294T cell line with and without 4 days 
pretreatment with a range of concentrations of RA. Figure 39B was used to determine tPA expression. All 
samples were performed in duplicate and values expressed as fg tPA/cell. Absorbances for all samples 
diluted 1/5 were outwith the valid range of the assay.
As was shown for the Hs294T and C8161 cells, expression of tPA from the A375 cells 
was increased in the more dilute sample (Table 9). Pretreatment of the tumour cells with 
10'7M RA caused a 1.7-fold increase in tPA secretion which was similar using 10'6M RA 
(Table 9).
A375 Control 10*10M
RA
10'9M
RA
10-8M
RA
10'7M
RA
lO^M
RA
10'5M
RA
1/50 15.01 11.39 17.43 16.73 27.89 26.63 23.36
1/200 27.98 23.10 27.05 32.72 46.82 48.62 33.31
Table 9. Determining the amount of secreted tPA from the A375 cell line with and without 4 days pretreatment 
with a range of concentrations of RA. Figure 39B was used to determine tPA expression. All samples were 
performed in duplicate and values expressed as fg tP A/cell. Absorbances for all samples diluted 1/5 were 
outwith the valid range of the assay and readings at the 1/400 dilution were zero.
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3.10.1. Repeating the experiments on a fresh batch of cells to determine the retinoid- 
induced modulation of tPA expression
It was not possible to repeat all the tPA assays due to the difficulty in obtaining more 
chicken anti-human tPA antibody. Therefore, since the maximum values of tPA expression 
were obtained with the RA-pretreated A375 cells at the chosen dilutions, it was decided to 
repeat the experiments with the Hs294T and C8161 cells at higher dilutions to obtain 
values for the maximum expression of secreted tPA with RA treatment.
Using the same supernatant as used to produce the data in figures 37A, B and 38, tPA 
expression was determined in the samples by first constructing a standard curve using 
known standards (Figures 40A and 40B).
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Figure 40A. Standard curve of tPA.
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Figure 40B. Linear part of figure 40A used to determine the amount of secreted tPA from the tumour cell 
lines where y=0.566x.
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Expression of tPA was increased with 10‘8M - 10'5M RA pretreatment of the C8161 cells 
(Figure 41 A). Maximum expression was reached using 10'6M RA which increased 
expression from 4.34fg/cell to 16fg/cell at the 1/400 dilution.
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Figure 41 A. Effect of RA(B10'10M; O10‘9M; ©lO^M; >10'7M; ♦ 1 0 '6M; "frlO^M; □  control) on secretion 
of tPA from C8161 cells . Data represents the average of duplicate samples where the secretion of tPA from 
the unknowns were calculated from the standards from Figure 40B. Absorbance readings at the dilution of 
1/800 were negative for all samples tested.
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tPA expression was also induced in the Hs294T cell line using RA at concentrations of 
10'9M - 10'5M (Figure 41B). At the 1/400 dilution expression was increased from 24.5fg/ 
cell to 92.4fg/cell using 10'6M RA.
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Figure 41B. Effect of RA (■ 10'10M; O 109M; • 1 0 8M; <M0'7M; ♦ 1 0 6M; ☆ 105M; Dcontrol) on secretion 
of tPA from Hs294T cells. Data represents the average of duplicate samples where the secretion of tPA 
from the unknowns were calculated from the standards from Figure 40B. Absorbance readings at the 
dilution of 1/4000 were negative for all samples tested.
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Figure 42 combines the data from Figures 41A and 41B and Table 9 at the highest dilution 
tested for each cell line (1/400 for the C8161 cells; 1/1000 for the Hs294T cells and 1/200 
for the A375 cells) to show a comparison between the retinoid-induced alterations in tPA 
expression in the 3 cell lines.
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Figure 42. Comparison of tPA secretion from C8161 cells (■); A375 cells (O) and Hs294T cells (•). 
Values represent the average of duplicate samples.
149
3.11. Pentoxifylline modulation of uPA expression
The ELISA assays analysing the effect of PX on uPA expression have only been performed 
once, and would need to be repeated before any final conclusions could be drawn.
Using the C8161 cells, the lower concentrations of PX fail to significantly modulate uPA 
expression. However, using 250|ig/ml PX, expression of uPA was greatly increased (2.6- 
fold at the 1/800 dilution) (Figure 43A).
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Figure 43A. Effect of PX (■10pg/ml; 0100|ig/ml; •250gg/ml; □  control) on secretion of uPA from the 
C8161 cell line. Figure 35 was used to determine uPA expression and all samples were performed in 
duplicate with values expressed as fg uPA/cell.
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The general trend appears to show that PX induces an increase in uPA secretion from the 
Hs294T cells with a maximum 2.7-fold increase being achieved after 4 days pretreatment 
with 250|ig/ml PX (Figure 43B).
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Figure 43B. Effect of PX (■lOpg/ml; O100|ig/ml; •250pg/ml; □control) on secretion of uPA from the 
Hs294T cell line. Figure 35 was used to determine uPA expression and all samples were performed in 
duplicate with values expressed as fg uPA/cell.
The effect of PX on uPA expression from the A375 cells (which had undetectable levels of 
secreted uPA) has yet to be analysed.
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3.12. PentoxifVlline modulation of tPA expression
The effect of PX on tPA secretion from the C8161 cell line was marginal, having a slight 
effect at the higher dilution where 250|ig/ml PX induced a 1.4-fold decrease in tPA 
expression (Figure 44). As the experiment has only been performed once, it would be 
necessary to repeat the experiment to confirm the data. The effect of PX on tPA secretion 
from the Hs294T and A375 cell lines has not been determined.
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Figure 44. The effect of PX (■ 1 Oug/ml; 0 1 OOug/ml; #250ug/ml; □control) on secretion of tPA expression 
in the C8161 cell line. Data represents the average of duplicate samples.
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3.13. Analysis of retinoic acid receptor expression
The following pSG5 vectors (Figure 45) containing either RARa, b or g inserts provided 
by P. Chambon (Inserm, France) were transformed into E.coli, purified and subjected to 
restriction enzyme digestion to confirm their identities.
RARa vector
RARp vector
RARy vector
EcoRl (1043)
Pstl (1480)
Pstl (2097) 
EcoRl (3956)
EcoRl (1043) 
EcoRl (2000)
EcoRl (2615)
EcoRl (1043) 
Sacl (1631) 
Pstl (2126)
EcoRl (2559)
Figure 45. pSG5 vectors containing RARa, (3 and y  inserts.
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Restriction enzyme digests of pSG5 RARa, p and y
Restriction digests of 3 clones of each pSG5 RARa, p and y gave the following patterns 
when visualised after agarose gel electrophoresis.
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RARa
Figure 46. Restriction enzyme digestion of RARa, P and y pSG5 vectors
The distance migrated by each band of the marker was measured and a graph plotted of the 
size in base pairs, versus log distance migrated. This was used to determine the sizes of 
the bands produced from the digests. Since the marker used was covering a wide range of 
sizes, 2 separate lines were plotted to produce a linear plot from which the unknown sizes 
could be determined.
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Figure 47A. Standard curve of the marker from Figure 46A covering the size range of 220 - lOOObp.
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Figure 47B. Standard curve of the marker from Figure 46A covering the size range of 1600 - 4000bp.
Marker (bp)
Figure 48A. Standard curve of the marker from Figure 46B covering the size range of 200 - lOOObp.
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Figure 48B. Standard curve of the marker from Figure 46B covering the size range of 1000 - 4500bp.
The distance migrated by each of the sample bands was measured to allow an approximate 
size of fragment (in base pairs) to be determined.
Vector Enzyme Digest Expected Result (b) Observed Result (b)
pSG5 alpha
EcoRl
Pstl
EcoRl/Pstl
4076, 2913 
6372,617
4076,1859,617, 437
4000, 1900 
>4000, 720 
4000,1900,(1300), 
720, 600
pSG5 beta
EcoRl 4262, 957,615, 4000, 720, 600
pSG5 gamma
EcoRl
Pstl
EcoRl/Pstl
4076, 1516 
5592
4076, 1083,433
4000, 2500 
>4000 
4000, 2500
Table 10. Size determination of the restriction enzyme fragments produced in Figure 46. The value in 
brackets denotes a possible partial digest product.
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The EcoRl digest product of pSG5 RARa vector (Table 10, Figure 46A) produced the 
expected size of band corresponding to cut vector (4kb) and also a second band (1.9kb) 
corresponding to the insert which was approximately lkb shorter than the expected size 
(Table 10). The Pstl digest product (Table 10, Figure 46A) was similar in size to the 
expected value (720 bases compared to 617 bases), and the double digest EcoRl/Pstl of 
the RARa vector (Table 10, Figure 46A) confirmed the missing lkb from the insert. A 
partial digest product of 1.3kb was also observed and this corresponded to either the 
digestion product between the EcoRl site at position 1043 with the Pstl site at position 
2097.
The expected pattern of results was produced for the pSG5 RARp vector with EcoRl 
digestion (Table 10, Figure 46B) yielding a fragment of 4kb corresponding to the cut 
vector and 2 fragments of 0.72kb and 0.6kb corresponding to the insert containing an 
internal EcoRl site, although the 0.72kb fragments appeared to be approximately 300 
bases smaller than expected.
EcoRl digestion of the pSG5 RARy vector (Table 10, Figure 46B) produced the expected 
size of band of 4kb corresponding to the cut vector whereas the insert appeared to be lkb 
larger (2.5kb) than the expected size of 1.5kb. The insert also appeared to lack an internal 
Pstl site as there was no corresponding band of 0.4kb visible on the gel (Table 10, Figure 
46A) using the double digest of EcoRl/Pstl.
The results produced from these digests raised serious doubts as to the identity of the 
supplied vectors. Therfore in an attempt to further characterise the probes, partial sequence 
analysis was performed from amplified regions of each insert.
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Amplification o f  the pSG5 Vector using Specific Internal Primers.
Amplification of the pSG5 RARa and p vectors was successful for all dilutions producing 
the expected bands of approximately 500 bases (Figure 49, lanes 1-3 for pSG5 RARa and 
lanes 4-6 for pSG5 RARp). PCR of the pSG5 RARy vector was unsuccessful using the 
chosen primers (Figure 49, lanes 7-9).
Figure 49. Amplification of pSG5 vectors containing RARa (lanes 1-3), RAR(3 (lanes 4-6) and RARy 
(lanes 7-9). * denotes the lOObp marker.
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EcoRl restriction enzyme digests o f  the purified pCR2.1 vector from  the RARa and P 
transformants, fo r  use in the sequencing reactions.
Out o f the ten clones picked from the colonies grown after transformation of E.coli with 
pCR2.1 RARa, 8 out of the 10 contained vector and insert (Figure 50, lanes 1-3, 5-7, 9- 
10). 2 of the clones contained vector only (lanes 4 and 8).
* 1 2 3 4 5 6 7 8 9  10
500bp — —  insert
Figure 50. EcoRl digestion of the RARa transformation reactions.
Only one clone selected from the pCR2.1 RARp transformations contained vector and 
insert (Figure 50B, lane 3) whilst the other 9 contained vector only.
insert
Figure 50B. EcoRl digestion of the RAR(3 transformation reactions.
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As larger quantities of vector were required for sequencing, the clones from lane 2, Figure 
50A and lane 3 Figure 50B were cultured in 100ml LB broth. The purified vector was 
sequenced (Figure 51A for RARa and Figure 5 IB for RARp).
G A T C
E5’..ACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGAT 
0  5'..ACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGAT
VECTOR INSERT 
< >
ATCTGCAGAATTCGGCTTACCTCCGGCGTCAGCGTGTAGCTCTCAGAGCAC 
ATCTGCAGAATTCGGCTTACCTCCGGCGTCAGCGT *t a g c t c t c a g a g c a c
TCGGGCTTG G G CA CCTCCTTCTTCTTCTTG TTTCG G TCG TTT....3 ' E 
TCGGGCTTG G G CA CCTCCTTCTTCTTCTTG TTTCG G TCG TTT....3 ' O
Figure 51 A. Partial sequencing of the RARa PCR product contained within the pCR2.1 vector. * 
denotes a missing base. The letters E and O represent "expected" and "observed" sequences respectively.
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G A T C
E 5'....ACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGAT 
O 5'....ACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGAT
VECTOR INSERT 
< >
ATCTGCAGAATTCGGCTTGGCTTGACCATCGCAGACCAAATTACCCTGCTGA
ATCTGCAGAATTCGGCTTGGCTTGACCATCCGAGACCAAATTACCCTCGTGA
& * jfc *
AGGCCGCCTGCCTGGACATCCTGATTCTTAGAATTT....3' E 
AGGCCGCCTGCCTGGACATCCTGATTCTTAGAATTT....3' O
t
T
Figure 51B. Partial sequencing of the RAR(3 PCR product contained within the pCR2.1 vector. * denotes 
an incorrect base. The letters E and O represent "expected" and "observed" sequences respectively.
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Preparation of the Probes for Northern Analysis
The remaining vector was subject to EcoRl digestion (Figure 52) for use as a probe in 
Northern analysis.
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Figure 52. Large scale EcoRl digestion of A) pCR2.1 RARa and B) pCR2.1 RAR(J
The bands corresponding to the inserts were excised from the gel and purified using the 
Gel Extraction kit. Successful purification was confirmed by running a small aliquot of 
each sample on a 1% agarose gel (Figure 53).
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Figure 53. RARa and (3 inserts produced after gel purification
163
Restriction Enzyme Digestion of the New Batch ofpSG5 RARy
Restriction enzyme digestion of pSG5 RARy produced similar results (Figure 54) to the 
digests on the previous pSG5 RARy sample (Figure 46) indicating the Pstl site was absent 
from the insert. Sacl digestion (Figure 54, lane 4) and the double digests of EcoRl/Pstl 
and EcoRl /Sacl (lanes 5 and 6 respectively) and Sacl/Pstl (lane 7) indicated the lack of 
a Sacl site in the insert.
Figure 54. Restriction enzyme digestion of the new pSG5 RARy.
Northern Blot Analysis o f  RARa and ft
Northern blot analysis of RARa and RARp produced no signal (data not shown) after 
overnight and 3 weeks exposure of the x-ray film.
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PCR amplification and Southern Blotting o f RARs
RAR expression in the cell lines was analysed by RT-PCR due to the failure of the Northern 
blot approach.
Using RT-PCR, RARa expression was undetectable in either RA-treated or untreated 
C8161 and Hs294T cells but was expressed in the control MCF-7 cell line and in untreated 
A375 cells (Figure 55A). Southern blotting revealed a band corresponding to the MCF-7 
and the A375 PCR product (Figure 55B).
Both RAR(3 and y  expression were detectable in treated and untreated cell lines (Figures 
55C and 55E respectively) which were confirmed by Southern blotting (Figures 55D and 
55F respectively).
The negative controls of template RNA, cDNA mix minus polymerase, cDNA mix minus 
RNA template, and PCR mix minus cDNA template were negative for RARs (Figure 56).
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Figure 55A. Expression of RARa (A) and RAR[3 (C) in human melanoma cell lines with and without 4 
days pretreatment of 10'6M RA. The corresponding Southern blots for RARa and RAR(3 are shown in 
Figures B and D respectively.
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Figure 55B. Expression of RARy (E) in human melanoma cell lines with and without 4 days pretreatment 
of 10‘6M RA. The corresponding Southern blot for RARy is shown in Figure F.
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Controls for the Expression of the RARs
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Figure 56. Amplification of RARa ( A) and RARp (B) using RNA templates from human melanoma cell 
lines. Other negative controls included were 1) PCR mix minus cDNA template 2) cDNA mix minus 
reverse transcriptase (RT) 3) cDNA mix with RT.
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Figure 56. Amplification of RARy (C) using RNA templates from human melanoma cell lines. Other 
negative controls included were 1) PCR mix minus template 2) cDNA mix minus RT 3) cDNA mix with 
RT.
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Chapter 4. Discussion
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Discussion
4.1. Retinoid induced modulation of tumour cell growth and adhesion to ECM 
components
The antiproliferative activity of retinoids has been extensively exploited for the treatment 
of various skin disorders (Kligman et al, 1986) and for the treatment of certain types of 
cancers (Castaigne et al, 1990; Kraemer et al, 1988; Boone et al, 1990) making the retinoids 
one of the most prominent chemopreventitive agents to reach clinical trials. There have 
been several reports to show that the retinoids are successful at inhibiting tumour cell 
proliferation including that from our own laboratory which has shown a decrease in B16 
cell growth with RA treatment (Edward et al, 1988). It has been suggested that the RA- 
induced inhibition in cell growth may involve supression of c-fos and c-jun which are 
proto-oncogenes encoding nuclear proteins. They form heterodimers constituting the 
activator protein complex, AP-1 which is involved in regulating a diverse set of genes 
important for cell growth and differentiation. Activation of c-fos and c-jun have been 
shown to induce cellular transformation and Busam et al, (1992) has demonstrated the 
supression of c-fos in B16 melanoma cells, suggesting this contributed to the observed 
decrease in cell growth by RA.
None of the three cell lines tested in this study were responsive to RA-induced growth 
inhibition (Edward et al, 1997). The exception was using prolonged pretreatment of the 
tumour cells with RA for 7 days at the higher concentrations which reduced cell numbers. 
At this point, viability of the tumour cells was also reduced, most likely due to the toxicity 
of the drug treatment. Hendrix et al, (1990) had previously reported on a 49% decrease in 
cell numbers using the A375 cells line, however, this data was obtained pretreating the 
tumour cells with 10‘5M RA for 7 days which, in our hands, significantly reduced viability 
of the tumour cells.
Several recent reports have shown RA has the ability to modulate adhesion of various cell 
lines to ECM components. Taraboletti et al, (1997) exposed acute promyelocytic leukemia 
cells to RA and found that adhesion of these cells to subendothelial matrix and to fibronectin 
was increased. He et al, (1998) demonstrated a RA-induced increase in adherence of 
NIH3T3 cells to fibronectin, whereas Nakagawa et al, (1998) reported on the ability of RA 
to increase adhesion of colon adenocarcinoma cell lines to the ECM. Matarrese et al, 
(1998) also observed an increase in adhesion of RA-treated cervical carcinoma cells to the
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ECM.
In our study, analysis of the adherence of C8161 cells to various ECM components was 
examined, as was the ability of RA to modulate this adherence. Performing the concentration 
response assays ensured that different concentrations of RA did not affect adhesion since 
we have shown using the B16 cell line, that RA concentrations did have an effect on B16 
cell adhesion to various ECM components (Edward et al, 1989). Since RA was unable to 
alter adhesion of the C8161 cells to laminin, fibronectin, collagens type I and IV, the 
effect of RA on adherence of the A375 cells, which had previously been reported to reduce 
adherence to basement membrane (Hendrix et al, 1990) was investigated. However, the 
authors used 10'5M RA for 7 days, and in our experiment, pretreatment of the A375 cells 
for 4 days with 10'6M RA, failed to have a significant effect on tumour cell adherence to 
basement membrane.
RA has been shown to modulate integrin profile in other cell types such as increasing 
a3p l expression and decreasing a5p l expression in embryonal carcinoma cells (Burdsal 
et al, 1994). The p4 integrin subunit was reduced by RA in Lewis lung carcinoma cells 
which was associated with an inhibition of the malignant phenotype (Gaetano et al, 1994). 
However, the initial plan to analyse alterations in integrin profile did not merit any further 
investigation, due to the inability of RA to alter tumour cell adhesion. In any case, very 
recent studies by He et al, (1998), Nakagawa et al, (1998), and Mataresse et al, (1998) 
failed to find any changes in integrin molecule profile between control and RA-treated 
cells, despite showing RA-induced increases in adhesion of the various cell lines to ECM 
components. Nevertheless, both Nakagawa et al, (1998) and Matarrese et al, (1998) did 
find an increase in the expression of focal adhesion kinase (FAK) with RA treatment 
suggesting a potential role for this protein in the RA-induced changes in cell adhesive 
properties.
4.2. Pentoxifylline-induced modulation of tumour cell growth and adhesion to ECM 
components
Tumour cell numbers were decreased in all three cell lines by PX-pretreatment in a dose 
and time dependent manner which is similar to the recent finding by Amirkhosravi et al 
(1997), who showed PX significantly decreased proliferation of Neuro2a cells in vitro as 
well as decreasing the growth of subcutaneously transplanted primary tumours in syngeneic
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A/J mice.
PX is known to affect cell adhesive properties, and a report by Franzini et al, (1995) 
demonstrated the ability of PX to reduce adherence of polymorphonuclear leukocytes to 
human umbilical vein endothelial cells. Using the C8161 cells, the research in this thesis 
demonstrates that PX is unable to alter adhesion of the highly metastatic C8161 cells to 
collagens type I and IV, laminin and basement membrane yet is successful at reducing the 
adherence of the tumour cells to fibronectin. Our results suggest that PX could possibly 
alter either expression or activity of those receptors which bind to fibronectin such as 
cx5pl and a3 p l, and this could perhaps account for the reduction in adherence to this 
substrate. Further work will be required to characterise the cell surface receptors involved 
in binding to fibronectin to explain more fully, the mechanism behind the PX-induced 
reduction in adherence of the C8161 cells to fibronectin.
4.3. Retinoid-induced modulation of tumour cell lysis
All three melanoma cell lines in this study were susceptible to attack by LAK cells to a 
varied extent. This variation depended on the origin of lymphocytes in use, as different 
donors produced lymphocytes of varying capacity to lyse target tumour cells. It would 
have been interesting to compare the susceptibility of the low metastatic cell lines with the 
highly metastatic C8161 cells. However, due to the variability between donors, such an 
experiment would have required the same lymphocytes to be used in all the assays. This 
was not practical since a large numbers of lymphocytes were needed for each assay which 
in turn, would have required large volumes of blood to be taken from one individual. 
Marrani et al (1994) reported on a microassay version of the classical chromium-51 release 
assay which used much smaller numbers of tumour cells. Therefore, in producing the E:T 
ratio, less lymphocytes were required. But, on attempting to reduce the number of tumour 
cells, the maximum release of chromium-51 from the cells (as measured in dpm) was 
extremely low. Therefore, the classical chromium-51 release assay was used in this study, 
hence it was not possible to compare the susceptibility of low with high metastatic cells as 
different lymphocytes were used for each separate assay. Despite this, the difference 
induced on drug treatment was always similar despite the variations in lytic capacity of the 
effector cells. Both RA and PX are known to affect lymphocytes as well as tumour cells, 
nevertheless, it was hoped in the assays, that by washing the tumour cells at least four
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times to remove excess chromium, any residual drug on the tumour cells would be removed 
and would not interfere with the lymphocytic response.
Recently, Chao et al, (1997) showed that RA decreased the susceptibility of gastric cancer 
cell lines towards LAK-cell mediated lysis. In contrast, the data produced in our study 
demonstrated that the C8161 and Hs294T human melanoma cell lines became more 
susceptible to lysis on treatment with RA. We speculated that alterations in mICAM-1 
levels may be responsible for this RA-induced modulation of lysis as alterations in mIC AM- 
1 expression have been correlated with changes of the immune response to tumours. For 
example, increases in ICAM-1 expression have previously been reported to increase LAK 
cell- mediated lysis of bladder cancer cells (Jackson et al, 1993; Campbell et al, 1994). 
Cytokines such as IFNy, TNFa and IL1 (Rothlein et al, 1988) are also able to induce 
mICAM-1 levels which has been reported to make the tumour cells more susceptible to 
lysis by cells of the immune system (Webb et al, 1991).
RA is known to increase mICAM-1 expression in several cell types (Bassi et al, 1995; 
Wang et al, 1992), including melanoma cells (Bouillon et al, 1991), mast cells (Babina et 
al, 1997), epithelial cells (Gao and MacKenzie, 1996) and cervical cancer cells (Santin et 
al, 1998), yet in the study by Chao et al, (1997), they were unable to show any effect of RA 
on mICAM-1 expression. FACs analysis of mICAM-1 in the A375, Hs294T and C8161 
cell lines demonstrated a RA-induced increased in mICAM-1 levels in all three cell lines. 
Subsequent examination of the correlation between ICAM-1 expression and the 
susceptibility of RA-treated cell lines to lysis by LAK cells followed. The data generated 
from our blocking ICAM-1 antibody studies indicate mICAM-1 to be partially involved 
in the tumour/PBL interaction of both treated and untreated Hs294T/C8161 tumour cells, 
providing further evidence for the involvement of ICAM-1 in the immune response to 
tumours (Maio et al, 1989; Vanky et al, 1990; Pandolfi et al, 1992). The increase in 
mICAM-1 expression in response to RA treatment cannot be solely responsible for the 
increase in LAK cell-mediated lysis of RA-treated tumour cells, as addition of blocking 
ICAM-1 antibody to the cytotoxicity assays did not reduce lysis to the same level of control 
experiments. The involvement of ICAM-1 in RA-treated A375 cells was completely 
abolished which could possibly be via inactivation of expressed ICAM, as levels were in 
fact increased with RA. It appears that RA modulates the expression of other molecules in 
addition to ICAM-1 on the tumour cell surface which could ultimately alter the sensitivity 
of the tumour cells to LAK cell-mediated lysis. Interest in tumour/lymphocyte biology
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has also focused upon how lymphocytes recognise the absence of major histocompatibility 
complex (MHC) class 1 (HLA-ABC) on tumour cells causing the tumour cells to be lysed 
(reviewed in Mingari et al, 1997). Reports have shown MHC class 1 expression correlates 
with an inhibitory effect on LAK cell-mediated killing (Kaufman DS, 1995; Litwin et al,
1994). Little data is available on the effects of RA on MHC class 1 expression, but Gross 
et al (1992) reported on the induction of MHC class 1 by RA in neuroblastoma cell lines 
whilst De Vries et al (1986) reported on the enhancement of MHC class 1 by RA in two 
melanoma cell lines. RA has also been shown to increase MHC class 1 expression in 
cervical cancer cells (Santin et al, 1998). In contrast to this, we speculated that in our cell 
lines which had become more susceptible to lysis on drug treatment, this increase might 
have been partially induced by loss of MHC class 1 expression. However, despite our 
findings that the tumour cells weakly expressed MHC class 1 molecules, we were unable 
to show that blocking of the HLA-ABC complex with antibody over a range of concentration 
to untreated or RA-treated tumour cells had any effect on lysis.
Another possible candidate which may be altered by RA and which is present on the 
tumour surface is LFA-3 (CD58). This molecule interacts with LFA-2 on the lymphocyte 
surface (reviewed in Springer TA, 1990). Recently, Gwin et al (1996) demonstrated LFA- 
3 expression correlates most strongly with LAK sensitivity on melanoma cell lines. 
Modulation by RA is possible; perhaps RA unveils previously masked LFA-3 binding 
sites or may induce LFA-3 expression or activity to increase the interaction of tumour 
cells with LAK cells and mediate lysis of a greater number of tumour cells. Future work 
would involve characterising the alterations in other cell surface molecules which could 
further explain the RA modulations of tumour cell lysis.
Previous reports indicate mICAM-1 expression in melanoma correlates with an increased 
risk of metastasis (Kageshita et al, 1993; Johnson et al, 1989). This somewhat conflicting 
statement may be explained by the existence of soluble ICAM-1 which can interact with 
LFA-1 on the lymphocyte and block the lymphocyte from interacting with and lysing the 
tumour cell. Nude mouse models have previously shown melanoma cells to be a source of 
sICAM-1 (Giavazzi et al, 1992), a finding supported by our ELISA results which show the 
C8161, Hs294T and A375 cell lines secrete sICAM-1. There is evidence to show that 
patients with malignant melanoma who have higher levels of sICAM-1 have a reduced 
survival rate (Haming et al, 1991). It is interesting to note that in our melanoma cell lines, 
the highly metastatic C8161 cells secrete 5-fold greater levels of sICAM-1 per cell than
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the poorly metastatic Hs294T cells which may contribute to the greater ability of the C8161 
cells to metastasise in the experimental metastasis model. Although mICAM-1 levels 
were increased with RA treatment, sICAM-1 levels remained unaltered in the Hs294T and 
C8161 cell lines. The mechanisms involved in the release of sICAM-1 are unclear, however, 
it is possible that the soluble form arises either by differential RNA splicing, as is true for 
P-selectin (Ishiwata et al, 1994), but no corresponding mRNA has been observed. Budnik 
et al (1996) have provided evidence which points at the the proteolytic cleavage of mlCAM- 
1 to form sIC AM-1. Using protease inhibitors, they were able to inhibit the production of 
sIC AM-1 from keratinocytes and showed, using a minimal peptide protection assay, that 
the production of sICAM-1 was inhibited without having any effect on mICAM-1 
expression. It would seem reasonable to speculate from the ELISA results that the 
immunological consequences of RA treatment in the C8161 and Hs294T cell lines is not 
via the induction of sICAM-1 and that the mechanisms of regulation of ICAM-1 and 
sIC AM-1 are independent of one another in these cell lines. This has also been observed 
by Heymann et al (1995) who reported that the induction of mICAM-1 by certain cytokines 
had no effect on sICAM-1 expression.
sIC AM-1 has been shown to bind to LFA-1 on the LAK cell surface which would ultimately 
prevent the lymphocytes from interacting with mICAM-1, preventing lysis of the tumour 
cell. The reports on a functional role for sIC AM-1 are conflicting. Various groups have 
reported on its ability to inhibit cell-cell adhesion events such as inhibition of rhinovirus 
infection (Marlin et al, 1990); T cell/tumour cell interactions (Becker et al, 1993); and 
lymphocyte/endothelial cell interactions (Rieckmann et al, 1995), and with regards to 
melanoma cells, Altomonte et al (1993) and Becker et al, (1991, 1993) reported on the 
inhibition of melanoma cell lysis by sICAM. However, in contrast, several other groups 
have reported on the failure of sICAM-1 to inhibit (Staunton et al, 1992; Welder et al,
1993) cell-cell interactions. We demonstrate that introduction of this soluble form to the 
lysis assay of both the Hs294T cells and the C8161 cells does not alter lysis, an observation 
supported by recent data from Young et al (1997), who found that addition of sICAM to 
the cytotoxicity assays of bladder cancer cell lines had no effect on lysis. This result is in 
view of the finding which shows sICAM-1 has a low affinity for LFA-1 (Reilly et al,
1995). Our data indicates sICAM-1 release from these melanoma cells appears to be 
unimportant in the evasion of these melanoma cells from the immune system in vitro. 
However, it does not rule out the possibility that in the in vivo situation, sICAM may exist
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bound to other proteins or as a multimeric form which may have a greater potential to bind 
to LFA-1 sites on the lymphocyte which could contribute to tumour cell evasion. sICAM- 
1 dimers have been shown to bind to solid phase purified LFA-1 with much higher avidity 
than monomeric forms (Miller et al, 1995). In the natural state, crosslinking of ICAM-1 
occurs which can deliver a signal to neutrophils to yield an oxidative burst (Rothlein et al,
1994) and to T cells to activate expression of surface proteins (Poudrier et al, 1994). 
Therefore crosslinking of sICAM-1 may indeed occur in vivo which could compete more 
effectively for LFA-1 than monomers.
sICAM-1 addition to RA-treated C8161 cells reduced lysis, suggesting sICAM-1 
interference of the tumour/LAK cell interaction plays a significant role in preventing lysis 
of RA-treated tumour cells. It appears that the combination of sICAM-1 and the RA- 
induced alterations in membrane molecules is sufficient to partially prevent lysis of the 
highly metastatic cells.
4.4. Pentoxifylline-induced modulation of tumour cell lysis
The PX-mediated effects on LAK cell-mediated lysis appeared to be cell type specific as 
treatment of the C8161 cells with PX made the tumour cells more susceptible to lysis 
whereas in contrast, the same treatment of the Hs294T cells made the tumour cells less 
susceptible to lysis.
Previous reports regarding the effect of PX on mICAM-1 expression have shown that 
expression of ICAM-1 on LPS-stimulated mononuclear cells was reduced with PX (Parhar 
et al, 1993), a similar finding with monocytes where PX reduced expression of mICAM-1 
(Neuner et al, 1997). Reports have indicated one mechanism of downregulation of ICAM- 
1 by increased cAMP levels is via the inhibition of TNFa release (Taffet et al, 1989; 
Doherty et al, 1991). Mizutani and Bonavida, (1994) demonstrated that the treatment of 
OVC-8 ovarian cancer cells with PX reduced TNF-a mRNA expression and both TNF 
production and ICAM-1 expression are inhibited by PX on mononuclear cells (Mandi et 
al, 1995). In contrast, a recent report by Zuckerman et al, (1998) showed that increases in 
cAMP levels was accompanied by an increase in mICAM-1 expression in rat microglial 
cell cultures. Although all three cell lines were expressing mICAM-1, we were unable to 
demonstrate any alterations in mICAM-1 expression in response to a range of concentrations 
of PX.
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Addition of blocking ICAM-1 antibody to PX cells reduced lysis but likewise for RA- 
treated cells, this reduction was similar to the control cells suggesting other molecules 
must also be affected by PX. Interestingly, the reduction in lysis of PX-pretreated Hs294T 
cells on addition of ICAM-1 antibody was less than in control cells and required a higher 
concentration of antibody before a significant reduction became evident.
PX and caffeine have previously been shown to affect MHC class 1 expression (Erusalimsky 
et al, 1989; Rosenthal et al, 1993) and certainly in murine cells, PX-enhanced MHC class 
1 expression has been shown to be partially blocked by an inhibitor of cAMP-dependent 
protein kinase A (Rosenthal et al, 1993) suggesting the involvement of cAMP in PX- 
induced MHC class 1 expression. Although we have yet to analyse the effect of PX on 
MHC class 1 expression, addition of blocking MHC class 1 antibody failed to alter tumour 
lysis, suggesting it is unimportant in the tumour/LAK cell response.
Whereas with PX which failed to alter mICAM-1 expression, sICAM-1 levels were greatly 
increased in all the tested cell lines. Similar results with PX treatment have been produced 
in vivo where plasma concentrations of circulating sICAM-1 have been shown to increase 
with PX treatment in patients with sepsis (Boldt et al, 1996). If indeed this is the case, then 
our data may suggest PX has the potential to alter the putative protease(s) involved in 
cleavage of mICAM-1 to produce the large increase in sICAM-1 expression, whereas RA 
is unable to effect such proteases. The cytokine profile of these tumour cells and the 
ability of PX to alter secretion of the cytokines has not been determined. This may also be 
another mechanism by which PX alters sICAM-1 expression by modulating cytokine 
expression since PX is known to affect the release of IL-1, IL-2, IL-6, IL-8 and IFNy 
(Thanhauser et al, 1993; Neuner et al, 1994).
It has yet to be determined whether this increase in sICAM-1 by PX plays an important 
role in evasion of these tumour cells from cells of the immune system.
The importance of research into ICAM-1 has contributed to the design of therapeutic 
agents targetting ICAM-1 expression in the clinical setting. Inhibiting leukocyte adhesion 
by monoclonal antibodies to ICAM-1, LFA-1 or Mac-1 or using soluble fragments of 
ICAM-1 and antisense oligonucleotides to inhibit ICAM expression has been attempted. 
Coupling sICAM to Ig produces a dimeric ICAM-1 which has been shown to block in 
vitro antigen-specific T cell proliferation whilst coupling of ICAM-1 monoclonal antibodies 
to the ricin A chain was shown to be cytotoxic to human melanoma cell lines.
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Recently, a new concept in tumour/lymphocyte biology has been proposed. It has been 
known for several years that clustering of ICAM-1 occurs in areas of cell-cell contact 
(Sanders and Vitetta, 1991). Recently, ICAM-2, which was discovered in 1989 (Staunton 
et al, 1989), has been shown to be important in the tumour/lymphocyte interaction. Helander 
et al (1996), demonstrated that tumour cells become sensitised to LAK cells when 
transfected with chromosome 6. Both the resistant and parental cells express similar 
amounts of ICAM-2. However, in the transfected cells, ICAM-2 was found to be 
concentrated in the tips of uropods and not evenly distributed in the membrane like the 
parent cells. The concentration of ICAM-2 was sufficiently high in the transfectants to 
allow recognition by LFA-1 to occur, causing lysis of the target cell. This redistribution 
was controlled by a protein found on chromosome 6 called erzin, which is an actin binding 
membrane cytoskeleton linker protein (Vaheri et al, 1997). Interestingly, the distribution 
of erzin has recently been shown to be altered during malignant transformation. The 
outcome of this work suggests that lymphocyte recognition of target cells may require the 
redistribution of target molecules such as ICAM-1, 2 and LFA-3. This opens up the 
possibility that PX, and indeed, RA may not simply alter expression of these molecules, 
but may also modulate the distribution of target molecules on the cells surface which 
could result in altered cell lysis.
4.5. Lung tumour colonising potential of the C8161, A375 and Hs294T cell lines and 
the secretion of uPA and tPA.
This section of the study has provided further evidence that the C8161 cell line is indeed 
more metastatic in vivo than either the Hs294T or the A375 cell line. The reservation with 
the experimental metastasis model is that by injecting the melanoma cells directly into a 
vein, the intial steps involved in metastasis such as local invasion and extravasation are 
bypassed. Despite this, the model does provide an indication of the metastatic capabilities 
of the tumour cell and has been widely accepted as a tool to study metastasis. What was 
surprising with the data obtained from the experimental metastasis work was the large 
variation in the number of lung tumours formed between each mice within a group. There 
are several possibilities for this -1) the injections may not have been accurate such that the 
target vein was missed or only a small volume of cells were correctly targeted. This 
appears the most likely explanation and may explain why some of the animals had zero
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counts whilst others in the same group had many more counts; 2) the amount of viable 
cells injected into each mouse may have varied although this was unlikely as viability of 
each pool of cells was always greater than 95% prior to the experiment; 3) assuming the 
same numbers of viable tumour cells were injected into each mouse and that the tumour 
cells were injected into the target vein, then the data shows that certain mice appear to be 
much more susceptible to forming lung tumours than other mice within the same 
experimental group. It is probably a combination of both biological and technical variation 
which has produced the wide range of results within each group. Increasing the sample 
size and repetition of the experiment would ensure the variation is not due only to technical 
error. As a result of this, it remains difficult to conclude whether RA or PX has any effect 
on the cell lines in vivo due to the variation in tumour counts.
The next stage of the project involved analysing the expression of PAs from human 
melanoma cell lines and examining the modulation of the PA components by RA and PX. 
An early investigation by Fraki et al, (1979) provided intial evidence for an increase in 
PAs during metastasis as extracts of primary melanomas and melanoma metastases 
contained significantly higher levels of plasminogen activators than extracts of naevi. 
The confocal microscopic analysis suggested that expression of tPA was significantly 
lower in the C8161 and Hs294T cell lines in comparison to uPA expression, but this 
statement would only stand true if the specific activity of the uPA and tP A antibodies were 
similar. Using the ELISA detection system as outlined in the methods section, the study 
began by analysing the expression of both uPA and tPA in untreated C8161, Hs294T and 
A375 cells using a range of dilutions. What clearly became evident was that as the samples 
were made more dilute, the absorbance values became higher until the sample was so 
dilute that any PA was undetectable. This pattern was consistent throughout the assays 
and there exists several possble explanations for this. The results suggest that some factor(s) 
present in the supernatant has the ability to interfere with antibody binding to the tPA or 
uPA, and when this factor(s) is diluted out, the uPA/tPA is able to bind to the appropriate 
antibody, hence the absorbance readings increase. Either the factor(s) could be preventing 
binding of uPA/tPA to the catching antibody or alternatively, reduce binding of the tagging 
antibody to uPA/tPA. Interference could take the form of altered conformation of the 
antibodies, or the uPA/tPA, so that binding is reduced, or indeed, the factor(s) may be 
large enough to block binding of the analyte to the antibodies. The factor(s) may itself 
bind to either the tagging or the catching antibody to prevent their binding to uPA/tPA.
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There is also the possibility that the inhibitory factor(s) may also influence binding of the 
detecting antibody such that binding of this antibody to the tagging antibody is reduced 
which would result in a decreased signal. In all cases, the absorbance would be reduced 
and only by removing the factor would the optical density readings be a true reflection of 
the quantity of uPA/tPA present in the sample. Diluting the factor out is one way to 
overcome this problem. Alternatively, if the experiments were to be repeated, another 
mechanism would be to charcoal strip the serum as serum contains many constituents 
which could have the potential to interfere with the ELISA, or to culture the cells under 
serum free conditions. The forseeable problem with removing the serum is that the tumour 
cells would not proliferate, or would do so very slowly.
There exists a general consensus whereby more invasive cell lines express higher levels of 
uPA, and anti-uPA antibody has been shown to reduce both invasion (Mignatti et al, 1986) 
and matrix degradation of uPA-positive tumour cells (Reiter et al, 1993). In this study, the 
C8161 cells were found to secrete on average, 215-fold higher levels of uPA than the 
Hs294T whilst the A375 cells lacked expression of secreted uPA. High expression of 
cell-associated uPA was observed in the C8161 and Hs294T cells, with weaker expression 
in the A375 cells. We speculate that the expression of such high levels of uPA from the 
C8161 cell line may contribute to the greater ability of these cells to metastasise in the 
experimental metastasis model, as expression of high levels of uPA have previously been 
correlated with a more metastatic phenotype (Yu et al, 1988). Metastatic subclones of 
melanoma cell lines have been shown to express higher levels of uPA compared with non 
metastatic parental melanoma cell lines (Yu et al, 1988), supporting a role for uPA in the 
metastatic process.
In contrast to uPA levels, many human tumours have been reported to lack the expression 
o f tPA. Human melanoma lesions (De Vries et al, 1995; Delbaldo et al, 1994) have been 
shown to produce considerable amounts of tPA and high levels of tPA secreted from 
malignant melanomas has been correlated with the greater potential of these cells to migrate 
and degrade the ECM (Meissauer et al, 1992). Increases in tPA expression have also been 
reported to occur during malignant melanoma progression. Using WM164 cells, Herlyn 
et al, (1990) showed the more metastatic variant, 451-LU, contained 3-fold higher tPA 
levels and invasion could be inhibited significantly using anti-tPA polyclonal antibodies 
in an invasion assay. Both the C8161 and Hs294T cells secrete tPA, but interestingly, in 
contrast to uPA, the poorly metastatic Hs294T and A375 cells secreted higher levels of
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tPA. Since uPA plasmin generation has been shown to be a much more efficient process 
than tPA when comparing uPA-producing MelJuso cells with tPA-producing MeWo cells 
(Meissauer et al, 1992), the biological significance of higher tPA expression from the 
poorly metastatic cell lines remains to be established. In the tissues of tumours of diverse 
origin, tPA levels are often much lower than in benign tissue whereas uPA levels are 
consistently increased in tumours of diverse origin (De Vries et al, 1996) which may indicate 
tPA is less important in uPA-producing tumour cells.
4.5.1. Retinoid-induced alterations in uPA and tPA expression
Reports indicate that there exists a RARE located within the promoter region of the gene 
for tPA (Bulens et al, 1995) suggesting RA has the potential to modulate expression of 
this component. Indeed, Kooistra et al, (1995) and Thompson et al, (1991) reported on the 
induction of tPA by RA in human endothelial cells, whereas Vangiezen et al, (1993) have 
reported on the induction of tPA by RA in vivo. The synthesis of tPA was also reported to 
increase on RA treatment in rat endothelial cells (Emeis et al, 1998). In support of this 
data, we have demonstrated a RA-induced increase in tPA expression in all three cell lines 
in a dose-dependent manner. Future studies will involve analysing the biological 
significance of this increase with the speculation that this RA-induced increase in tPA 
expression may favour an increase in the invasive potential of the tumour cell, as Tiberio 
et al, (1997) recently reported on the RA-enhanced human neuroblastoma cell invasion of 
reconstituted basement membrane, which was associated with the induction of tPA 
expression and a putative tPA receptor, amphoterin. Previous reports on the effect of RA 
on uPA expression show RA decreases levels of uPA in prostate carcinoma cells (Waghray 
et al, 1995). This is in contrast to the study by Miwa et al, (1995), who demonstrated a 
RA-induced increase in receptor bound uPA in fibrosarcoma cells. We have also 
demonstrated a RA-induced increase in uPA expression in all three cell lines. However, 
these results are in contrast to other reports showing RA treatment of prostatic carcinoma 
cells decreased uPA expression (Waghray and Webber, 1995). All-trans RA treatment of 
prostate carcinoma cells has also been reported to reduce uPA-mediated degradation of 
fibronectin and laminin and to decrease the ability of the tumour cells to invade matrigel 
(Webber and Waghray, 1995). The lack of correlation with our results may reflect the 
possibility that the RA-mediated alterations in uPA expression may be dependent on specific
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tumour cell types in vitro. Whether this increase in total uPA expression corresponds to 
an overall increase in activated uPA has yet to be determined. Kim et al, (1995) 
demonstrated that despite RA increasing the total activatable uPA expression in human 
prostate adenocarcinoma cell lines, there was, in contrast, a decrease in uPA activity. This 
decrease was thought to be due to an increase in PAI-1 production. The expression of 
PAI-1/2 have not been determined in the C8161 and Hs294T cell lines, however, it is 
possible that RA may affect levels of these inhibitors as Tienari et al, (1991) have reported 
on an upregulation of PAI-1 by RA, and the gene for PAI-2 has been shown to contain a 
RARE (Schuster et al, 1994) allowing for the potential of PAI-2 to be regulated by RA. 
RA has also been shown to increase the uPAR and to stimulate plasmin generation (Mustjoki 
et al, 1998) and the availability and numbers of the uPAR may also reflect the potential of 
the tumour cell to invade. Therefore, the ability of RA to modulate invasion of these 
tumour cells may not only be determined by uPA and tPA levels, but also by expression of 
both inhibitors and surface expression of uPAR.
4.5.2. Pentoxifylline-induced modulation of uPA and tPA expression
Little data is available on the effects of cAMP-inducing agents such as PX to modulate PA 
expression. However, the reports on the ability of PX to alter experimental metastasis, 
suggests PX may affect proteinase expression which would contribute to the observed 
changes in metastasis. There is a cAMP responsive element in the human tPA gene 
suggesting PX would have the potential to modulate tPA expression. Yet, in this study, it 
appears PX has very little effect on expression of tPA, certainly in the C8161 cells.
With regards to uPA expression, Miraylopez et al (1991), reported on the induction of 
uPA mRNA, protein and activity by cAMP-inducing agents. We have shown that in both 
the C8161 and Hs294T cell lines, PX induces uPA secretion. In a small series, Markus et 
al (1984), attributed 77% of plasminogen activator activity in melanoma tissue to uPA, 
and therefore, increases in uPA by PX may contribute to increases in the overall activation 
of plasmin.
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4.6. Retinoic Acid Receptor Expression
In this section, the expression of the 3 retinoic acid receptors was analysed and we 
demonstrated expression of RARp and y in all 3 human melanoma cell lines. We were 
unable to demonstrate expression of RARa in the Hs294T or the C8161 cells and although 
the A375 cell lines expressed RARa, this was downregulated on treatment of these tumour 
cells with RA.
The initial plan of study was to use the vectors from Pierre Chambon to act as probes for 
Northern blot analysis to allow relative quantification of the results. A fasta data search 
was carried out to determine the presence of any internal recognition sites which could be 
used to produce a suitable probe for use in the Northern blot analysis of the RARs. RARa 
was found to have 2 internal Pstl sites within the insert which could have been used 
whereas RARp had an internal EcoRl recognition site which would have also been 
appropriate. RARy had a Sacl and a Pstl site within the insert which could have been 
utilised to produce a smaller probe. However, on restriction enzyme digestion of the 
vectors, there appeared to be some discrepancies comparing the results with the restriction 
enzyme maps. The RARa insert lacked lkb and RARy insert lacked the Sacl and Pstl 
sites. Therefore, in an attempt to try to partially identify the inserts, primers were chosen 
to amplify specific regions of the vectors to use in subcloning and sequencing of the 
fragments. Both RARa and RARP vectors were amplified succesfully however, RARy 
failed to become amplified under the selected conditions. Partial sequencing of RARa and 
p inserts were successful but, RARy was unable to be sequenced. The only caution with 
the RARy result is that a different primer was used in the sequencing reaction since a 
different vector was being sequenced (pSG5 rather than the pCR2.1 vector) and any faults 
with the primer may have accounted for the inability to sequence RARy. This seemed 
unlikely as successful sequencing of other samples in the laboratory had been achieved in 
previous research work. Not only did RARy lack internal recognition sites, but it was also 
unable to be sequenced, so a fresh batch of RARy vector was sent from France. Again, the 
internal recognition sites were missing and sequencing of the pure vector was unsuccessful. 
It may have been possible to try to cut out a digest fragment of RARy from the gel and try 
to subclone this fragment to reveal the partial identity of the insert, however, it was decided 
to focus the efforts on RARa and p.
In producing the probes for RARa and P there were 2 possibilities; one was to simply take 
the PCR product and label this. The other method would be to purify the bands from the
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gel and use this as a probe. Since pure vector was being amplified and not cDNA (where 
there is the possibility that regions other than the chosen area may be amplified but which 
are not visible on the gel), it would be reasonable to simply use the PCR product. However, 
to be certain that the probe used was definitely RARa or p, the probe DNA was excised 
from pCR2.1 RARa and RARp. The initial attempt to produce a probe of high specificity 
by end-labelling failed to produce any signal on a blot. The likely reason for this was that 
this form of labelling only produces probes with low levels of activity since only the end 
of the probes are labelled. Therefore random labelling was chosen as this produces a 
probe of much higher specific activity as labelling occurs throughout the probe and not 
just at the 5' phosphate group. The intial blots of RARa and RARp produced only non­
specific signal. There was a possibility to try to overcome the problem of non-specific 
binding using poly A columns to purify out the mRNA. This also would be beneficial if 
the message for the receptors was of a very low level. The other method was to try to load 
more RNA into the wells such that more expressed RAR signal would be present. However, 
this method would also increase non-specific binding sites at the same time as increasing 
specific binding sites and would not have helped the initial problem of non-specific binding. 
Also, loading of the wells with high amounts of RNA was very problematic as the RNA 
samples became very viscous. Taking into account that even if the blots for RARa and p 
were successful, there still remained the problems with the identity of the RARy vector. 
On pricing the polyA columns for purifying mRNA , which were shown to be expensive, 
and having no idea as to whether the receptors were even being expressed, I decided to 
analyse the RAR expression using RT-PCR to amplify regions of the cDNA using specific 
primers, then confirm the identity of the PCR amplicons by Southern blotting. This proved 
to be successful and we were able to demonstrate expression of RARP and RARy in all 
three cell lines with and without RA treatment. High levels of RARy have also been 
reported to occur in the RA insensitive F9 tetracarcinoma cell line (Wan et al, 1995) whereas 
in contrast, acinar pancreatic tumour cells which are unresponsive to RA have been shown 
to lack expression of RARy. Rarrangement of RARp due to the insertion of the hepatitis 
B virus has been reported in human hepatocellular carcinoma (Dejean et al, 1986) whilst 
loss of RARp has also been shown to be an early event in oral carcinogenesis (Lotan R,
1995). Treatment with RA results in clinical improvement with an increase in RARp mRNA. 
RARp has been shown to be highly inducible for RA (Hoffmann et al, 1990) however, it 
was not possible to say whether RA increased RARp expression in the cell lines using the
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non-quantitative PCR method. The study successfully shows the absence of RARa in two 
cell lines with the downregulation of RARa in the A375 cell line on treatment with RA. 
Loss of normal RARa expression is known to be associated with malignant transformation. 
Acute promyelocytic leukemia (APL) is the translocation of part of chromosome 17 onto 
the long arm of chromosome 15. This breakpoint on chromosome 17 is located close to 
the RARa gene (Borrow et al, 1990; de The et al, 1990) producing abnormal transcripts 
for RARa which may block differentiation at the promyelocytic stage. The RA-induced 
maturation of APL cells into mature granulocytes (Breitman et al, 1990) is associated with 
a marked reduction in expression of these abnormal transcripts (Zhu et al, 1995). A stably 
transfected truncated RARa (lacking the E/F domain) into F9 cells induces a repression of 
the retinoid response and the cells reveal a RA-resistant phenotype ie they were blocked in 
differentiation (Espeseth et al, 1989). In P I9 cells selected for RA nonresponsiveness, a 
rearrangement that results in truncation of 70 amino acids from the c-terminal end of 
RARa was detected and this truncated RARa was found to act as a dominant negative 
regulator (Pratt et al, 1990). We have recently shown that all-trans RA is unable to inhibit 
growth of the Hs294T and C8161 cell line (Edward et al, 1997) and may be as a result of 
lacking the expression of RARa, as the RARs have been implicated in repression of the 
transcription factor AP-1 (reviewed in Pfahl M, 1993) which has been shown to influence 
cell growth. Lee et al, (1998) recently reported on the ability of RA to reduce c-fos 
expression where antagonists of RARa-supressed c-fos activity.
4.7. Correlation of RAR profile with ICAM-1 and PA expression
A specific role for the various subtypes of RAR has been demonstrated in the retinoid- 
induced modulation of plasminogen activation. It has been suggested that the RA-induced 
increase in tPA expression requires the involvement of the RARa (Kooistra et al, 1995). 
However, in contrast to this, we were unable to demonstrate expression of RARa in two 
of the cell lines in which RA-induced tPA increases occurred. Clearly, there must be 
another mechanism(s) which exists to regulate the RA-induced increase in tPA expression 
in these cell lines which does not require the expression of RARa. Lansink et al, (1996) 
provided evidence for the involvement of RARP in the induction of tPA by RA in human 
endothelial cells. We were able to show the presence of RARP and y in both cell lines and 
postulate a possible role for these receptor subtypes in the RA regulation of both tPA and
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uPA. It is also possible that the RXRs might also be involved as these can form heterodimers 
with the RARs to regulate target gene expression. The use of specific inhibitors for each 
receptor subtype would provide further evidence for the involvement of each subtype. 
RARp has been shown to increase along with ICAM-1 on treatment with RA (Bouillon et 
al; 1991) and Aoudjit et al, (1995) have postulated a potential role for RARP (and RXRa) 
in the upregulation of ICAM-1 by RA. This is in accordance with the study by Cilenti et 
al, (1995) who have demonstrated the ICAM-1 promoter region binds RXRa and RARp 
with high efficiency. Certainly, all three cell lines express ICAM-1, which was increased 
with RA treatment, and it would be interesting to quantitate the expression of RARp to see 
if indeed it does increase in response to RA. The use of antisense ICAM-1 oligonucleotides 
would prevent an increase in mICAM-1 levels in response to RA, which may in turn, be 
able to prevent an induction of RARp. Alternatively, specific antagonists of RARP could 
be used to see whether preventing RARp from interacting with the target response genes, 
would prevent increases in mICAM-1 expression.
187
4.8. Future Studies
The following areas of research relating to this project merit further investigation:
1) Characterising the alterations in adhesion molecule profile induced by PX which would 
possibly allow an understanding of the mechanisms responsible for the reduced adhesion 
of PX-pretreated C8161 cells to fibronectin.
2) Analysis of the modulation and involvement of cell surface molecules implicated in 
the tumour/LAK cell interaction may further explain the alterations in tumour lysis by 
RA and PX.
3) Repeat the plasminogen activation ELISAs using charcoal stripped serum cultured 
cells and measure the activity of the PAs to determine whether the increase in tPA and 
uPA expression by RA corresponds to an increase in "activated" tPA or uPA.
4) Examine the expression of PAI-1, PAI-2 and the uPAR by the three cell lines as RA 
and PX may also influence expression of these proteins, which could ultimately have 
a significant effect on the invasiveness of the tumour cells.
5) Determine the biological significance of uPA and tPA expression using an in vitro 
invasion assay system, to test if levels of expression of the PA components correlates 
with invasive capacity. Examining the effects of RA and PX on the tumour cell's 
invasiveness would also be of interest.
6) Analyse the expression and involvement of other protease systems such as the MMPs 
which are known to be altered by RA and cAMP inducing agents.
7) Use specific RAR antagonists to depict a role for each RAR subtype in the RA-induced 
increases in ICAM-1, uPA and tPA expression.
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